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Biodiversity of natural resources like plants, animals, microbes, minerals and 
marine sources has served not only the primary human needs but also health 
care since time immemorial (Patwardhan et al., 2004). In every culture, in every 
age, there are different theories of disease and different systems employed in 
medicine, but botanical remedies are universal. The healing power of medicinal 
plants has a long established history. For thousands of years all the cultures have 
utilized herbs for health care. The widespread use of herbal remedies and 
healthcare preparations, as those described in ancient texts such as the Veda 
and the Bible, has been traced to the occurrence of natural products with 
medicinal properties. Civilized societies have bequeathed myths and 
compendiums of healing herbs and the herbal remedies from people of preliterate 
societies continue to surprise us with their extensive green pharmacy (Balick and 
Cox, 1996). The herbal healing lore was passed from generation to generation by 
word of mouth. 
1.1 HISTORY OF HERBAL MEDICINE
Herbal medicine is the oldest form of healthcare known to mankind. It was an 
integral part of the development of modern civilization. Fossil records date human 
use of plants as medicines at least to the Middle Paleolithic age some 60,000 
years ago which was evidenced by a burial site of a Neanderthal man uncovered 
in 1960 (Solecki, 1975). Primitive man observed and appreciated the great 
diversity of plants available to him. Gradually, each tribe added the medicinal 
power of herbs in their area to its knowledgebase. All cultures have long folk 
medicine histories that include the use of numerous plants. Even in ancient 
cultures, people methodically and scientifically collected information on herbs 
and developed well-defined herbal pharmacopoeias. Perhaps one of the earliest 
pharmacopoeias is the De Materia Medica (ca. 79 A.D.) by the Greco-Roman 
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stmilitary physician Dioscorides in the 1  century A.D (Ackerknecht, 1973). Later, in 
the second century of the present era, Galen (131201 A.D.) shaped 
pharmaceutical practice for centuries to come (Christopher, 2002). Indeed, well 
thinto the 20  century much of the pharmacopoeia of scientific medicine was 
derived from the herbal lore of native people. 
As mute witness to this fact, marshmallow root, hyacinth, and yarrow have been 
found carefully tucked around the bones of a Stone age man in Iraq. These three 
medicinal herbs continue to be used today. Marshmallow root is a demulcent 
herb, soothing to inflamed or irritated mucous membranes, such as sore throat or 
irritated digestive tract. Hyacinth is a diuretic that encourages tissues to give up 
excess water. Yarrow is a time-honored cold and fever remedy that may once 
have been used much as aspirin is used today (Zand et al., 1994).
The entire Middle East has a rich history of herbal healing. There are texts 
surviving from the ancient cultures of Mesopotamia, Egypt, and India that 
describe and illustrate the use of many medicinal plant products. The Ebers 
Papyrus, the most important of the preserved Egyptian manuscripts, was written 
around 1500 B.C. and includes much earlier information. It contains 876 
prescriptions made up of more than 500 different substances, including many 
herbs (Ackerknecht, 1973). 
In 2735 B.C., the Chinese emperor Shen Nong wrote an authoritative treatise on 
herbs that is still in use today. Traditional Chinese medicine was brought to Japan 
via Korea, and Chinese-influenced Korean medicine was adapted by the 
Japanese during the reign of Emperor Ingyo (411-453 A.D.).
The records of King Hammurabi of Babylon (1800 B.C.) include instructions for 
using medicinal plants and prescribed the use of mint for digestive disorders. 
Modern research has confirmed that peppermint does indeed relieve nausea and 
vomiting by mildly anesthetizing the lining of the stomach. 
The principal storehouse of the Muslim materia medica is the text of Jami of Ibn 
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Baiar (1248 A.D.), which lists more than 2,000 substances; including many plant 
products (Ackerknecht, 1973). The principal Ayurvedic book on internal medicine, 
the Chark Samhita, describes 582 herbs (Majno, 1975). The main book on 
surgery, the Sushruta Samhita, lists some 600 herbal remedies. Most experts 
agree that these books are at least 2,000 years old. 
By the seventeenth century, the knowledge of herbal medicine was widely 
disseminated throughout Europe. The first U.S. Pharmacopoeia was published in 
1820. This volume includes an authoritative listing of herbal drugs, with 
descriptions of their properties, uses, dosages, and tests of purity. It was 
periodically revised and became the legal standard for medical compounds in 
1906. 
But as Western medicine evolved from an art to a science in the nineteenth 
century, information that had at one time been widely available became the 
domain of comparatively few. The use of herbs, which had been mainstream 
medical practice, began to be considered unscientific or at least unconventional, 
and began to fall into relative obscurity. 
1.2 MEDICINAL PLANTS: INDIAN WEALTH AND HERITAGE
India is a varietal emporium of medicinal plants and is one of the richest countries 
in the world as regards to genetic resources of medicinal plants. All known types 
of agroclimatic, ecologic and edaphic conditions are met within India. The 
biogeographic position of India is unique which makes India rich in all the three 
levels of biodiversitysuch as species diversity, genetic diversity and habitat 
diversity (Krishnaraju et al., 2005). A survey conducted by the All India 
Coordinated Research Project on Ethnobiology (AICRPE) during the last decade 
recorded over 8000 species of wild plants used by the tribals and other traditional 
communities in India for treating various health problems (Laloo et al., 2006). 
The Indian subcontinent, with the history of one of the oldest civilization, harbors 
many traditional health care systems. One of the ancient classics, “Charak 
Samhita” (Chandra and Sharma, 1986) is the oldest text available on the 
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complete treatment of diseases which specifies the use of hundreds of herbs in 
the complete treatment of diseases. The Ayurveda, whose history goes back to 
500 B.C., is one of the ancient health care systems, which is a potential source of 
indigenous drugs. A large number of such herbs are mentioned in “Bhavprakash” 
(Vaishya, 1835) as well as "Aryavaidhya Kalanidhi” (Kavade Krishnamurthi, 
1986). “Indian Materia Medica” (Nandkarni, 1976) also gives a large number of 
medicinal plants for the treatment of various diseases. 
In rural areas, 75 percent of the population is dependent on herbal medicines for 
healthcare. In the last few decades, herbal medicine has been found to have some 
impressive credentials. In India, over 2600 plant species have been considered 
useful in the traditional system of medicine like Ayurveda, Unani, Siddha and 
Home remedies (Khandelwal, 1999). Number of herbal drugs and their 
compositions are recommended for combating human ailments in the ancient 
texts as well as in modern medicine (Sastri, 1962).
1.3 SYNTHETIC DOMINANCE: GROWING THREAT OF ANTIMICROBIAL 
RESISTANCE
thMankind's discovery of antibiotics ushered in a new age of medicine during the 19  
century, an age wherein many predicted an end to diseases that had plagued the 
mankind for centuries with the appearance of penicillin during World War II as the 
first miracle drug (Wainwright, 1990). From 1940s to almost 1980s many classes 
of antibiotics discovered have helped tame many of the terrors of human health. 
The use of these "wonder drugs", combined with improvements in sanitation, 
housing, nutrition, and the advent of widespread immunization programmes, led 
to a dramatic drop in deaths from diseases that were previously widespread, 
untreatable, and frequently fatal. Over the years, antimicrobials have saved the 
lives and eased the suffering of millions of people. 
Advances in synthetic chemistry for identification of many key chemical molecules 
offered more opportunities to develop novel compounds. Numerous drugs like 
sulphonamides, isoniazid, anti-psychotics, anti-histamines and penicillin were 
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developed from thousands of chemicals (Projan and Shlaes, 2004). Emergence 
of modern pharmaceutical industry is an outcome of all these different activities 
that developed potent single molecules with highly selective activity for a wide 
variety of ailments. These successes resulted in reduced interest in natural 
products drug discovery. Thus, herbal medicines became the domain of 'old 
wives tales'.
It was not until the 1970s that antibiotic resistance was considered to be a real 
threat.  In the past, medicine and science were able to stay ahead of this natural 
phenomenon through the discovery of potent new classes of antimicrobials, a 
process that flourished from 1930-1970 and has since slowed to a virtual 
standstill, partly because of misplaced confidence that infectious diseases had 
been conquered, at least in the industrialized world. In just the past few decades, 
the development of resistant microbes has been greatly accelerated by several 
concurrent trends like urbanization, pollution, AIDS epidemic, etc (Levy, 1992). 
These have worked to increase the number of infections and thus expand both 
the need for antimicrobials and the opportunities for their misuse. 
Recently, infections have become the leading cause of death world-wide which 
has led to an increase in antibacterial resistance, making it a global growing-
problem (Westh et al., 2004). More and more bacteria are developing a 
resistance to antibiotics (Zajicek, 1996) conferred by randomly mutated genes. 
Each year infectious diseases cause 14 million deaths worldwide, with mortality 
increasing even in the United States at an annual rate of 4.8 percent. In 2000, the 
World Health Organization (WHO) estimated that pneumonia, diarrhoeal 
disease, and tuberculosis accounted for more than half the deaths due to 
infectious disease worldwide. The problem is worsened by antibiotic resistance, 
as well as the emergence of new pathogens with the potential for rapid global 
spread (Davis, 1994; Service, 1995). In addition to this problem, antibiotics are 
sometimes associated with adverse effects on the host including hypersensitivity, 
immume-supression and allergic reactions (Ahmad et al., 1998).
The alarming incidence of antibiotic resistance forced scientists for developing 
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new and effective therapeutic agents with new principles from botanical medicine 
with novel modes of action that render them impervious to existing resistance 
mechanisms (Bhavnani and Ballow, 2000; Essawi and Srour, 2000; Shahidi and 
Karimi, 2004, Parekh et al., 2005; Nair et al., 2007). Natural products of higher 
plants may give a new source of antimicrobial agents with possibly novel 
mechanisms of action (Hamil et al., 2003; Machado et al., 2003; Motsei et al., 
2003; Barbour et al., 2004). Contrary to the synthetic drugs, antimicrobials of 
plant origin are affordable and are not associated with many side effects and have 
an enormous therapeutic potential to heal many infectious diseases (Iwu et al., 
1999). 
The study of natural products has advantages over synthetic drug design as it 
leads optimally to materials having new structural features with novel biological 
activity. Not only do higher plants continue to serve as important source of new 
drugs, but phytochemicals derived from them are also extremely useful as lead 
structures for synthetic modicfication and optimization of bioactivity. The starting 
materials for about one-half of the medicines used today come from natural 
sources. Virtually every pharmacological class of drugs includes a natural product 
prototype. Undisputedly, the history of herbal medicine is inextricably intertwined 
with that of modern medicine. Many drugs listed as conventional medications 
were originally derived from plants. Salicin, a precursor of aspirin, was originally 
derived from Salix alba (white willow bark) and flowers of Filipendula ulmaria 
(meadowsweet plant) are used as analgesic. Digoxin derived from Digitalis 
lantana (foxglove) is included in a drug class cardiotonic. Cinchona ledgeriana 
bark is the source of malaria-fighting quinine. Vincristine, used to treat certain 
types of cancer, comes from Catharantus roseus. Ephedrine, a bronchodilator 
used to decrease respiratory congestion, comes from Ephedra sinica. The 
Papaver somniferum (opium poppy) yields morphine, codeine, and paregoric, a 
treatment for diarrhoea. Laudanum, a tincture of the opium poppy, was the 
favored tranquilizer in Victorian times (Farnsworth and Morris, 1976). The future 
of higher plants is very promising as they can serve as best sources of medicinal 
agents in the prevention and treatment of diseases.
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1.4 REVIVAL OF TRADITIONAL MEDICINE
The history of interest in phytochemicals reveals that crude drugs were the 
thdominant therapy until the time of World War II. During the late 19  century, 
Western medicine began to supersede the folk and learned medicine that had 
been gathered and traded between cultures since the time of the Ancient 
Egyptians (Root-Bernstein, 1998) and moved away from any interest in folk 
knowledge of medicinal plants. Today, pendulum is swinging back to an interest in 
the value of traditional medicine. There is currently a rising recognition of the 
value of experience and historical knowledge gathered by indigenous cultures 
with medicinal plants.
Medicinal plants can save lives, livelihood and cultures. Herbal medicines are an 
important part of the culture and traditions worldwide. It is therefore no surprise 
that medicinal plants have raised their importance all over the globe. Recently, the 
renewed interest in medicinal plants as a re-emergent health aid has been fuelled 
by the extensive antimicrobial resistance along with rising costs of prescription 
drugs in the maintenance of personal health and well-being and the 
bioprospecting of new plant-derived drugs (Hoareau and  DaSilva, 1999). 
The revival of interest in herbal medicines is firstly due to increased awareness of 
the limited horizon of synthetic pharmaceutical products to control major diseases 
and secondly due to the current widespread belief that 'green medicine' is safe 
and more accessible and affordable (Mander, 1998) than the costly synthetic drug 
many of which have adverse side effects. The past decade has witnessed a 
tremendous resurgence in the interest and use of medicinal plant products 
especially from developed countries. According to a WHO estimate, about 80% of 
the world population relies on traditional systems of medicines for primary health 
care, where plants form the dominant component over other natural resources 
(Duraipandiyan et al., 2006). 
Today, the renewed interest in traditional pharmacopoeias reveals that 
researchers are concerned not only with determining the scientific rationale for 
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the plant's usage, but also with the discovery of novel compounds of 
pharmaceutical value. Instead of relying on trial and error, as in random screening 
procedures, traditional knowledge helps scientists to target plants that may be 
medicinally useful (Cox and Balick, 1994). The burgeoning interest in medicinal 
plants reflect recognition of the validity of many of the traditional claims for the 
value of natural products in health care. Many medicinal plants exert specific 
medicinal actions and may be used in response to specific health problems over 
short or long term intervals. It is estimated that total of 122 drugs from 94 plant 
species have been discovered through ethnobotanical leads (Fabricant and 
Farnsworth, 2001). Now-a-days, many scientists have isolated the medicinal 
properties of a large number of botanicals, and their healing components have 
been extracted and analyzed (Nair and Chanda, 2005; Elizabeth, 2005; Aliero 
and Afolayan, 2005; Rajeshwar et al., 2005; Parekh et al., 2006; Tadhani and 
Subhash, 2006; Kuzmaa et al., 2007; Parekh and Chanda, 2007). Many plant 
components are now synthesized in laboratories for use in pharmaceutical 
preparations.
1.5 HERBAL DRUG RESEARCH TODAY 
The goal of herbal drug research and development program is to discover single 
entity and multicomponent bioactive natural products that may serve as leads for 
the development of new pharmaceuticals which address unmet therapeutic 
needs. 
Traditional knowledge-driven drug discovery will serve as a powerful search 
engine and most importantly, will greatly facilitate the focused and safe natural 
products research to rediscover the drug discovery process. There are over 
750,000 plants on earth. Relatively speaking, only a very few of the healing herbs 
have been studied scientifically. Of these, only about 6% have been screened for 
biologic activity, and a reported 15% have been evaluated phytochemically 
(Verpoorte, 2000). 
Recently, all over the world, there is an upsurge and interest among scientific 
institutions, biological research institutions in the use of medicinal plants, crude 
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extracts or active ingredients to treat various ailments. Almost all of the current 
research validating herbal medicine has been done in Germany, Japan, China, 
India, Taiwan, and Russia (Hoareau and DaSilva, 1999). Most of the research that 
is done on plants continues to focus on identifying and isolating active ingredients, 
rather than studying the medicinal properties of whole plants. Herbalists, 
however, consider that the power of a plant lies in the interaction of all its 
ingredients. Plants used as medicines offer synergistic interactions between 
ingredients both known and unknown.
Today, rather than using a whole plant, pharmacologists identify, extract, isolate 
and synthesize individual components to capture the active properties. In addition 
to active ingredients, plants contain minerals, vitamins, volatile oils, glycosides, 
alkaloids, bioflavonoids, and other substances that are important in supporting a 
particular herb's medicinal properties. These elements also provide an important 
natural safeguard. 
Furthermore, an increasing reliance on the use of herbal products in the 
industrialized societies has led to the extraction and development of several 
drugs and chemotherapeutics from plants (UNESCO, 1998). Some of the wild 
plants, traditionally used as herbal remedies by ayurvedic practitioners, secured 
an important place in modern medicine. Nevertheless, many plants, which have 
curative properties, are yet to be seriously screened for their medicinal value. In 
an extensive screening programme of plants used in traditional medicine, 
researchers provide scientific evidence for their rational use in treating infections 
and diseases.
1.6 A GLOBAL TREND IN HERBAL DRUG MARKET
Many drugs commonly used today are of herbal origin. Indeed, about 25% of the 
prescription drugs available in markets contain at least one active ingredient 
derived from plant material. The World Health Organization (WHO) estimates that 
4 billion people, 80% of the world population, presently use herbal medicine for 
some aspect of primary health care. WHO also notes that of 122 plant-derived 
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pharmaceutical medicines, about 80% are used in modern medicine that 
correlated directly with their traditional uses as plant medicines by native 
cultures.  
The herbal drug industry is considered to be a high growth industry of the late 90s 
and seeing the growing demand, it is all set to flourish in the next century. The 
trend for the increasing popularity of medicinal herbs in developing countries is 
well supported by statistical data. The world market for plant-derived chemicals 
alone exceeds several billion dollars per year. Trade in medicinal plants is 
growing in volume and in exports. It is estimated that the global trade in medicinal 
plants is US$ 800 million per year (Wakdikar, 2004). The botanical market, 
inclusive of herbs and medicinal plants, in the USA, is estimated, at 
approximately US$ 1.6 billion p.a. China with exports of over 120,000 tonnes p.a., 
and India with some 32,000 tonnes p.a. dominate the international markets  
(Dhar et al., 2002). The annual export of medicinal plants from India is valued at 
Rs. 1200 million (Ramakrishnappa, 2002). It is estimated that Europe, annually, 
imports about 400,000 tonnes of medicinal plants with an average market value 
of US$ 1 billion from Africa and Asia (Wakdikar, 2004). A growing awareness of 
this new contributor to the foreign-exchange reserves of several national 
treasuries is beginning to emerge. To satisfy growing market demands, surveys 
are being conducted to unearth new plant sources of herbal remedies and 
medicines. Based on current research and financial investments into medicinal 
plants, it seems that they will continue to play important roles in human health 
(Hoareau and DaSilva, 1999).
1.7 APPROACHES TO HERBAL DRUG DISCOVERY USING HIGHER 
PLANTS
The plant kingdom harbors an inexhaustible source of active ingredients 
invaluable in the management of many intractable diseases. Folk medicine is one 
of the sources to discover new antimicrobial compounds and systematic 
screening of them may result in the discovery of novel effective compounds 
(Janovska et al., 2003). The quest for plants with medicinal properties continues 
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to receive attention as scientists survey plants for a complete range of biological 
activities, which range from antibiotics to antitumor.  
In the light of evidence for the rapid global spread of resistant clinical isolates and 
the appearance of drug resistant strains among community acquired infections 
as well as appearance of undesirable side effects of certain antibiotics (WHO, 
2002), the need for discovery or development of new antimicrobial agents is of 
paramount importance (Bradford, 2001). For this reason the search for new 
antimicrobial drugs became an important alternative. Higher plants have been 
proved to be a potential source for new antimicrobial agents (Mitscher et al., 
1987). Plant based natural constituents can be derived from any part of the plant 
like bark, leaves, flowers, roots, fruits, seeds, etc (Gordon and David, 2001) i.e. 
any part of the plant may contain active components.  Knowledge of the chemical 
constituents of plants is desirable because such information may be of value for 
the synthesis of complex chemical substances.  
There are many approaches to the search for new biologically active principles in 
higher plants (Farnsworth and Loub, 1983). Several reviews pertaining to 
approaches for selecting plants as candidates for drug discovery programs have 
been published (Farnsworth, 1966; Farnsworth and Bingel, 1977; Farnsworth, 
1984; Phillipson and Anderson, 1989; Kinghorn, 1994; Clark, 1996; Harvey, 
2000; Newman et al., 2000). Different approaches include (i) Random selection 
followed by chemical screening, (ii) Random selection followed by one or more 
biologic assays, (iii) Follow-up of biologic activity reports, (iv) Follow-up of 
ethnomedical uses of plants, (v) Plants used in organized traditional medical 
systems and (vi) Use of databases (Fabricant and Farnsworth, 2001). 
Scientific analysis of plant components follows a logical pathway. Plants are 
collected either randomly or by following leads supplied by local healers. Random 
collection is to collect readily available plant, prepare extracts, and test each 
extract for one or more types of pharmacological activity. This, broad screening 
method is a reasonable approach that eventually should produce useful drugs. 
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Initial screening of plants for possible antimicrobial activities typically begins by 
using crude aqueous or alcohol extraction method and can be followed by various 
organic extraction methods. Since nearly all of the identified components from 
plants which are active against microorganisms, are aromatic or saturated 
organic compounds, they are often obtained through initial ethanol or methanol 
extraction (Vileges et al., 1997). The research on the medicinal plants should be 
extended with the identification of the active principles in the plants. Scientific 
examination of the remedies could lead to standardization and quality control of 
the products to ensure their safety. It is after such evaluations that they can be 
approved for use in the primary health care. Such research activities could also 
lead to the development of new drugs. 
With the development of various analytical methods of high precision, and 
advances in molecular biology and genetic engineering, it is now possible to 
isolate compounds in extremely small quantities, study their chemical structure 
and therapeutic potentialities and then to alter the molecule to be suitable for 
production of novel and more selective new therapeutic agents. A number of 
active constituents have been isolated from plants like Azardirachta indica 
(Randhawa and Parmar, 1993), Senna alata (Adedayo, 2001), Terminalia 
bellerica (Elizabeth, 2005).
Major pharmaceutical companies are currently conducting extensive research on 
plant materials and encourage large scale pharmacological screening of herbs. 
Natural products to be used in pharmaceutical preparations are either pure 
compounds or extracts.  The screening of plant extracts has been of great 
interest to scientist for the discovery of new drugs effective in the treatment of 
several diseases (Dimayuga and Garcia, 1991). Extraction of bioactive 
compounds from medicinal plants permits the demonstration of their 
physiological activity and facilitates pharmacology studies leading to synthesis of 
a more potent drug with reduced toxicity (Pamplona-Roger, 1999; Manna and 
Abalaka, 2000).  Many reports concerning the antibacterial screening of plant 
extracts of medicinal plants have appeared in the literature (Vlietinck et al., 1995; 
Lin et al., 1999; Janovska et al., 2003; Geyid and Andualem, 2005; Parekh et al., 
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2005; Parekh and Chanda, 2006). 
1.8 PHYTOMEDICINAL ACTIONS 
The beneficial medicinal effects of phytomedicines typically result from 
synergistic actions of secondary products present in the plants (Wink, 1999). 
Plant secondary products have a defensive role against pathogen attack, an 
attractant role towards pollinators, protective actions to abiotic stresses such as 
temperature, water status, light levels, UV exposure and mineral nutrients and its 
role at cellular level as plant growth regulators, modulators of gene expression, 
and in signal transduction have also been shown (Kaufman et al., 1999; Wink, 
1999). In contrast to synthetic pharmaceuticals based upon single chemicals, 
many phytomedicines exert their beneficial effects through the additive or 
synergistic action of several chemical compounds acting at single or multiple 
target sites assiociated with a physiological process. This synergistic or additive 
pharmacological effect can be beneficial by eliminating the problematic side 
effects associated with the predominance of a single xenobiotic compound in the 
body (Tyler, 1999). In the role of secondary products as defence chemicals, a 
mixture of chemicals having additive or synergistic effects at multiple target sites 
would not only ensure effectiveness against a wide range of herbivores or 
pathogens but would also decrease the chances of these organisms developing 
resistance or adaptive responses (Kaufman et al., 1999; Wink, 1999).
1.9 PHYTOMEDICINE: A STRATEGY FOR FUTURE
stFor future drug development in the 21  century, research should focus not only on 
bioactive principles (lead compounds or leads), but also on active fractions and 
active formulations from medicinal herbs.
In vitro screening programmes, using Ethnobotanical approach, are important in 
validating the traditional use of herbal remedies and for providing leads for newer 
drugs. The activity identified by an in vitro test provides a basic understanding of a 
plant's efficacy but it does not necessarily confirm that a plant extract is an 
effective medicine or a suitable candidate for drug development. Certainly this is a 
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primary concern of ethnopharmacological research in developing new lead 
compounds. Scientific validation of use of herbal medicine lends support to the 
continued practice of traditional medicine. Eventually this may lead to more 
widespread use of traditional medicine in health care system, as in India and 
China provided thorough toxicological investigations are carried out (Myers, 
1984).
The purpose of the present research work is to screen the extracts of some 
randomly selected plant species from the Saurashtra region of western India that 
could be useful for the development of new tools for the control of infections and 
diseases. While pursuing this goal, a systematic evaluation of aqueous and 
alcoholic extracts of 108 randomly selected plant extracts against a diverse range 
of bacteria, fungi and yeast was done. Further, the most active plant extract was 
selected for investigation of pharmacognostical analysis, phytochemical 
analysis, toxicological studies and pharmacological studies.
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2.1 INTRODUCTION
Infectious diseases caused by bacteria, fungi, viruses and parasites are still a 
major threat to public health, despite the tremendous progress in human 
medicine. Their impact is particularly large in developing countries due to the 
relative unavailability of medicines and the emergence of widespread multiple 
drug resistance due to indiscriminate use of commercial antimicrobial drugs 
commonly employed in the treatment of infectious diseases (Okeke et al., 2005). 
Moreover, antimicrobial drugs are sometimes associated with adverse effects on 
the host including hypersensitivity, immune-supression and allergic reactions 
(Ahmad et al., 1998). Research on new antimicrobial substances must therefore 
be continued and all possible strategies should be explored. Besides small 
molecules from medicinal chemistry, natural products are still major sources of 
innovative therapeutic agents for various conditions, including infectious 
diseases (Clardy and Walsh, 2004). The success story of chemotherapy 
therefore lies in the continuous search for new drugs to counter the challenge 
posed by resistant strains of microorganisms. Current research on natural 
molecules and products primarily focuses on plants since they can be sourced 
more easily and be selected on the basis of their ethno-medicinal use (Verpoorte 
et al., 2005). 
Medicinal plants, which form the backbone of traditional medicine, have in the last 
few decades been the subject of very intense pharmacological studies (Zakaria, 
1991; Nascimento, 2000; Bonjar SGH, 2004; Kuzmaa, 2007; Parekh and 
Chanda, 2007a). In this connection, higher plants continue to be a rich source of 
therapeutic agents since they produce hundreds to thousands of diverse 
chemical compounds as secondary metabolites with different biological activities 
(Hamburger and Hostettmann, 1991). The compounds produced by plants are 
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active against plant and human pathogenic microorganisms (Mitscher et al., 
1987). The remarkable contribution of plants to the drug industry was possible, 
because of the large number of phytochemical and biological studies carried out 
all over the world. 
Herbal remedies used in the folk medicine provide an interesting and still largely 
unexplored source for the creation and development of potentially new drugs for 
chemotherapy which might help overcome the growing problem of resistance and 
also the toxicity of the currently available commercial antibiotics. From an 
estimated 250,000 higher plants in the world (Wilson, 1988), only 5-15 % have 
been studied for a potential therapeutic value (Balandrin et al., 1985; Kinghorn, 
1992). A large number of plant species remain yet to be investigated. Therefore it 
is of great interest to carry out screening of the unexplored plants in order to 
validate their use in folk medicine and to reveal the active principle by isolation 
and characterization of their constituents (Kianbakht and Jajaniani, 2003). 
Initial screening of plants for possible antimicrobial activities typically begins by 
using crude aqueous or alcohol extraction and can be followed by various organic 
extraction methods. Since nearly all of the identified components from plants, 
active against microorganism are aromatic or saturated organic compounds, they 
are often obtained through initial ethanol or methanol extraction (Vilegs et al., 
1997, Parekh et al., 2005). The screening of plant crude extracts and plant 
products for antimicrobial activity has shown that higher plants represent a 
potential source of novel antibiotic prototypes (Maurer-Grimes et al., 1996; Rabe 
and van Staden, 2000; Srinivasan et al., 2001; Zgoda-Pols et al., 2002; Afolayan, 
2003; Nair et al., 2004; Elizabeth, 2005; Parekh et al., 2005; Prashanth Kumar, 
2006; Parekh and Chanda, 2006a; Parekh and Chanda, 2007b). Validation and 
selection of primary screening assays are pivotal to guarantee sound selection of 
extracts or molecules with relevant pharmacological action and worthy follow-up.
In the light of recent problems of multiple drug resistance and intractable microbial 
diseases, the need to find new entities with antimicrobial properties becomes 
pertinent. The present work encompasses the screening of aqueous and 
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methanol/ethanol extracts of 108 plant species randomly colleted, for their 
antibacterial property against a wide array of microorganisms. Further, the most 
active plant extracts showing best antibacterial activity were screened for 
antifungal activity. The most promising plant extract was selected for further 
phytochemical and pharmacological activities. This is in pursuance of the efforts 
to search for drugs from plants and the verification of the scientific basis of some 
known practices in traditional medicine.
2.2 MATERIALS AND METHODS
2.2.1 ANTIBACTERIAL SCREENING
2.2.1.1 Plant collection
Fresh plants/plant parts were collected randomly from the semi-arid region of 
western Saurashtra, Gujarat, India. The taxonomic identities of these plants were 
confirmed by Dr. P. S. Nagar and Dr. N. K. Thakrar, Department of Biosciences, 
Saurashtra University, Rajkot. The ethnobotanical information on all the 
plants/plant parts collected for screening along with the voucher specimen 
numbers and their therapeutic uses are reported in Table 2.1. Fresh plant 
materials were washed under running tap water, air dried and homogenized to 
fine powder and stored in air-tight bottles.
2.2.1.2 Preparation of crude plant extract
2.2.1.2.1 Aqueous extraction
Ten grams of dried plant material was extracted in distilled water for 6 h at slow 
heat. After every two hours it was filtered through eight layers of muslin cloth and 
centrifuged at 5000 rpm for 15 min. The supernatant was collected. This 
procedure was repeated twice and after 6 h, the supernatant was concentrated to 
make the final volume one-fifth of the original volume. The extract was then 
autoclaved at 121°C and 15 lbs pressure and stored at 4°C (Parekh et al., 2005).
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2.2.1.2.2 Solvent extraction
Ten grams of dried plant material was extracted with 100 ml of ethanol/ methanol 
kept on a rotary shaker for 24 h at room temperature. Thereafter, it was filtered and 
centrifuged at 5000 rpm for 15 min. The supernatant was collected and the solvent 
was evaporated to make the final volume one-fifth of the original volume (Parekh 
et al., 2005). It was stored at 4°C in airtight bottles for further studies.
2.2.1.3 Bacterial strains and growth conditions
The investigated microbial strains are identified strains and were obtained from 
the National Chemical Laboratory (NCL), Pune, India. The test microorganisms 
include 5 Gram-positive bacteria Bacillus cereus ATCC11778, Bacillus 
megaterium ATCC9885, Bacillus subtilis ATCC6633, Staphylococcus aureus 
ATCC25923, Staphylococcus epidermidis ATCC12228 and Staphylococcus 
subfava NCIM2178; 9 Gram-negative bacteria Alcaligenes fecalis ATCC8750, 
Enterobacter aerogenes ATCC13048, Escherichia coli ATCC25922, Klebsiella 
pneumoniae NCIM2719, Proteus mirabilis NCIM224, Proteus vulgaris 
NCTC8313, Pseudomonas aeruginosa ATCC27853, Pseudomonas 
pseudoalcaligenes ATCC17440 and Salmonella typhimurium ATCC23564 and    
1 yeast Candida tropicalis ATCC4563. Bacterial cultures were grown on nutrient 
broth (Hi-Media) at 37°C for 24 h and yeast was grown on sabouraud dextrose 
broth (Hi-Media) at 28°C for 48 h. All the microbial cultures were maintained at 4°C 
on nutrient agar slants (for bacteria) and MGYP slants (for yeast).
2.2.1.4 Assay for antibacterial activity
2.2.1.4.1 Preparation of inoculum
The test bacterial strains were inoculated into nutrient broth and were incubated at 
37°C on shaker while yeast culture was inoculated into sabouraud dextrose broth 
and incubated at 28°C on shaker. The inoculum size was maintained as per 0.5 
8 McFarland standard (1x10 cfu/ml). The activated inoculum was used for 
antibacterial assay.
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2.2.1.4.2 Antibacterial susceptibility testing
2.2.1.4.2.1 Agar disc diffusion method 
The screening of aqueous extracts of different plant species for antibacterial 
activity was determined by agar disc diffusion method (Bauer et al., 1966; Parekh 
and Chanda, 2006b). The molten Mueller Hinton Agar No. 2 media (Hi-Media) 
8was inoculated with 200 µl of the inoculum (1x10  cfu/ml) when the temperature of 
media reached 40-42°C and then poured into the Petri plate (Hi-Media). Sterile 
disc (7 mm) (Hi-Media) was saturated with 100 µl of the extract and allowed to dry.  
The disc was then introduced on the upper layer of the seeded agar plate. For 
each bacterial strain controls were maintained where pure solvents were used 
instead of the extract.  The plates were incubated at 37°C for 24 h. The result of 
antibacterial activity was obtained by measuring the diameter of the zone of 
inhibition. The experiment was performed under strict aseptic conditions for three 
times to minimize error and the mean values are presented in Table 2.2. 
2.2.1.4.2.2 Agar well diffusion method
The screening of alcoholic extracts of different plant species for antibacterial 
activity was determined by agar well diffusion method (Perez et al., 1990; Parekh 
et al., 2005). The molten Mueller Hinton Agar No. 2 media (Hi-Media) was 
8inoculated with 200 µl of the inoculum (1x10  cfu/ml) when the temperature of 
media reached 40-42°C and then poured into the Petri plate (Hi-Media). After the 
media was solidified, a well was prepared in the plates with the help of a cup-borer 
(8.5 mm). The well was filled with 100 µl of the extract. For each bacterial strain 
controls were maintained where pure solvents were used instead of the extract.  
The plates were incubated at 37°C for 24 h. The result of antibacterial activity was 
obtained by measuring the diameter of the zone of inhibition. The experiment was 
performed under strict aseptic conditions for three times to minimize error and the 
mean values are presented in Table 2.2.
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2.2.2 ANTIFUNGAL SCREENING
2.2.2.1 Plant selection
The primary screening of 108 plant species for antibacterial property yielded 
many active plant extracts. Amongst them, 20 most active plant extracts were 
selected for further screening for antifungal property. The selected plants are 
listed in Table 2.3. 
2.2.2.2 Preparation of crude plant extract
Ten grams of dried plant material was extracted with 100 ml of methanol and kept 
on a rotary shaker for 24 h at the room temperature. Thereafter it was filtered and 
centrifuged at 5000 rpm for 15 min. The supernatant was collected and 
evaporated to dryness to give the crude dried extract (Parekh and Chanda, 
2006b). The extractive yield (%) of all the plant extracts is shown in Table 2.3.
2.2.2.3 Fungal strains used
The investigated fungal strains are identified strains and were obtained from the 
National Chemical Laboratory (NCL), Pune, India. The test fungal strains include 
7 yeasts viz. Candida albicans (1) ATCC2091, Candida albicans (2) ATCC18804, 
Candida glabrata NCIM3448, Candida tropicalis ATCC4563, Cryptococcus 
luteotus ATCC32044, Cryptococcus neoformans ATCC34664, Trichosporon 
beigelli NCIM3404, and 4 moulds viz. Aspergillus candidus NCIM883, Aspergillus 
flavus NCIM538, Aspergillus niger ATCC6275 and Mucor heimalis NCIM873. The 
fungal strains were grown on sabouraud broth and maintained on MGYP slants 
(yeast) and potato dextrose agar slants (mould) at 4°C. 
2.2.2.4 Assay for antifungal activity
2.2.2.4.1 Preparation of inoculum
The test fungal strains were inoculated into sabouraud dextrose broth and 
incubated at 28°C on a rotary shaker. The inoculum size was maintained as per 
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8the 0.5 McFarland standard (1x10  cfu/ml). The activated inoculum was used for 
antifungal assay.
2.2.2.4.2 Preparation of test compound
The methanol extracts of selected plant species were diluted in 100 % 
dimethylsulphoxide (DMSO) and the stocks were prepared at the concentration of 
25mg/ml, 12.5 mg/ml and 6.75 mg/ml. The antifungal activity was evaluated at 
three different concentrations viz. 500 µg/disc, 250 µg/disc and 125 µg/disc.
2.2.2.4.3 Antifungal susceptibility testing
The screening of methanol extracts of selected plant species for antifungal 
activity was determined by agar disc diffusion method (Bauer et al., 1966; Parekh 
and Chanda, 2006b). The molten sabouraud dextrose agar media (Hi-Media) was 
8inoculated with 200 µl of the inoculum (1x10  cfu/ml) when the temperature of 
media reached 40-42°C and then poured into the Petri plate (Hi-Media). Sterile 
disc (7 mm) (Hi-Media) was saturated with 20 µl of the extract with the 
concentration of 500 µg/disc, 250 µg/disc and 125 µg/disc and allowed to dry.  
The disc was then introduced on the upper layer of the seeded agar plate. For 
each fungal strain, controls were maintained where pure solvents were used 
instead of the extract. The plates were incubated at 28°C for 48 h. The result of 
antifungal activity was obtained by measuring the diameter of the zone of 
inhibition. The experiment was performed under strict aseptic conditions for three 
times to minimize error and the mean values are presented in Tables 2.4a and 
2.4b. 
2.3 RESULTS AND DISCUSSION
2.3.1 Antibacterial screening
Although India possesses a rich tradition in the use of medicinal plants and an 
outstanding flora diversity of vascular plants, little research has been done in the 
context of phytochemical leads for therapeutic use. The present study 
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demonstrated that the medicinal knowledge held by the Indian native people is 
relatively measurable in laboratory-based assays. Moreover, to address the 
present situation of microbial resistance to antimicrobial agents, evaluation of 108 
different plant species from western region of Saurashtra (India) was carried out 
for potential anti-infective property.
The ethno-botanical details of the plants screened in this work are shown in Table 
2.1. As indicated, in some cases leaves, stem, root, bark, rhizomes or whole plant 
was extracted as it is already known that any part of the plant may contain active 
constituents (Gordon and David, 2001). In all a total of 216 extracts (aqueous and 
methanol/ethanol) of 108 different plant species belonging to 54 different families 
were screened for potential antimicrobial activity. Out of 216 extracts, 143 plant 
extracts (35 aqueous and 108 methanol/ethanol) showed activity against at least 
one of the tested microorganism.  Although plants differed significantly in their 
activities against microorganisms tested, more of the extracts showed 
antibacterial activity against Gram-positive bacteria than Gram-negative bacteria 
(Rabe and van Staden, 1997; Parekh et al., 2005). Amongst aqueous and 
methanol/ethanol extracts of the studied plant species, methanol/ethanol extracts 
were found to be more active against the test microbial strains than the aqueous 
extracts (Table 2.2). 
Some commonly encountered pathogens have been associated with some of the 
human diseases. The Gram-positive bacterium Bacillus subtilis occasionally 
produce diseases such as meningitis, endocarditis, endophthalmitis, 
conjunctivitis or acute gastroenteritis in immunocompromised patients. Bacillus 
cereus is a spore forming pathogen associated with various opportunistic clinical 
infections (Boyd, 1995). Staphylococcus aureus is a facultatively anaerobic, 
Gram-positive bacteria which causes food poisoning and usually grow on the 
nasal membranes and skin. It also causes boils, abscesses, wound infection, 
pneumonia, endocarditis, osteomyelitis, toxic shock syndrome and other 
diseases (Cheesbrough, 2000). The Gram-negative bacterium Escherichia coli is 
present in human intestine and causes lower urinary tract infection, coleocystis or 
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septicemia (Levine, 1987; Singh et al., 2000). Proteus mirabilis which is also 
Gram-negative motile rod, causes urinary tract infections in the elderly and young 
males often following catheterization or cystoscopy, wound infection also often as 
a secondary invader of ulcer, pressure sores, burn and damaged tissue and 
septicemia and occasionally meningitis and chest infections (Cheesbrough, 
2000). Salmonella typhi  is also a pathogenic bacteria causing enteric fevers such 
as typhoid and paratyphoid, gastroenteritis and septicemia (Cheesbrough, 2000). 
Infections caused by Pseudomonas aeruginosa are among the most difficult to 
treat with conventional antibiotics (Levison and Jawetz, 1992). P. aeruginosa is 
the most prevalent pathogen capable of causing life-threatening illnesses (Lory, 
1990). This bacterium can cause clinically significant infections such as wounds 
and burn infections, when it is introduced by lumbar punctures and urinary tract 
infections when introduced by catheters and instruments or irrigating solutions 
(Murray et al., 1990). In infants or debilitated persons the bacterium may invade 
the blood stream and result in fatal condition (Lory, 1990). Some strains causing 
septicemia and pneumonia in cystic fibrosis and immunocompromised patients 
are becoming difficult to treat with currently available antimicrobial agents (Senda 
et al., 1996). This organism is one of the most common pathogens associated 
with bacterial corneal ulcers. Keratitis due to this pathogen also has been 
observed in those who wear extended-wear contact lenses (Lory, 1990).  The 
yeast Candida albicans is common commensals of the gastrointestinal and 
urogenital tracts of human (Black, 1996; Cheesbrough, 2000) and is the cause of 
candidiasis in woman (Demarch et al., 1995). 
The present investigation revealed that all the plant species from 54 families 
showed varied levels of antimicrobial activity against tested microorganisms 
(Table 2.2). Acanthaceae (2 plants) inhibited 28.33 %  of the  tested 
microorganisms; Amaranthaceae (2 plants) inhibited 25 %; Anacardiaceae          
(1 plant) inhibited 70 %; Apocynaceae (5 plants) inhibited 31.33 %; Araceae         
(1 plant) inhibited 33.33 %; Aristolochiaceae (1 plant) inhibited 20 %; 
Asclepiadaceae (2 plants) inhibited 18.33 %; Asteraceae (5 plants) inhibited 
26.66 %; Balanitaceae (1 plant) inhibited 33.33  %; Bignonaceae (2 plants) 
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inhibited 23.33 %; Caesalpiniaceae (7 plants) inhibited 39.52 %; Capparidaceae 
(1 plant) inhibited 20 %; Casuarinaceae (1 plant) inhibited 73.33 %; 
Chenopodiaceae (3 plants) inhibited 13.33 %; Combretaceae (2 plants) inhibited 
68.33 %; Commelinaceae (1 plant) inhibited 10 %; Connaraceae (1 plant) 
inhibited 26.67 %; Convolvulaceae (3 plants) inhibited 16.67 %; Cruciferae          
(1 plant) inhibited 8.33 %; Cucurbitaceae (3 plants) inhibited 22.22 %; 
Cyperaceae (2 plants) inhibited 35 %; Ehretiaceae (1 plant) inhibited 33.33 %; 
Euphorbiaceae (4 plants) inhibited 50 %; Fabaceae (10 plants) inhibited 22.33 %; 
Fumariaceae (1 plant) inhibited 30 %; Gentianaceae (1 plant) inhibited 33.33 %; 
Guttiferae (1 plant) inhibited 33.33 %; Labiatae (4 plants) inhibited 25 %; 
Lauraceae (1 plant) inhibited 36.67 %; Liliaceae (2 plants) inhibited 23.33 %; 
Lythraceae (2 plants) inhibited 60 %; Malvaceae (2 plants inhibited 28.33 %; 
Moraceae (3 plants) inhibited 21.12 %; Musaceae (1 plant) inhibited 36.67 %; 
Casuarinaceae (1 plant) inhibited 73.33 %; Myrsinaceae (1 plant) inhibited 40 %; 
Myrtaceae (1 plant) inhibited 66.67 %; Oleaceae (1 plant) inhibited 23.33 %; 
Pedaliaceae (1 plant) inhibited 30 %; Piperaceae (2 plants) inhibited 30 %; 
Plumbaginaceae (1 plant) inhibited 40 %; Poaceae (3 plants) inhibited 22.22 %; 
Rubiaceae (1 plant) inhibited 26.67 %; Santalaceae (1 plant) inhibited 26.67 %; 
Sapindaceae (1 plant) inhibited 10 %; Sapotaceae (1 plant) inhibited 60 %; 
Scitaminaceae (1 plant) inhibited 33.33 %; Scrophulariaceae (1 plant) inhibited 
30 %; Solanaceae (2 plants) inhibited 15 %; Thujaceae (1 plant) inhibited 30 %; 
Trapaceae (1 plant) inhibited 73.33 %; Umbelliferae (2 plants) inhibited 25 %; 
Verbenaceae (3 plants) inhibited 23.33 %; Vitaceae (2 plants) inhibited 50 % and 
Zygophyllaceae (1 plant) inhibited 33.33 % of the tested microorganisms. 
Amongst the 15 microbial strains tested, the most susceptible bacteria was           
B. cereus  which is a Gram-positive bacteria and the most resistant bacteria was 
E. coli  which is a Gram-negative bacteria. The results (Table 2.2) obtained from 
screening showed that 47.03 % Gram-positive bacteria while 23.62 % Gram-
negative bacteria were inhibited by the aqueous as well as methanol/ethanol 
extracts. The aqueous extracts were active against 26.11% Gram-positive 
bacteria and 11.12 % Gram-negative bacteria whereas the methanol/ethanol 
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extracts were active against 67.96 % Gram- positive bacteria and 36.12 % Gram-
negative bacteria.  Amongst 108 plant species, the most active plant was 
Terminalia chebula Retz. while the most inactive plant was Solanum surattense 
Burm.f.  
For Gram-positive bacteria, the results (Table 2.2) showed that 58.33 % extracts 
(29.63 % of aqueous extract and 87.04 % of methanol/ethanol) were active 
against B. cereus; 49.07 % extracts (17.6 % of aqueous extract and 80.55 % of 
methanol/ethanol) were active against B. subtilis; 40.74 % extracts (37.96 % of 
aqueous extract and 43.52 % of methanol/ethanol) were active against                 
S. aureus, 35.18 % extracts (29.63 % of aqueous extract and 40.74 % of 
methanol/ethanol) were active against S. epidermidis and  51.84 % extracts 
(15.74 % of aqueous extract and 87.96 % of methanol/ethanol) were active 
against S. subfava. For Gram-negative bacteria, the results showed that 25 % 
extracts (12.96 % of aqueous extract and 37.03 % of methanol/ethanol) were 
active against A. fecalis; 15.74 % extracts (2.77 % of aqueous extract and 28.70 
% of methanol/ethanol) were active against E. aerogenes; 7.40 % extracts (1.85 
% of aqueous extract and 12.96 % of methanol/ethanol) were active against         
E. coli; 54.16 % extracts (22.22 % of aqueous extract and 86.12 % of 
methanol/ethanol) were active against K. pneumoniae; 53.70 % extracts (25 % of 
aqueous extract and 82.40 % of methanol/ethanol) were active against                  
P. mirabilis; 16.67 % extracts (4.63 % of aqueous extract and 28.70 % of 
methanol/ethanol) were active against P. vulgaris; 12.96 % extracts (4.63 % of 
aqueous extract and 21.30 % of methanol/ethanol) were active against                  
P. aeruginosa; 17.12 % extracts (16.67 % of aqueous extract and 17.60 % of 
methanol/ethanol) were active against P. pseudoalcaligenes and 9.72 % extracts 
(9.25 % of aqueous extract and 10.18 % of methanol/ethanol) were active against 
S. typhimurium. For an yeast strain, 18.98 % extracts (0.93 % of aqueous extract 
and 37.03 % of methanol/ethanol) were active against C. tropicalis.
Successful prediction of botanical compounds from plant material is largely 
dependent on the type of solvent used in the extraction procedure. Traditional 
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healers use primarily water as solvent but in the present study it was observed 
that the plant extracts extracted in organic solvent (methanol or ethanol) showed 
profoundly distinct antibacterial activity than aqueous extract. This shows that the 
active components are better soluble in organic solvent as also suggested by de 
Boer et al., (2005). These observations can be rationalized in terms of the polarity 
of the compound being extracted by each solvent and, in addition to their intrinsic 
bioactivity, by their ability to dissolve or diffuse in the media used in the assay.  
The growth media also seem to play an important role in the determination of the 
antibacterial activity. Lin et al., (1999) reported that Mueller-Hinton agar appears 
to be the best medium to explicate the antibacterial activity and the same was 
used in the present study.
In general, the plant antibiotic substances appear to be more inhibitory to Gram-
positive organisms that to the Gram-negative type since Gram-negative bacteria 
can be accounted for the presence of thick murein layer, which prevents the entry 
of inhibitors (Martin, 1995). In present findings also Gram-positive bacteria were 
found to be more susceptible than Gram-negative bacteria. This could be due to 
the fact that the cell wall of Gram-positive bacteria is less complex and lack the 
natural sieve effect against large molecules due to the small pores in their cell 
envelope (Hawkey, 1998; Gould and Booker, 2000; Parekh et al., 2005; Parekh 
and Chanda, 2006c; Parekh and Chanda, 2007a).  The fact that extracts are 
more active against Gram-positive bacteria can be attributed to the fact that the 
cell wall of the Gram-positive bacteria is easier to penetrate than that of Gram-
negative bacteria (Rang et al., 1987). Also the organic solvents extracts of all the 
plant species were found to have good activity against bacteria than yeast.  
These differences in the activity may be due to the difference in the cell wall 
pattern (Ozcelik , 1998; Yao and  Moellering, 1995). 
The negative results obtained against Gram-negative bacteria were not 
unexpected since this class of bacteria is usually more resistant than Gram-
positive bacteria (Tomas-Barberan et al., 1988). Antimicrobial extracts from 
plants can be assumed to be useful in combating infectious diseases. Therefore, 
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there is a compelling reason to suppose that anti-infective agents could be active 
against human pathogens as was suggested by folkloric and historical accounts 
(Kirtikar and Basu, 1968; Nandkarni, 1976).
The present investigation justified the folklore use of some plant species. The 
potential for developing antimicrobial drug through screening of higher plants is 
rewarding as it will lead to the development of a phytomedicine to act against 
microbes (Hostettmann and Terreaux, 2000). Plant based antimicrobials have 
enormous therapeutic potential as they can serve the purpose without any side 
effects that are often associated with synthetic compounds (Hamburger and 
Hostettmann, 1991).  The most active plant extracts was further subjected for the 
evaluation of antifungal potency.
2.3.2 Antifungal screening
Fungal infections remain a significant cause of morbidity and mortality despite 
advances in medicine and the emergence of new antifungal agents (McNeil et al., 
2001). Immunocompromised patients are particularly at risk of developing these 
infections with Candida and Aspergillus spp. as mycoses being the most 
commonly identified (Florea et al., 2002). Patients who develop candidemia have 
a greater chance of prolonged hospitalization and have a mortality rate as high as 
60%. Also the prevalence of Candida spp. that are resistant to triazole antifungal 
agents is increasing, making treatment options a concern. Aspergillosis carries a 
100% mortality rate if left untreated (Denning, 2000). In addition to this, there is a 
high incidence of cryptococcal infections which can be due to the explosion of 
acquired immune deficiency syndrome (AIDS) epidemic around the world and the 
use of more potent immunosuppressive agents by increasing numbers of organ 
transplant recipients (Mitchell and Perfect, 1995; Dromer et al., 1996). 
Cryptococcal meningitis, the most common infection of cryptococcosis is usually 
chronic and uniformly fatal if untreated (Collazos, 2003). 
Some antifungal drugs, such as polyene macrolides (amphotericin-B) and azoles 
(itraconazole and fluconazole) are currently used in antifungal therapies with 
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certain limitations due to side effects as toxicity and emergence of resistant 
strains (Terrel, 1999; Saag et al., 2000). Although there are numerous treatment 
options, no broad-spectrum antifungal agents with an acceptable safety profile 
and with both intravenous and oral formulations are available at this time. These 
factors prompt the need for development of new antifungal agents in order to 
widen the spectrum of activities against pathogenic fungal species and combat 
strains expressing resistance to the available antifungals (Selitrennikoff, 2001).  
The methanol extracts of twenty selected medicinal plants were screened for 
antifungal activity against 11 fungal strains.  The extractive yields of the selected 
plants are summarized in Table 2.3. The results of antifungal activity of screened 
plant species against some strains of yeast is shown in Table 2.4a and that 
against moulds are shown in Table 2.4b. The antifungal activity was evaluated at 
three different concentrations (500 µg/disc, 250 µg/disc and 125 µg/disc). The 
moulds were more susceptible than yeast.  All the concentrations of the extracts 
investigated, inhibited the fungal species with varying degree of sensitivity. 
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Table 2.3 Extractive yields (%) of the plant species selected for determining 
antifungal activity 
 
Plant species 
Ammannia baccifera L. 
Bauhinia variegata L. 
Caesalpinia pulcherrima (L.) Swartz. 
Casuarina equissetifolia Forest. 
Cyperus rotundus L. 
Euphorbia hirta L. 
Euphorbia tirucalli L. 
Eucalyptus citriodora Hook. 
Glycyrrhiza glabra L. 
Holarrhena antidysenterica (Heyne. ex Roth.) A. DC. 
Launaea procumbens Ram. & Raj. 
Manilkara hexandra (Roxb.) Dubard 
Mangifera indica L.  
Mesua ferra L. 
Saussurea lappa Costus. 
Terminalia chebula Retz. 
Trapa natans L. 
Vitex negundo L. 
Vitis vinifera L. 
Woodfordia fruticosa kurz. 
Extractive yield (%) 
08.13 
05.46 
10.27 
13.17 
07.35 
09.70 
08.10 
21.33 
11.90 
15.60 
09.43 
19.98 
10.58 
07.29 
11.56 
36.92 
02.49 
13.48 
07.00 
20.93 
Ahmad et al., (1998) and Sengul et al., (2005) reported that methanol was a better 
solvent for the consistent extraction of antimicrobial substances from medicinal 
plants compared to other solvents such as water, ethanol, and hexane.  Our work 
also supported this conclusion (Parekh and Chanda, 2006c). Therefore methanol 
was used for plant extraction in this study and antimicrobial activities were 
quantitatively assessed by the presence or absence of inhibition zone and zone 
diameters.
Amongst  Candida spps., Candida glabrata  was the most resistant strain 
followed by Cryptococcus neoformans and Candida tropicalis. The methanol 
extracts of Glycyrrhiza glabra showed moderate activity against Candida 
glabrata, that of Eucalyptus citriodora, Holarrhena antidysentrica, Trapa natans 
and Woodfordia fruticosa showed some activity against Candida tropicalis at the 
lowest concentration (125 µg/disc). The higher concentrations (500 and 250 
µg/disc) of all the screened plants did not show any activity against Candida 
albicans (1) and Candida albicans (2) except Glycyrrhiza glabra extract which 
was active against both these strains while Bauhinia variegata extract was active 
against Candida albicans (1) (Table 2.4a).
Similarly the higher concentrations (500 and 250 µg/disc) of all the screened 
plants did not show any activity against Cryptococcus luteolus and Cryptococcus 
neoformans. These were resistant to most of the screened plant extracts except 
Trapa natans and Woodfordia fruticosa which showed slight activity at two lower 
concentrations (250 and 125µg/disc) (Table 2.4a).
The most susceptible yeast was Trichosporon begelli. All the 3 concentrations of 
all the plant extracts showed some activity against this fungal strain but to a varied 
degree. Euphorbia hirta, Trapa natans, Vitis vinifera extracts were active only at 
the lowest concentration. The methanol extract of Holarrhena antidysentrica, 
Bauhinia variegata and Glycyrrhiza glabra, showed best antifungal activity 
against Trichosporon begelli. Bauhinia variegata, Caesalpinia pulcherrima, 
Casuarina equissetifolia, Meusa ferra, Mangifera indica, Woodfordia fruticosa, 
Saussurea lappa, Terminalia chebula and Glycyrrhiza glabra showed antifungal 
60
Chapter 2 Results & Discussion
activity in all the three concentrations against Trichosporon begelli. Poor activity 
was shown by Cyperus rotundus and Trapa natans (Table 2.4a). These two plants 
showed good antibacterial activity (Parekh and Chanda, 2006b; Parekh and 
Chanda, 2006c) but they turned out to be poor antifungal agents. 
The inability of the extracts to inhibit the growth of Candida spps. in the 
experiment showed that the plant drug cannot be used in treatment of fungal 
infections, like eczema, candidiasis which is caused by Candida albicans.
The methanolic extracts of all the screened plants showed good antifungal 
activity against the strains of moulds screened (Table 2.4b). The three Aspergillus 
spps. were more susceptible than Mucor heimalis.  The lowest concentration of 
all the plants almost did not show any activity against Aspergillus candidus and 
Mucor heimalis, while the other two higher concentrations showed good 
antifungal activity. The lowest concentration of all the plants showed good 
antifungal activity against Aspergillus flavus while the highest concentration 
showed inhibitory effect against Aspergillus flavus and Aspergillus niger.  
The effect of plant extracts was different with different fungal strains.  The 
methanolic extracts of Caesalpinia pulcherrima, Cyperus rotundus and 
Woodfordia fruticosa showed best antifungal activity against Aspergillus 
candidus.  Manilkara hexandra showed the best antifungal activity against 
Aspergillus flavus followed by Eucalyptus citriodora, Ammania baccifera, 
Glycyrrhiza glabra and Trapa natans. The methanolic extract of Bauhinia 
variegata followed by Holarrhena antidysentrica, Eucalyptus citriodora and 
Euphorbia tirucalli showed best antifungal activity against Aspergillus niger and 
Glycyrrhiza glabra was the best plant active against Mucor heimalis. The most 
resistant mould was Mucor heimalis where only highest concentration i.e.          
500 µg/disc showed activity in almost all the plant extracts. Amongst all the plant 
extracts screened, Glycyrrhiza glabra and Bauhinia variegata extracts showed 
remarkable antifungal activity against all the tested moulds in all the three 
concentrations. The minimum antifungal activity was shown by methanol extract 
of Ammania baccifera (Table 2.4b). 
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The overall results suggest that Aspergillus flavus was the most susceptible 
fungal strain and the most resistant was Candida glabrata. The results of 
antifungal activity of the screened plants did not show any concentration effect.  
Certainly indigenous plants are reservoirs of novel antimicrobials; they would play 
important roles in providing us with newer bioactive leads in future.  Plants with 
high anti-mould activity presented here or in similar studies would act as bedrocks 
for expanding our knowledge to attain novel antimicrobial agents. 
2.4 CONCLUSIONS
From our investigation for screening of different plant species for antibacterial and 
antifungal potency, the results obtained confirm the therapeutic potency of some 
plants used in traditional medicine. The results obtained revealed that plant 
extracts in organic solvent proved to be more active than those in water. The 
plants species determind better antibacterial activity than antifungal activity. The 
most susceptible bacteria was B. cereus  which is a Gram-positive bacteria and 
the most resistant bacteria was E. coli  which is a Gram-negative bacteria. Some 
of the plant species namely Woodfordia fruticosa kurz., Trapa natans L., 
Terminalia chebula Retz., Mesua ferra L., Manilkara hexandra (Roxb.) Dubard, 
Mangifera indica L., Eucalyptus citriodora Hook., Bauhinia variegata L.,  
Caesalpinia pulcherrima (L.) Swartz., Vitis vinifera L. and  Euphorbia hirta L. 
showed the best antimicrobial activity amongst all the screened plant species. 
Therefore, these results form a good basis for selection of candidate plant 
species for further phytochemical and pharmacological investigation. 
On the basis of the results evaluated for in vitro antibacterial and antifungal 
potencies of the selected plants, availability and literautre search, Manilkara 
hexandra (Roxb.) Dubard leaf (Sapotaceae) was selected for further 
pharmacognostic, phytochemical, toxicological and pharmacological 
evaluations.
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Section III
This chapter is divided into two parts. Part I describes the pharmacognostical 
studies and Part II describes the phytochemical studies.
PART- I 
3.1 INTRODUCTION
Knowledge of plants and healing has been closely linked from the time of man's 
earliest social and culture grouping. Besides medicine, mankind is almost 
completely dependent on plants for requirements such as food, shelter and 
clothing. Therefore, one of the biggest myth attending the use of herbs today is 
the idea that because something is "natural", it is completely safe. This is 
dangerous notion because some of the drugs that are available from plants are 
very toxic in natural state. So, the use of herbal medicine however, can be made 
relevant and popular after evaluating them for their quality, safety and efficacy 
(WHO, 1991).
The therapeutic activity of herbs is because of various constituents present in 
them. The therapeutic effects of herbal products is inconsistent and varies 
because the chemical constituents vary; they depend on various factors and one 
of them is the source. In some plants toxic constituents are also present therefore 
it is essential to evaluate their quality, safety and efficacy. Correct Identification 
and quality assurance of the starting material is, therefore an essential 
prerequisite to ensure reproducible quality of herbal medicine, which contributes 
to its safety and efficacy (Joshi et al., 2004). The present work is aimed at the 
pharmacognostical and phytochemical analysis of Manilkara hexandra (Roxb.) 
Dubard leaf.
ASSESSMENT OF QUALITY OF MANILKARA 
HEXANDRA (ROXB. )  DUBARD LEAF 
(SAPOTACEAE): PHARMACOGNOSTICAL 
AND PHYTOCHEMICAL PROFILE
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T
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3.2 MATERIALS AND METHODS
3.2.1 Identification and collection of the plant material
Fresh leaves of Manilkara hexandra (Roxb.) Dubard were collected in the month 
of August 2005, from Anand Agricultural University, Anand. The authenticity of the 
plant was confirmed by comparing their morphological characters with the 
description in books (Anjaria et al., 2002). Besides, the identity of the plant was 
also confirmed by Dr. Sriram, Research Scientist, Anand Agricultural University, 
Anand and Dr. P. S. Nagar, former taxonomist, Department of Biosciences, 
Saurashtra University, Rajkot. The voucher specimen (PSN 428) was deposited 
at Department of Biosciences, Rajkot. For further confirmation, the microscopic 
characteristics of this plant was studied and compared with available literature. 
The fresh plant material collected was thoroughly cleaned by washing under 
running tap water and air-dried in shade for seven days. It was then homogenized 
to fine powder and stored in air-tight bottles for further studies. 
3.2.2 Successive extraction
Ten grams of dried leaf powder of Manilkara hexandra (Roxb.) Dubard was 
successively extracted by Soxhlet extraction method using three solvents with 
increasing polarity viz. petroleum ether, acetone and methanol. The solvent was 
evaporated under reduced pressure and the extract thus obtained was stored in 
air-tight bottles at 4ºC for further experiments. The respective yields (%) are 
shown in Table 3.1.
3.2.3 Pharmacognostical studies
The quality of Manilkara hexandra (Roxb.) Dubard leaf was assessed as per 
WHO guideline (WHO, 2000)
3.2.3.1 Determination of macroscopic characteristics
Macroscopic observations of M. hexandra (Roxb.) Dubard leaf was done. It 
comprised of shape, size, surface characteristics, texture, color, consistency, 
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odour, taste, etc (Khandelwala, 1988). 
3.2.3.2 Determination of microscopic characteristics                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             
Microscopic evaluation of M. hexandra (Roxb.) Dubard leaf was done as a whole 
(leaf) as well as in the powder form (Khandelwala, 1988).
3.2.3.2.1 Paraffin method for microtomy
Transverse sections of the leaves of M. hexandra (Roxb.) Dubard were taken by 
using a microtome. Permanent mount of leaf was prepared using paraffin method 
(Johansen, 1940). It involved the following steps:-                             
1) Collection of material and fixing:
The leaves of M. hexandra (Roxb.) Dubard were collected in a single collection 
since only one kind or type of material in a collection gives uniform fixation, 
dehydration and infiltration. FAA (Formaldehyde: Acetic acid: Absolute alcohol: 
Distilled water, 10: 5: 70: 15) (Berlyn and Miksche, 1976) was used as a fixing fluid 
which gives perfect fixation. The fixing fluid (FAA) was placed in a vial which was 
atleast ten times the volume of plant material. The plant material was kept in the 
fixing fluid (FAA) for atleast 24 h.
2) Washing:
The plant tissue was washed with 70 % alcohol since It is essential to wash out the 
fixing fluid (FAA) thoroughly before proceeding with dehydration and infiltration. 
3) Dehydration:
The plant tissue was subjected to dehydration for complete removal of water. For 
the process of dehydration, the plant tissue was passed through TBA series 
(Tertiary butyl alcohol series).  The following table shows the solutions taken in 
the TBA series for dehydration.
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TBA series for dehydration
The plant tissue was kept for 24 h in each series. The plant tissue was then ready 
for infiltration.  Now equal parts of paraffin wax was transferred to the glass vials 
containing plant tissue till the solution was saturated with wax. During this stage 
paraffin diffused gradually to all the plant tissues with tert-butyl alcohol. 
Thereafter, the vials containing tissue and those containing only paraffin wax were 
placed in oven at 56°C overnight. This allowed tert-butyl alcohol to evaporate. 
Next day the tissues were transferred in the vial containing only pure paraffin wax 
and kept in oven at 56°C for complete evaporation of tert-butyl alcohol. This 
process was repeated twice during the next 6 h.  
1) Embedding:
In the process of embedding the melted wax was poured into the Petri-dishes and 
then the plant tissues were properly arranged onto the base. Thereafter, the Petri-
dish was fully covered with rest of the melted paraffin wax. The entire mass within 
the dish was cooled. The blocks were prepared to be attached to wooden blocks. 
2) Microtoming and Mounting:
The section of the plant tissue was obtained by a rotary microtome. The micron 
scale was set for the desired thickness of 10-15 µm. The sections were placed on 
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Volume of solution (ml)   
% TBA
 
  n-Butanol Alcohol D/W 
   
  10 % 10 50 40 
   
  30 % 30 50 20 
   
  50 % 50 50 - 
   
  70 % 70 30 - 
   
  90 % 90 10 - 
   100 % 100 - - 
   100 % 100 - - 
 
Part I : Materials & Methods
the slides and fixed by egg albumin.
3) Staining and Mounting:
Before staining, paraffin wax was totally removed from the slides by passing them 
through xylene and alcohol series. The sections were stained by Safranin and 
Fast green (Berlyn and Miksche, 1976). After staining, the slides were mounted 
with DPX.  
The slides were passed through the following series:-
100 % Xylene (5 min) à 100 %  Xylene (5 min) à Alcohol : Xylene (1:3) (3 min) à 
Alcohol : Xylene (1:1) (3 min) à Alcohol :  Xylene (3:1) (3 min) à 100 % Alcohol  
(3 min) à 90 % Alcohol (3 min) à 70 % Alcohol (3 min) à 50 % Alcohol (3 min) à 
30 % Alcohol (3 min) à 20 % Alcohol (3 min) à 10 % Alcohol (3 min) à D/W        
(3 min) à SAFRANIN (overnight) à D/W (1 h) à 10 % Alcohol (3 min) à 20 % 
Alcohol (3 min) à 30 % Alcohol (3 min)  à 50 % Alcohol (3 min) à 70 % Alcohol (3 
min) à 90 % Alcohol (3 min) à FAST GREEN  (2-3 dips) à 100 % Alcohol (3 min) 
à 100 % Alcohol (3 min) à Xylene : Alcohol (1:3) (5 min) à Xylene : Alcohol (1:1) 
(5 min) à Xylene : Alcohol (3:1) (5 min) à Xylene (5 min) à Xylene (5 min) à  
DPX à cover slip 
3.2.3.2.2 Method for powder study
Manilkara hexandra (Roxb.) Dubard leaf powder was cleared with chloral hydrate 
solution, stained with phloroglucinol and HCl staining reagent and mounted with 
glycerin. The different characteristics of powder are shown in the Figure 3.3.
3.2.3.3 Determination of proximate parameters
Proximate analysis of crude powder and different extracts of Manilkara hexandra 
(Roxb.) Dubard leaf (MCR, MPE, MAC and MME) was done. Following 
determinations were made:- 
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Ø Loss on drying
Ø Total Ash
Ø Acid insoluble ash
Ø Petroleum ether soluble extractive
Ø Alcohol soluble extractive
Ø Water soluble extractive
Ø Solubility
Ø Melting point
Ø pH
Ø Heavy metal analysis
3.2.3.3.1 Determination of loss on drying 
The loss on drying was determined by weighing 2 g of crude powder of M. 
hexandra (Roxb.) Dubard leaf (MCR) in an evaporating dish and then dried in an 
oven at 105ºC till constant weight was obtained. The weight after drying was 
noted and loss on drying was calculated. The percentage was calculated on the 
basis of sample taken initially.
3.2.3.3.2 Determination of total ash
The total ash value of crude powder of M. hexandra (Roxb.) Dubard leaf (MCR) 
was determined by incinerating 1 g of accurately weighed crude powder in a 
tarred silica crucible. It was incinerated in a muffle furnace at a temperature not 
exceeding 450ºC until free from carbon, then cooled and weighed.
3.2.3.3.3 Determination of acid insoluble ash
The total ash obtained as described in the section 3.2.3.3.2 was boiled for 5 min 
with 25 ml dilute HCl. The insoluble matter was collected on the filter paper placed 
in a Gooch crucible, washed with water and heated till the constant weight was 
obtained. The percentage of acid insoluble ash was calculated with reference to 
the sample taken initially.
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3.2.3.3.4 Determination of petroleum ether soluble extractive
Five grams of crude powder of M. hexandra (Roxb.) Dubard leaf (MCR) was 
macerated with 100 ml of petroleum ether in a closed flask and was kept on a 
rotary shaker for 24 h. Thereafter, it was filtered and the filtrate was evaporated to 
dryness at 105ºC till constant weight was obtained. From the weight of the dried 
residue, the percentage of extractable matter was calculated with reference to the 
sample taken initially. 
3.2.3.3.5 Determination of alcohol soluble extractive
Five grams of crude powder of M. hexandra (Roxb.) Dubard leaf (MCR) was 
macerated with 100 ml of alcohol in a closed flask and was kept on a rotary shaker 
for 24 h. Thereafter it was filtered and the filtrate was evaporated to dryness at 
105ºC till constant weight was obtained. From the weight of the dried residue, the 
percentage of extractable matter was calculated with reference to the sample 
taken initially. 
3.2.3.3.6 Determination of water soluble extractive
Five grams of crude powder of M. hexandra (Roxb.) Dubard leaf (MCR) was 
macerated with 100 ml of water in a closed flask and was kept on a rotary shaker 
for 24 h. Thereafter it was filtered and the filtrate was evaporated to dryness at 
105ºC till constant weight was obtained. From the weight of the dried residue, the 
percentage of extractable matter was calculated with reference to the sample 
taken initially. 
3.2.3.3.7 Determination of solubility 
The qualitative solubility test of the different extracts of M. hexandra (Roxb.) 
Dubard leaf (MPE, MAC, and MME) was determined for different solvents with 
different polarities. 
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3.2.3.3.8 Determination of melting point
The melting point of the crude powder and different extracts of M. hexandra 
(Roxb.) Dubard leaf (MCR, MPE, MAC, and MME) were done at Department of 
Chemistry, Saurashtra Unviersity, Rajkot, by open capillary method (Apparao et 
al., 1971; Sukhwal et al., 1995).
3.2.3.3.9 Determination of pH 
The crude powder of M. hexandra (Roxb.) Dubard leaf and its different extracts 
(MCR, MPE, MAC, and MME) were dissolved in distilled water and were kept in 
water bath for 20 min. It was then filtered and the pH of the filtrate was noted down 
with the help of a Systronic pH meter ( pH system 361). 
3.2.3.3.10 Determination of heavy metals
Contamination of medicinal plant materials with heavy metals can be attributed to 
many cases including environmental pollution and traces of pesticides. 
Therefore, detection of heavy metals is important for herbal drugs. The analysis 
for heavy metals like arsenic, chromium, cobalt, lead, mercury and nickel for 
crude powder and different extracts of M. hexandra (Roxb.) Dubard leaf (MCR, 
MPE, MAC, and MME) were done at Choksi Laboratries Limited, Vadodara. 
3.2.3.4 Determination of microorganisms
Medicinal plant materials normally carry a great number of bacteria and moulds, 
often originating in soil. Current practices of harvesting, handling and production 
may cause additional contamination and microbial growth. The determination of 
bacteria and moulds may indicate the quality of the plant material. Therefore, total 
bacterial and total fungal counts as well as specific count for Escherichia coli, 
Salmonella typhi and Pseudomonas aruginosa for crude powder of M. hexandra 
(Roxb.) Dubard leaf was carried out using reported methods (Pharmacopoeia of 
India, 1985).
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3.3 RESULTS AND DISCUSSION
The extractive yield of MPE, MAC and MME is shown in Table 3.1. Maximum 
extractive yield was obtained by MME which was 23 % while minimum extractive 
yield was of MAC which was 4.8 %. 
Table 3.1 The extractive yields of different extracts of Manilkara hexandra 
(Roxb.) Dubard leaf
MPE: Petroleum ether extract, MAC: Acetone extract, MME: Methanol extract
3.3.1 Pharmacognostical studies
3.3.1.1 Macroscopic characteristics (Figure 3.1)
Plant: Manilkara hexandra (Roxb.) Dubard; Syn. Mimusops hexandra Roxb.
Family: Sapotaceae
Vernacular name: Bakula (Kannad), Khiri, Khirakuli (Oriya); Khirkhejur 
(Bengali); Khirni (Hindi); Ranjana, Rayan, Raini (Marathi); Rayana, khirni 
(Gujarati); Mangi-pala, Pala (Telugu); Palla, Palai (Tamil).
Habit: It is an evergreen, glabrous tree with shady head. It measures about          
10-15 m.
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Plant extract Extractive yield (%)
MPE 5.5
MAC 4.8
MME 23
Kingdom Plant
Division Angiospermae
Class Dicotyledons
Subclass Gamopetalae
Series Heteromerae
Order Ebenales
Family Sapotaceae
Genus Manilkara 
Species hexandra
Part I : Results & Discussion
Chapter - 3 Results
Leaf: The leaves are alternate, coriaceous, elliptic, oblong or obovate, oblong, 
rounded or emarginated at apex, glabrous, dark green and polished above, paler 
beneath. It measures about 2.5-11 x 1-6 cm. Its taste is slightly bitter.
Flower: Inflorescence is axillary, solitary or in fascicles of 2-6 flowers. Flowers 
are creamy-white and small. Calyx consists of 6 sepals in 2 whorls of 3 each with 
rusty-tomentose outside. Corolla consists of 18 petals, gamopetalous, white, 
brownish red when dry. Androecium consist of 16 stamens in 2 series of 6 each, 
alternating with staminodes, inner whorl stamens 6, epipetalous; outer whorl 
reduced to 6 staminodes, alternating with the stamens, bifid or denticulate at the 
apex, glabrous, toothed or laciniate but not petaloid. Gynoecium consist of 12 
carpels, ovary syncarpous, 12-celled with one ovule in each cell.
Fruit: Berries, oblong, ovoid or ellipsoid, smooth, with plenty of latex, slightly 
curved, 1/2 seeded, reddish yellow when ripe.
Seeds: Ovoid, smooth, reddish-brown to black in color, shining surface.
3.3.1.2 Microscopic characteristics 
3.3.1.2.1 T.S. of leaf (Figure 3.2)
The transverse section (T.S.) of M. hexandra (Roxb.) Dubard leaf was examined 
for microscopic characteristics. The T.S. of leaf showed following tissue system: 
(1) Epidermis, (2) Mesophyll and (3) Midrib.
(1) Epidermis:
Upper Epidermis: The single layered epidermal cells were straight wall, 
rectangular in shape and covered with thin cuticle. The simple, unicellular, conical 
and thick trichomes with single covering were present. 
Lower Epidermis: Similar to upper epidermis. The lower epidermis had more 
number of trichomes than the upper epidermis. The anomocytic stomata were 
present in lower epidermis. Prisms of calcium oxalate were present in the lower 
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epidermal cells. 
(2) Mesophyll: 
Leaf was dorsiventral. Therefore, mesophyll was divided in to single layered 
elongated palisade cells under upper epidermis and a loose tissue of irregular 
spongy parenchymatous cells having large intercellular spaces above lower 
epidermis.  
(3) Midrib:
The T. S. of midrib showed meristele in the form of an arc which contained xylem 
towards the dorsal side and phloem towards the ventral side. Epidermal layers 
were continuous. Below upper epidermis and above lower epidermis, the thick 
walled cellulosic collenchyma cells were present. The vascular bundle was 
collateral i.e. xylem and phloem were present on the same radius side by side. 
The xylem was lignified while phloem was non-lignified. Thick walled pericyclic 
fibers containing sclerenchyma cells were present between the phloem and 
cortical region and surrounded the vascular bundle. 
3.3.1.2.2 Powder characteristics (Figure 3.3)
The crude powder of M. hexandra (Roxb.) Dubard leaf was dark green in color 
with characteristic odour and slightly bitter taste. The specific characteristics 
determined from the powder study were:-
Ø Upper epidermis in surface view showed straight wall cells 
Ø Lower epidermis in surface view showed some what wavy walled cell with 
anomocytic stomata
Ø Simple covering unicellular trichome
Ø Group of pericyclic fibers
Ø Prisms of calcium oxalate crystals were found
Ø Xylem vessels in longitudinal sectional view showed spiral thickening.
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3.3.1.3 Proximate analysis
The results obtained from various determinations are complied in Table 3.2- 3.4.
Table 3.2 Determination of proximate parameters of crude powder of 
Manilkara hexandra (Roxb.) Dubard leaf  
The result of proximate analysis of crude powder of M. hexandra (Roxb.) Dubard 
leaf (MCR) is shown in Table 3.2. The average values are expressed as 
percentage of air-dried material. MCR showed 4 % of loss on drying. It contained 
6 % of total ash and about 1 % of acid insoluble ash. The percent  extractive yield 
of crude powder extracted in petroleum ether was 3.74 %; that extracted in 
alcohol was 10.60 % and extracted in water was 12.30 %. 
Table 3.3 Determination of solubility of different extracts of Manilkara 
hexandra (Roxb.) Dubard leaf 
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Proximate parameters Average value  % w/w
Loss on drying 4
Total ash 6
Acid insoluble ash 1
Petroleum ether soluble extractive 3.74
Alcohol soluble extractive 10.6
Water soluble extractive 12.3
MPE MAC MME
Hexane ++ + +
Heptane ++ + +
Benzene +++ ++ ++
Diethyl ether ++ +++ ++
Petroleum ether ++ + +
1-4 dioxan ++ +++ ++
Tetrahydrofuran - ++ +++
Ethyl acetate ++ ++ ++
Chloroform +++ ++ ++
Acetone ++ ++ ++
Dimethylformamide + +++ +++
Dimethylsulphoxide ++ +++ +++
Solvents Solubility
Part I : Results & Discussion
 (-): Not Soluble, (+): Sparingly soluble, (++): Soluble, (+++): Highly soluble, MPE: Petroleum 
ether extract, MAC: Acetone extract, MME: Methanol extract
The three extracts MPE, MAC and MME of M. hexandra (Roxb.) Dubard were 
evaluated for qualitative solubility test for about 29 solvents with varied polarities 
(Table 3.3). MME and MAC were almost soluble in all the solvents while MPE 
showed comparatively less solubility due to its hydrophobic nature. 
Table 3.4 Determination of melting point and pH of the crude powder and 
different extracts of Manilkara hexandra (Roxb.) Dubard leaf 
MCR: Crude powder, MPE: Petroleum ether extract, MAC: Acetone extract, MME: Methanol 
extract, ND: Not done
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Plant 
extract pH 
MCR < 300 5.51 
MPE 206-210 ND 
MAC < 300 5.01 
MME < 300 4.82 
 
Melting Point (°C)
MPE MAC MME
Dimethylsulphoxide ++ +++ +++
1-Butanol ++ ++ ++
1-Propanol ++ +++ +++
Acetic acid ++ ++ ++
Ethanol ++ +++ +++
Methanol + +++ +++
2-methoxy ethanol ++ +++ +++
Triacetin + + +
Toluene - ++ +++
Distilled water - + +
Tap water - ++ ++
2-methyl Propanol ++ ++ +
Dichloromethane +++ ++ ++
Amyl alcohol ++ ++ +
Benzyl alcohol ++ +++ ++
Benzaldehyde +++ +++ ++
Orthophosphoric acid + ++ +++
Formic acid ++ +++ +++
Solvents Solubility
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The results of melting point and pH of the crude powder and different extracts of 
M. hexandra (Roxb.) Dubard are shown in Table 3.4. The melting point of crude 
powder (MCR), acetone extract (MAC) and methanol extract (MME) was < 300°C 
and that of petroleum ether extract (MPE) was 206-210°C. All the samples were 
acidic in nature. The methanol extract (MME) was the most acidic in nature. 
Table 3.5 Determination of heavy metals in crude powder and different 
extracts of Manilkara hexandra (Roxb.) Dubard leaf
MCR: Crude powder, MPE: Petroleum ether extract, MAC: Acetone extract, MME: Methanol 
extract, NDT: Not detected
The presence of heavy metals in the medicinal plants exceeding certain limit 
tends to cause a health hazard. Thus, the crude leaf powder of M. hexandra 
(Roxb.) Dubard and its extracts (MPE, MAC and MME) were analysed for the 
presence of heavy metals. The results (Table 3.5) showed that lead, chromium 
and nickel were not present in any of the sample drugs; mercury and cobalt was 
present in all the four sample drugs with varying values. The presence of arsenic 
was present only in two sample drugs (MPE and MAC). The crude drug contained 
0.071 ppm mercury and 2.07 ppm cobalt; MPE had 0.09 ppm mercury, 2.36 ppm 
cobalt and 0.045 ppm arsenic; MAC had 0.046 ppm mercury, 2.12 ppm cobalt and 
0.027 ppm arsenic and MME had 0.094 ppm mercury and 2.02 ppm cobalt. 
Although, there was minor presence of some heavy metals but the extracts did 
not exceed the limit given according to the WHO guidelines (1991). Therefore, the 
sample drugs investigated were free from heavy metal contamination.
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MCR 0.071 NDT NDT 2.07 NDT NDT
MPE 0.09 NDT NDT 2.36 0.045 NDT
MAC 0.046 NDT NDT 2.12 0.027 NDT
MME 0.094 NDT NDT 2.02 NDT NDT
Plant extract
Heavy Metals (ppm)
Mercury 
(Hg)
Chromium 
(Cr)
Cobalt 
(Co)
Arsenic 
(As)
Nickel 
(Ni)
Lead
(Pb)
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3.3.1.4 Determination of microorganisms
The crude powder of Manilkara hexandra (Roxb.) Dubard leaf was evaluated for 
2microbial contamination. They were free from moulds; however 10  colonies of 
2yeast were observed per gram. The samples possessed around 10  colonies of 
Enterobacteriaceae but were free from P.aeruginosa and S. typhimurium.
PART- II
3.4 INTRODUCTION
Plant cells are highly sophisticated chemical factories where a large variety of 
chemical compounds are manufactured with great precision and ease from 
simple raw materials at normal temperature and pressure. The knowledge of 
chemical constitutions of plants is desirable for the discovery of therapeutic 
agents. In addition, the knowledge of the chemical constituents of plants would 
further be valuable in discovering the actual value of folkloric remedies 
(Farnsworth, 1966).
Medicinal plants are of great importance to the health of individuals and 
communities. The medicinal value of these plants lies in some chemical 
substances that produce a definite physiological action on the human body. The 
most important of these bioactive constituents of plants are saponins, alkaloids, 
tannins, flavonoids, steroids and phenolic compounds (Hill, 1952).
3.5 MATERIALS AND METHODS
3.5.1 Phytochemical studies
The qualitative phytochemical analysis and HPTLC fingerprinting were done to 
evaluate the phytochemical constituents from the crude powder and different 
extracts of Manilkara hexandra (Roxb.) Dubard leaf (MCR, MPE, MAC, and 
MME). 
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3.5.1.1 Qualitative Phytochemical Screening
Preliminary chemical tests were carried out for MCR, MPE, MAC, and MME to 
identify different phyto-constituents (Harborne, 1973; Trease and Evans, 1989). 
3.5.1.1.1 Alkaloids
The methanolic extract of the sample drug was evaporated to dryness on a boiling 
water bath.  The residue was dissolved in 2 N HCl. The mixture was filtered and 
the filtrate was divided into 3 equal portions.  One portion was treated with few 
drops of Mayer's reagent; one portion was treated with equal amount of 
Dragondroff reagent and the other portion was treated with equal amount of 
Wagner's reagent. The creamish precipitate, orange precipitate and brown 
precipitate indicated the presence of respective alkaloids. A (+) score was 
recorded if the reagent produced only a slight opaqueness; a (++) score was 
recorded if a definite turbidity but no flocculation was observed and a (+++) score 
was recorded if heavy precipitate or flocculation was observed (Salehi-Surmaghi 
et al., 1992).
3.5.1.1.2 Flavonoids
The presence of flavonoids was estimated by Shinoda test. The alcoholic extract 
of the sample drug was treated with few drops of concentrated HCl and 
magnesium ribbon.  The appearance of pink or tomato red colour within few 
minutes indicated the presence of flavonoids (Somolenski et al., 1972). 
3.5.1.1.3 Saponins
The presence of saponins was determined by Frothing test. The sample drug was 
vigorously shaken with distilled water and was allowed to stand for 10 minutes 
and classified for saponin content as follows: no froth indicates absence of 
saponins and stable froth more than 1.5 cm indicated the presence of saponins 
(Kapoor et al., 1969).
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3.5.1.1.4 Tannins
The water extract of the sample drug was treated with alcoholic FeCl  reagent.  3
Blue color indicated the presence of tannins (Segelman et al., 1969).
3.4.1.1.5 Steroids
Liebermann-Burchard reaction was performed for the presence of steroids. A 
chloroformic solution of the sample drug was treated with acetic anhydride and 
few drops of concentrated H SO  were added down the sides of test tube.  A blue 2 4
green ring indicated the presence of terpenoids. 
3.5.1.1.6 Cardiac glycosides
Keller-kiliani test was performed for the presence of cardiac glycosides. The 
sample drug was treated with 1ml mixture of 1 volume of 5% FeCl  solution and 99 3
volume of glacial acetic acid.  To this solution few drops of concentrated H SO  2 4
was added.  Appearance of greenish blue color within few minutes indicated the 
presence of cardiac glycosides (Ajaiyeobu, 2002).  
3.5.1.2 HPTLC fingerprinting 
High Performance Thin Layer Chromatography (HPTLC) technique is most 
simple and fastest separation technique available today which gives better 
precision and accuracy with extreme flexibility for various steps. The HPTLC 
fingerprinting of the different extracts of M. hexandra (Roxb.) Dubard leaf (MPE, 
MAC and MME) was carried out at Anchrom Enterprises (I) Pvt. Ltd., Mulund, 
Mumbai. 
3.5.1.2.1 Sample preparation
100 mg of different extracts of M. hexandra (Roxb.) Dubard leaf (MPE, MAC, and 
MME) were dissolved in 10 ml methanol and centrifuged for 15 min. The 
supernatant was then loaded on the plates. The amount of each sample loaded 
was 100 µg.
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3.5.1.2.2 Development of HPTLC plates 
The HPTLC was carried out using a Hemilton 100 µl HPTLC syringe, Camag 
Linomat IV automatic spoting device, Camag twin trough chamber, Camag TLC 
scanner-3, win CATS integration software, aluminium sheet precoated with silica 
gel G 60F   (Merck, India), 200 µm thickness.254
Prior to use, these plates were washed with methanol in a pre-saturated twin 
trough chamber. 10 µl of test sample was spotted in the form of band using 
Linomat IV automatic spotter (Camag, Switzerland). The plates were developed 
using the solvent system Toluene: Ethyl acetate: Formic acid (7: 2.5: 0.5), 
Rectangular twin trough chambers were used for development. Chamber was 
saturated with solvent system for about 10 min before inserting the plates. The 
plates were developed to a height of 5-6 cm, then the plates were taken out and air 
dried.
3.5.1.2.3 Detection and scanning of HPTLC 
Using UV light at 254 nm, substances which had fluorescence in this region 
appeared as dark zones against yellow-green fluroscent background. One of the 
TLC plates were derivatized by spraying with anisaldehyde-sulphuric acid 
reagent till the band developed. The plates were scanned at 366 nm using Camag 
scanner-3. Number of peaks and peaks height of the resolved bands were 
recorded.
3.6 RESULTS AND DISCUSSION 
3.6.1 Preliminary phytochemical analysis
The results of preliminary phytochemical analysis of the crude powder and the 
different extracts of M. hexandra (Roxb.) Dubard leaf (MCR, MPE, MAC and 
MME) is shown in Table 3.6. All the four samples contained maximum amount of 
cardiac glycosides and steroids. Tannins and saponins were present in all the 
extracts except MPE. Alkaloids were present in MCR, MPE, MAC and MME with 
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Wagner's test. The alkaloids were present only in MCR and MPE with 
Dragendroff's test and in MCR and MME with Mayer's test. Flavonoids were 
absent in all the four drug samples. 
Table 3.6 Preliminary qualitative phytochemical analysis of crude powder 
and different extracts of Manilkara hexandra (Roxb.) Dubard leaf 
(-): No presence, (+): Less presence, (++): Moderate presence, (+++): High presence, MCR: 
Crude powder, MPE: Petroleum ether extract, MAC: Acetone extract, MME: Methanol extract, 
3.6.1 HPTLC fingerprinting
The three extracts of M. hexandra (Roxb.) Dubard leaf (MPE, MAC and MME) 
were subjected to HPTLC fingerprinting. The results showing the Rf values and 
the percentage of the constituents in each extract are shown in Table 3.7. The 
HPTLC plates showing different bands for all the extracts are shown in Figure 3.4. 
The MPE showed 7 peaks, MAC showed 14 peaks and MME showed 13 peaks 
(Figure 3.5). There were four constituents common in MAC and MME with Rf 
values of 0.06, 0.21, 0.50 and 0.55 and there were two constituents common in 
MPE and MAC with Rf values of 0.23 and 0.67. None of the constituents were 
MCR MPE MAC MME
Alkaloids
Dragondroffs test + + - -
Mayers test ++ - - +
Wagners test +++ + + + + +++
Flavonoids
Shinoda test - - - -
Saponins
Frothing test + - +++ ++
Tannins
FeCl3 test +++ - +++ + ++
Steroids
Liebermann-Burchard reaction +++ +++ +++ +++
Cardiac glycosides
Keller-kilianni test +++ +++ +++ +++
Phytochemical tests Manilkara hexandra leaf extracts
Part II : Results & Discussion
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Figure 3.5 HPTLC spectra of (A)  Petroleum ether extract (B) Acetone extract  
(C) Methanol extract of Manilkara hexandra (Roxb.) Dubard leaf.
[A]
[B]
[C]
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common in MPE and MME. The constituents can be further isolated and purified 
to find its potency for biological activities.
Table 3.7 HPTLC (High Performance Thin Layer Chromatography) 
fingerprinting of different extracts of Manilkara hexandra (Roxb.) Dubard 
leaf 
MPE: Petroleum ether extract, MAC: Acetone extract, MME: Methanol extract
 3.7 CONCLUSIONS
From the present study, it can be concluded that crude powder (MCR) of 
Manilkara hexandra (Roxb.) Dubard leaf was dark green in color with 
characteristic odour and bitter taste. The extractive yield of MPE, MAC and MME 
was 5.5 %, 4.8 % and 23 % respectively. The crude powder and different extracts 
of M. hexandra (Roxb.) Dubard leaf (MCR, MPE, MAC and MME) were free from 
heavy metal and microbial contamination. All the four sample drugs were acidic in 
nature. MPE, MAC and MME were maximally soluble in polar solvents. All the 
sample drugs (MCR, MPE, MAC and MME) possessed maximum amount of 
Conclusions
Peak Max Rf Area 
(%)
Peak Max Rf Area 
(%)
Peak Max Rf Area 
(%)
1 0.23 2.08 1 0.06 1.19 1 0.06 5.58
2 0.3 8 2 0.16 2.99 2 0.08 9.95
3 0.49 5.06 3 0.2 3.68 3 0.13 6.61
4 0.56 14.49 4 0.21 3.31 4 0.18 0.81
5 0.67 26.17 5 0.24 5.79 5 0.21 3.47
6 0.87 5.95 6 0.25 2.41 6 0.23 6.88
7 0.93 38.25 7 0.29 7.79 7 0.27 7.17
8 0.33 2.88 8 0.32 2.27
9 0.5 10.17 9 0.5 6.26
10 0.55 10.13 10 0.55 4.04
11 0.59 2.9 11 0.58 5.43
12 0.69 15.6 12 0.67 14.3
13 0.71 28.47 13 0.7 27.23
14 0.76 2.69
Methanol Extract
(MME)
Petroleum ether 
(MPE)
Acetone Extract
(MAC)
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cardiac glycosides and steroids while they were totally devoid of flavonoids. 
Except MPE, all the other sample drugs contained tannins and saponins. 
Alkaloids were present in all sample drugs with varying degree. The HPTLC 
fingerprinting showed maximum 14 peaks for MAC, followed by 13 peaks for 
MME and 7 peaks for MPE. Hence, the determination of pharmacognostical and 
phytochemical profile of Manilkara hexandra (Roxb.) Dubard leaf authenticates 
the further usage of this plant material for evaluating safety and efficacy.
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4.1 INTRODUCTION
Nature has been a source of medicinal agents for thousands of years since it 
comprises of compounds that are highly diverse and often provide highly specific 
biological activities. This follows from the proposition that essentially all natural 
products have some receptor binding capacity (Verdine, 1996). Herbal medicines 
have been the basis of treatment for various diseases and physiological 
conditions in traditional methods practiced such as Ayurveda, Unani and Siddha 
(Kumar et al., 2006). To promote the proper use of herbal medicine and to 
determine their potential as sources for new drugs, it is essential to study 
medicinal plants, which have folklore reputation in a more intensified way (Awadh 
Ali et al., 2001). Over the past 20 years, there has been a lot of interest in the 
investigation of natural materials as sources of new antimicrobial agents (Recio, 
1989). Some natural products have been approved as new antimicrobial drugs, 
but there is a continuous and urgent need to screen more and more plant species 
and discover new antimicrobial compounds with diverse chemical structures and 
novel mechanisms of action to combat new and re-emerging infectious diseases 
of today's era (Rojas et al., 2003; Bonjar, 2004; Prashanth Kumar, 2006).
Bacteria and fungi cause some important human diseases, especially in 
immunocompromised or immunodeficient patients. Despite the existence of 
potent antibacterial and antifungal agents, the past three decades have seen a 
dramatic increase in microbial resistance to antimicrobial agents (Baquero, 1997) 
that lead to repeated use of antibiotics and insufficient control of diseases (NCID, 
2002), imposing the need for a permanent search and development of new drugs 
(Benkeblia, 2004). Many infectious diseases are known to be treated with herbal 
remedies throughout the history of mankind. Even today, plant materials continue 
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to play a major role in primary health care as therapeutic remedies in many 
developing countries (Zakaria, 1991). In an effort to discover new lead 
compounds, many researchers are increasingly turning their attention to folk 
medicine looking for new leads to develop better drugs against microbial 
infections (Benkeblia, 2004; Parekh et al., 2005). 
Plant based antimicrobials represent a vast untapped source of medicines and 
there is a need for further exploration of plant antimicrobials. It is estimated that 
several plant-derived drugs prescribed in the industrialized world were 
discovered by studying folk knowledge. However, less than one-half of 1 percent 
of all plant species in the world has been studied for potential pharmacological 
activity (Balick and Cox, 1996). Plant based natural constituents can be derived 
from any part of the plant like bark, leaves, flowers, roots, fruits, seeds, etc 
(Gordon and David, 2001; Parekh et al., 2006) i.e. any part of the plant may 
contain active components. Scientific analysis of plant components may give a 
new source of antimicrobial agents with possibly novel mechanisms of action 
(Motsei et al., 2003; Barbour et al., 2004). World Health Organization has also 
approved the study of medicinal plants for the development of new drug lead 
(WHO, 2000). In recent years, many researchers all over the world have 
screened plant extracts to detect and utilize secondary metabolites with relevant 
biological activities as medicinal agents (Balandrin et al., 1985; Aliero and 
Afolayan, 2005; Parekh and Chanda, 2006a; Parekh and Chanda, 2007). 
The primary screening of several plant extracts resulted in the selection of 
Manilkara Hexandra (Roxb.) Dubard (Sapotraceae) as the promising plant to be 
investigated for further experiments. This work is aimed at the investigation of 
antibacterial as well as antifungal property of different extracts of Manilkara 
hexandra (Roxb.) Dubard leaf against an array of human pathogens including 
Gram-positive and Gram-negative bacteria as well as some fungi like yeast and 
moulds. The impelling motive behind the present work was to emphasize the 
possibilities and scientific importance for the use of M. hexandra (Roxb.) Dubard 
leaf extracts in treating common ailments due to microbial infections encountered 
worldwide.
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4.2 MATERIALS AND METHODS
4.2.1 Plant collection
As per section 3.2.1 from chapter 3
4.2.2 Successive Extraction
As per section 3.2.2 from chapter 3
4.2.3 Microorganisms and growth conditions
The investigated microbial strains were obtained from the National Chemical 
Laboratory (NCL), Pune, India. The microbial strains investigated include 9 Gram-
positive bacteria: Bacillus cereus ATCC11778, Bacillus megaterium ATCC9885, 
Bacillus subtilis ATCC6633, Corynebacterium rubrum ATCC14898, Micrococcus 
flavus ATCC10240 Staphylococcus aureus (1) ATCC25923, Staphylococcus 
aureus (2) ATCC29737, Staphylococcus epidermidis ATCC12228, 
Staphylococcus subfava NCIM2178; 14 Gram-negative bacteria: Alcaligenes 
fecalis ATCC8750, Citrobacter freundii ATCC10787, Enterobacter aerogenes 
ATCC13048, Escherichia coli ATCC25922, Klebsiella aerogenes NCTC418, 
Klebsiella pneumoniae NCIM2719, Proteus mirabilis NCIM2241, Proteus 
morganii NCIM2040, Proteus vulgaris NCTC8313, Pseudomonas aeruginosa 
ATCC27853, Pseudomonas pseudoalcaligenes ATCC17440, Pseudomonas 
putida ATCC12842, Pseudomonas testosteroni NCIM5098,  Salmonella 
typhimurium ATCC23564; 7 yeast: Candida albicans (1) ATCC2091, Candida 
albicans (2) ATCC18804, Candida glabrata NCIM3448, Candida tropicalis 
ATCC4563, Cryptococcus luteolus ATCC32044,  Cryptococcus  neoformans 
ATCC34664, Trichosporon beigelii NCIM3404 and 4 moulds: Aspergillus 
candidus NCIM883, Aspergillus flavus NCIM538, Aspergillus niger ATCC6275, 
Mucor hiemalis wehmer NCIM873. Bacterial cultures were grown on nutrient 
broth (Hi-Media) at 37°C for 24 h and the fungal cultures were grown on 
sabouraud dextrose broth (Hi-Media) at 28°C for 48 h. All the microbial cultures of 
bacteria, yeast and mould were maintained on nutrient agar slants, MGYP slants, 
PDA (potato dextrose agar) slants respectively at 4° C.
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4.2.4 Standard antimicrobics Used
The investigated microorganisms were tested against standard antimicrobics. 
The standard antimicrobics used for bacterial strains were Piperacillin                
(100 µg /disc) and Gentamicin (10 µg/disc) and that for fungal strains were 
Amphotericin B (100 units/disc) and Fluconazole (10 µg/disc).
4.2.5 Antimicrobial assay
4.2.5.1 Preparation of inoculum
The test bacterial strains were inoculated into nutrient broth and were incubated at 
37ºC on a rotary shaker whereas test fungal strains were inoculated into 
sabouraud dextrose broth and incubated at 28ºC on a rotary shaker. The inoculum 
8size was maintained as per the 0.5 McFarland standard (1x10  cfu/ml). The 
activated inoculum was used for antimicrobial assay. 
4.2.5.2 Preparation of test compound
The petroleum ether, acetone and methanol extracts of M. hexandra (Roxb.) 
Dubard leaf were diluted in 100 % dimethylsulphoxide (DMSO) and the stocks 
were prepared at a concentration of 25mg/ml and 12.5 mg/ml. The antimicrobial 
activity was evaluated at two different concentrations viz. 500 µg/disc and              
250 µg/disc. 
4.2.5.3 Antimicrobial susceptibility testing
The antimicrobial activity of petroleum ether, acetone and methanol extracts of M. 
hexandra (Roxb.) Dubard leaf was determined by agar disc diffusion method 
(Bauer et al., 1966; Parekh and Chanda, 2006b). The molten Mueller Hinton Agar 
No. 2 media (Hi-Media) for bacteria and Sabouraud dextrose agar media (Hi-
8Media) for fungi was inoculated with 200 µl of the inoculum (1x10  cfu/ml) when the 
temperature of media reached 40-42°C and then poured into the Petri plate (Hi-
Media). Sterile disc (7 mm) (Hi-Media) was saturated with 20 µl of the test 
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compound (MPE, MAC and MME) with the concentration of 500 µg/disc and 250 
g/disc and allowed to dry. The disc was then introduced on the upper layer of the 
seeded agar plate. For each microbial strain negative controls were maintained 
where pure solvent (DMSO) were used  instead of the extract since it does not 
possess any antimicrobial effect (Pelczar et al., 1993) and for positive control the 
standard antimicrobics with known concentration were used. The bacterial plates 
were incubated at 37°C for 24 h and the fungal plates at 28°C for 48 h. The result 
of antimicrobial activity was obtained by measuring the diameter of the zone of 
inhibition. The values in the result are expressed as mean ± SEM. The values 
were compared with the standard antimicrobics. The experiment was performed 
under strict aseptic conditions for three times to minimize error. The results are 
presented in Table 4.1. 
4.2.6 Determination of Minimum Inhibitory Concentration (MIC)
The minimum inhibitory concentration was determined by disc diffusion method 
(NCCLS, 1993 protocol, Okigbo et al., 2005). The Mueller Hinton agar plates for 
bacteria and sabouraud dextrose agar plates for fungi, containing an inoculum 
8size of 1x10  cfu/ml, were used. Two-fold serial dilutions of petroleum ether, 
acetone and methanol extracts of M. hexandra leaf, ranging from 250-32,000  
µg/ml, were prepared in 100 % pure DMSO (dimethylsulphoxide). The prepared 
dilutions were impregnated on sterile discs and were placed aseptically on 
seeded agar plates. Appropriate controls were maintained. All the plates were 
incubated at 37°C for bacteria and at 28°C for fungi.  The lowest concentration 
within the plate, which did not show any clear zone around the disc, was 
considered as MIC. The results of MIC are presented in Table 4.2.
4.3 RESULTS AND DISCUSSION
4.3.1 Antimicrobial activity
The presence of antibacterial and antifungal substances in higher plants is well 
established (Dhar et al., 1968; Bhakuni et al., 1974). Plants have provided 
sources for novel drug compounds as plants derived medicines have made 
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significant contribution towards human health. Phytomedicine can be used for the 
treatment of diseases as is done in case of Unani and Ayurvedic system of 
medicines or it can be the base for the development of medicine, a natural 
blueprint for the development of new drugs (Javed and Ali, 2002). Much of the 
exploration and utilization of natural products as antimicrobial agents arise. 
Though soil microorganisms or fungi produce most of the clinically used 
antibiotics, higher plants can be very good source of antibiotics.
Present study was conducted to investigate the antimicrobial potential of the 
petroleum ether, acetone and methanol extracts of M. hexandra (Roxb.) Dubard 
leaf at two different concentrations. The microorganisms used for the 
antimicrobial studies were Gram-positive and Gram-negative bacteria, yeast and 
moulds. The results of antimicrobial activity of M. hexandra (Roxb.) Dubard leaf 
extracts are summarized in Table 4.1.
The results showed that methanol extracts (MME) were better than the other two 
extracts (MPE and MAC) which implied that antimicrobial activity is better with the 
polar solvents. Also, the antimicrobial activity observed was concentration 
dependent for each extract. The mean zones of inhibition produced against the 
test microorganisms ranged between 8-22 mm. The highest zone of inhibition 
was obtained at the higher concentration with Enterobacter aerogenes. Amongst 
all the microbial strains investigated, a Gram-negative bacteria- Citrobacter 
freundii, yeasts- Candida albicans (2), Candida glabrata, Cryptococcus luteolus, 
Cryptococcus lneoformans and amongst moulds- Aspergillus candidus, 
Aspergilllus niger were most resistant strains which did not show any activity at all 
whereas a Gram-positive bacteria - Bacillus cereus and Gram-negative bacteria 
Enterobacter aerogenes and Pseudomonas putida were most susceptible 
bacteria (Table 4.1). However, all the three extracts were more active against 
bacterial strains than the fungal strains.
The methanol extract inhibited 76.47 % of microbial strains a higher concentration 
and 64.70 % at lower concentration. The methanol extract was totally inactive at 
the lower concentration (250 µg/disc) against Staphylococcus epidermidis, 
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Alcaligenes fecalis, Citrobacter freundii and all the seven yeast spps. tested. In 
case of acetone extract, 58.82 % of microorganisms were inhibited at higher 
concentration while 35.30 % were inhibited at lower concentration. On the other 
hand the petroleum ether extract did not show any appreciable activity against all 
the microorganisms used in present investigation; it could inhibit only 20.58 % of 
microorganisms at higher concentration while 26.47 % at the lower concentration 
(Table 4.1).
The extracts were compared to the standard antibiotics. The standard 
antibacterial agents used were Piperacillin (100 µg/disc) and Gentamicin            
(10 µg/disc) while the standard antifungal agents used were Amphotericin-B        
(100 units/disc) and Fluconazole (10 µg/disc) (Table 4.1). 
4.3.2 Minimum Inhibitory Concentration (MIC)
The minimum inhibitory concentrations of the extracts of M. hexandra (Roxb.) 
Dubard are reported in Table 2. The most active extracts were subjected to the 
evaluation of MIC. The MIC of M. hexandra was evaluated within a range of 
concentration from 250-32,000 µg/ml. 
The results of petroleum ether extract (MPE) showed MIC ranging from 2000-
16000 µg/ml. The MIC of petroleum ether extract for Bacillus cereus and 
Micrococcus flavus was 2000 µg/ml; for Proteus mirabilis and Pseudomonas 
putida it was 4000 µg/ml; for Bacillus subtilis, Enterobacter aerogenes, 
Escherichia coli, Pseudomonas pseudoalcaligenes, Aspergillus flavus and 
Mucor hiemalis was observed as 8000 µg/ml and MIC for Klebsiella pneumoniae 
was observed as 16,000 µg/ml (Table 4.2).
The results of acetone extract (MAC) showed MIC ranging from 250-16,000 
µg/ml. The MIC of acetone extract for Pseudomonas testosteroni was 250 µg/ml 
while for Klebsiella pneumoniae it was <250 µg/ml; for Bacillus cereus, 
Micrococcus flavus, Klebsiella aerogenes, Proteus morganii, Pseudomonas 
aeruginosa and Pseudomonas pseudoalcaligenes MIC was 2000 µg/ml; for 
103
Chapter 4 Results & Discussion
Bacillus megaterium, Corynebacterium rubrum, Staphylococcus aureus (2), 
Pseudomonas putida and Trichosporon beigelii it was 4000 µg/ml; for  
Staphylococcus aureus (1), Staphylococcus epidermidis, Enterobacter 
aerogenes,  Proteus  mirabilis,  and Mucor hiemalis was 8000 µg/ml and the MIC 
values for Candida albicans (1) was 16,000 µg/ml. 
The results of methanol extract (MME) showed MIC ranging from 250-8000 
µg/ml. The MIC of methanol extract for Klebsiella pneumoniae was < 250 µg/ml; 
for Bacillus cereus, Micrococcus flavus, Klebsiella aerogenes, Proteus mirabils 
and Proteus morganii was 1000 µg/ml; for Alcaligenes fecalis, Pseudomonas 
pseudoalcaligenes, Pseudomonas testosteroni, Salmonella typhimurium, 
Trichosporon beigelii and Aspergillus flavus it was 2000 µg/ml; the MIC value for 
Bacillus megaterium, Corynebacterium rubrum, Staphylococcus aureus (1), 
Staphylococcus aureus (2), Proteus  vulgaris,  Pseudomonas aeruginosa, 
Pseudomonas putida and Mucor hiemalis was 4000 µg/ml and that for Bacillus 
subtilis, Staphylococcus epidermidis, Staphylococcus subfava, Enterobacter 
aerogenes, Escherichia coli, and Candida albicans (1) it was 8000 µg/ml.
The results showed that methanol extract of M. hexandra (Roxb.) Dubard leaf 
possessed measurable in vitro antimicrobial activity against many of the 
microorganisms implicated in the pathogenesis of the human infections. The 
broad range of inhibition found implied that the extract had a comparable 
antimicrobial activity. This may be because of presence of tannins which were 
detected to an appreciable amount in phytochemical analysis. Tannins, (non-
crystalizable substances), have astringent actions, which form the basis for their 
therapeutic applications (Edward et al., 1970). It has been found that plants which 
contain tannins possess antimicrobial activity (Trease and Evans, 1989). Hence 
the significant antibacterial activity of the extract could be ascribed to the tannins 
constituent. However, further work is needed to isolate the active principle from 
the active plant extracts and to carry our pharmaceutical studies.
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Table 4.2 Minimum Inhibitory Concentration (MIC) of methanol extract of 
Manilkara hexandra (Roxb.) Dubard. 
Microorganisms 
MIC of  Manilkara hexandra  
 leaf extracts (µg ?g /ml) 
  
MPE MAC MME 
Gram-positve bacteria    
Bacillus cereus ATCC 11778  2000 2000 1000 
Bacillus megaterium ATCC 9885  NA 4000 4000 
Bacillus subtilis ATCC 6633  8000 NA 8000 
Corynebacterium rubrum ATCC 14898  NA 4000 4000 
Micrococcus flavus ATCC 10240 2000 2000 1000 
Staphylococcus aureus (1) ATCC 25923  NA 8000 4000 
Staphylococcus aureus  (2) ATCC 29737  NA 4000 4000 
Staphylococcus epidermidis ATCC 12228  NA 8000 8000 
Staphylococcus subflava NCIM 2178 NA NA 8000 
Gram-negative bacteria    
Alcaligenes fecalis ATCC  8750  NA NA 2000 
Enterobacter aerogenes ATCC 13048  8000 8000 8000 
Escherichia coli ATCC 25922  8000 NA 8000 
Klebsiella aerogenes NCTC 418 NA 2000 1000 
Klebsiella pneumoniae NCIM 2719 16000 <250 <250 
Proteus mirabilis NCIM 2241 4000 8000 1000 
Proteus morganii NCIM 2040 NA 2000 1000 
Proteus vulgaris NCTC 8313 NA NA 4000 
Pseudomonas aeruginosa ATCC 27853  NA 2000 4000 
Pseudomonas putida ATCC 12842  4000 4000 4000 
Pseudomonas pseudoalcaligenes ATCC 17440  8000 2000 2000 
Pseudomonas testosteroni NCIM 5098 NA 250 2000 
Salmonella typhimurium ATCC 23564  NA NA 2000 
Yeast    
Candida albicans (1) ATCC 2091  NA 16000 8000 
Trichosporon beigelii NCIM 3404 NA 4000 2000 
Mould    
Aspergillus flavus NCIM 538 8000 4000 2000 
Mucor hiemalis wehmer NCIM 873 8000 8000 4000 
NA: No activity
MPE: Petroleum ether extract of M. hexandra, 
MAC: Acetone extract of M. hexandra,
MME: Methanol extract of M. hexandra.
Results & Discussion
The potential for developing antimicrobials from higher plants appears rewarding 
as it will lead to the development of a phytomedicine to act against microbes. Plant 
based antimicrobials represents a vast untapped source of medicine. Plant based 
antimicrobials have enormous therapeutic potential as they can serve the 
purpose without any side effects that are often associated with synthetic 
antimicrobials. Therefore, continuous further exploration of plant derived 
antimicrobials is needed today.
4.4 CONCLUSIONS
The present study for assessing the potent extracts of Manilkara hexandra 
(Roxb.) Dubard leaf, reveals that methanol extract was the most active amongst 
the three extracts. Methanol extract was thus selected for further studies on 
toxicity and pharmacological effect on diabetes.
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5.1 INTRODUCTION
Toxicology basically is defined traditionally as "the science of poisons." The word 
toxicology is derived from toxicon - a poisonous substance into which arrow 
heads were dipped and toxikos - a bow (Robyn, 1996). A poison is any substance 
has a harmful effect on a living system (EHSC, 2004). A more descriptive 
definition of toxicology is "the study of the adverse effects of chemicals or physical 
agents on biological material with special emphasis on the harmful effects." After 
gaining relevant information on the harmful effects of a compound the levels for its 
safe usage or the degree of its safeness is established, this is known as its 
'Biosafety level'.
Toxicology is a relatively young biological science that involves a complex 
interrelationship among dose, absorption, distribution, metabolism and 
elimination (Robyn, 1996). A toxic substance is a material which has toxic 
properties. Knowledge of how toxic agents damage the body has progressed 
along with medical knowledge.  Toxicity depends not only on the dose of the 
substance but also on the toxic properties of the substance. The relationship 
between these two factors is important in the assessment of therapeutic dosage 
in pharmacology and herbalism (Klaassen et al., 1995; Hayes, 2001).
5.1.1 History
The historical development of toxicology began with early cave dwellers who 
recognized poisonous plants and animals and used their extracts for hunting or in 
warfare. By 1500 BC, written records indicated that hemlock, opium, arrow 
poisons, and certain metals were used to poison enemies or for state executions. 
Gradually the concept of toxicology was developed to determine the 
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effectiveness of a particular compound.
By the time of the Renaissance certain concepts fundamental to toxicology began 
to take shape. Orfila, a Spanish physician, is often referred to as the founder of 
toxicology. 
Orfila was the first one who prepared a systematic correlation between the 
chemical and biological properties of poisons. He demonstrated effects of 
poisons on specific organs by analyzing autopsy materials for poisons and their 
associated tissue damage. Paracelsus (1493-1541) was one of the first to 
distinguish between the therapeutic and toxic properties of substances. 
Paracelsus is often quoted for his statement: "All substances are poisons; there is 
none which is not a poison. The right dose differentiates a poison and a remedy." 
He determined that specific chemicals were actually responsible for the toxicity of 
a plant or animal poison. He further documented that the body's response to those 
specific chemicals depended on the dose received.  His studies revealed that 
small doses of a substance might be harmless or beneficial whereas larger doses 
could be toxic. This is now known as the dose-response relationship, a major 
concept of toxicology (EHSC, 2004).
thThe 20  century is marked by an advanced level of understanding of toxicology.   
The knowledge of toxic effects on organs and cells is now being revealed at the 
molecular level. It is recognized that virtually all toxic effects are caused by 
changes in specific cellular molecules and biochemicals.
5.1.2 Toxicity effects
In traditional toxicology the organism tends to be regarded as the primary unit for 
the expression of toxic effects. The adverse effects caused by a toxic substance 
may occur in many forms, ranging from immediate death to subtle changes not 
realized until months or years later. Consequently, the onset and duration of 
effects, as well as the effects themselves (e.g., changes in behavior and 
alterations in blood flow, renal functions, and metabolic parameters), become 
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signs of impaired homeostasis and are inevitably bound to the intact organism. 
All chemicals are toxic under some condition of exposure. Therefore, it is 
necessary to define these conditions as well as the quantity involved in the 
exposure in order to compare the toxicity characteristics of chemicals.  
Toxic effects are classified as either acute, sub chronic or chronic. The dose-
response concept is the basis for all toxicity assessments. It is used differently to 
evaluate acute effects, sub chronic effects and chronic effects.
5.1.3 Acute Toxicity                                     
Acute toxicity studies are the most common of the toxicity or safety evaluations. 
Acute toxicity is usually defined as the adverse change(s) occurring immediately 
or after short time following a single dose or short period of exposure to a 
substance or substances within 24 h. An adverse effect is any effect that results in 
functional impairment and/or biochemical lesions that may affect the performance 
of the whole organism or that reduce the organ's ability to respond to an additional 
challenge. Consequently, a chemical that enters the organism via the oral route 
during a restricted time and produces any adverse effect with little delay is acutely 
toxic. However, the term acute oral toxicity is most often used in connection to 
lethality and LD  determinations. 50
5.1.3.1 Objective
In the assessment and evaluation of the toxic characteristics of a substance, 
determination of acute oral toxicity is usually an initial step. Acute studies are 
generally performed first to generate data to improve the design and conduct of 
longer-term studies including sub chronic and chronic toxicity tests and others 
devoted to reproductivity, carcinogenicity and neurotoxicity testing. If designed 
appropriately, these studies may also provide initial information on the biological 
activity, toxicokinetics of a chemical and useful to gain insight into its mechanism 
of action (Fan and Chang, 1996; Walum, 1998).
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The short-term hazard from a chemical is determined by identifying the acute 
toxicity by the most likely routes of exposure. Acute toxicity effects are also 
investigated when exposed to a chemical taken orally, absorbed through the skin 
or by inhalation. A study of acute toxicity determines the dose-dependent adverse 
effect and from the comprehensive acute toxicity profile of a substance various 
appropriate data may be collected. This may include the incidence of lethality. If 
the dose-dependent lethality incidence is determined in a precise manner, it is 
usually expressed as an LD  (Gad and Chengelis, 1988). 50
5.1.3.2 Median lethal dose test (LD50) 
The term LD  (lethal dose 50 or median lethal dose) is defined as statistically 50
derived dose of a substance that, when administered in an acute toxicity test, is 
expected to cause death in 50 % of the treated animals exposed for a specified 
time (Oliver, 1986).  For a classical LD  study, laboratory mice and rats are 50
species typically selected. Materials can be classified as hazardous waste on the 
basis of LD of the material. A number of protocols exist for conducting LD  50 50
studies (Litchfield and Wilcoxon, 1949; Bruce, 1985). 
Determination of lethality (LD ) is one of the many measures of toxicity evaluated 50
in acute toxicity studies. The focus of acute toxicity is to identify lethal effects and 
target organs, with emphasis on behavioral, gross anatomical, hematological 
biochemical and histopathological changes. Dose selection in acute toxicity tests 
should aim to produce a dose-response curve that will enable an acceptable 
estimation of the median lethal dose (LD ) which usually occurs within 24 h after 50
initiation of exposure (Fan and Chang, 1996).
The LD  value (precise or approximate) is currently the basis for toxicologic 50
classification of chemicals. Thus, LD  values based on animal experiments are 50
used to estimate the lethal dose of substances for humans (Martin et al., 1989). 
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5.1.3.3 Application
Acute toxicity studies in animals are usually necessary for any pharmaceutical 
intended for human use. The information obtained from these studies is useful in 
choosing doses for repeat-dose studies, providing preliminary identification of 
target organs of toxicity, and, occasionally, revealing delayed toxicity. Acute 
toxicity studies may also aid in the selection of starting doses for Phase 1 human 
studies, and provide information relevant to acute overdosing in humans 
(Guidance for Industry, 1996).
5.1.4 Botanicals: Toxicological evaluation
Plants are an important part of culture and traditions all over the globe. Most of the 
people today are reliant on herbal medicines for their health care needs. Herbal 
prescriptions and natural remedies are commonly employed in developing 
countries for the treatment of various diseases, which is an alternative way to 
compensate for some deficiencies in orthodox pharmacotherapy (Sofowora, 
1989; Zhu et al., 2002). The fact that herbal medicines contain ingredients to 
maintain health and to cure ailments is well known. However, the fact that they 
may contain toxic substances which are harmful or even dangerous to health is 
least known. Moreover there is limited scientific evidence regarding safety and 
efficacy to back up the continued therapeutic application of these remedies. 
Plants commonly used in traditional medicine are assumed to be safe. This safety 
is based on their long usage in the treatment of diseases according to knowledge 
accumulated over centuries. Virtually all our knowledge is derived from human 
exposures to herbs leading to acute toxicities and little information is available 
from prior animal experimentation (Sheehan, 1998). 
It has been reported by researchers that many plants used as food or in traditional 
medicine are potentially toxic, mutagenic and carcinogenic (Schimmer et al., 
1988, 1994; Higashimoto et al., 1993; Kassie et al., 1996; De Sa Ferrira and 
Ferrao Vargas, 1999). Herbs may be contaminated with undeclared toxic 
botanicals or heavy metals (De Smet, 1992).  Several plants used in traditional 
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medicine can cause damage to the genetic material and therefore have the 
potential to cause long-term damage in patients when administered as medical 
preparations. Thus, the rationale for their utilization has rested largely on the 
treatment of various ailments with caution and rigorous long-term toxicological 
and clinical studies (Zhu et al., 2002; Santamaria et al., 2007). Now, with the 
upsurge in the use of herbal medicines, a thorough scientific investigation of 
these plants will go a long way in validating their folkloric usage (Sofowora, 1989). 
It is essential to evaluate the quality and safety of herbs before being prescribed 
for any medicinal use. Considering the aforesaid, crude powder (MCR) and 
methanol extract (MME) of Manilkara hexandra (Roxb.) Dubard leaf was 
evaluated for the acute toxicity studies.
5.2 MATERIAL AND METHODS
5.2.1 Experimental animals
Swiss albino mice of either sex were used for acute toxicity studies. The animals 
were obtained from Sarabhai Research Center (SRC), Baroda. All the mice were 
housed in standard plastic cages with stainless steel coverlids and wheat straw 
as bedding material at the animal house of Department of Biosciences, 
Saurashtra University, Rajkot. The animals were kept in a group of 6-8 per cage 
and facilitated with standard environmental condition of photoperiod (12:12 h 
dark:light cycle) and temperature (27 ± 2ºC). They were provided with commercial 
rat and mice feed (Pranav Agro Industries Ltd., Amruth Brand rat & mice pellet 
feed) and water given ad libitum. The use of these animals and the study 
protocols were approved by CPCSEA ethical committee.
5.2.2 Drug preparation
The crude powder (MCR) and methanol extract (MME) of Manilkara hexandra 
(Roxb.) Dubard leaf was suspended in water (5% gum acacia drops as 
-1surfactant) and four doses of 390, 780, 1560 and 3120 mg kg  body weight were 
prepared.
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5.2.3 Experimental groups
Nine groups of mice, each consisting of three mice were kept for determination of 
acute toxicity of MCR and MME at four doses as mentioned in section 5.2.2. 
Amongst nine groups, one group was the control group. The bioassays were 
conducted according to the World Health Organization guideline for the 
evaluation of the safety and efficiency of herbal medicines (WHO, 1992).
5.2.4 Drug administration
The test drug, MCR and MME as mentioned in section 5.2.2, was administered 
orally (p.o.) to all the groups of mice. The control group received water. The test 
drug (MCR and MME) was administered one hour prior to the experiment. 
5.2.5 Behavioural assessment
The acute toxicity effect of MCR and MME of Manilkara hexandra (Roxb.) Dubard 
leaf was assessed by gross behaviour model (Morpugo, 1971). The mice were 
placed one by one at the centre of three concentric circles drawn on a rubber 
sheet with diameter of 7 cm, 14 cm and 21 cm. The animals were observed for 
different parameters of bahavioural changes. After drug administration, the 
behaviour modifications were observed every hour till 5 h and then at 24 h, 48 h 
and 72 h. The mortality was observed for 10 days after treatment. The observed 
result was recorded as the score of 0-3 point scale relative to the average intensity 
of the phenomena observed. Various parameters of gross behaviour studied are 
(Figure 5.1):    
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                                    Exitus
                                    Hypoactivity
                                    Passivity
CNS Depression-        Relaxation
                                    Narcosis
                                    Ataxia
                                     Ptosis                                                                      
          ANS Effect-                                            
                                     Exophthalmia
                                     Hyperactivity
                                     Irritability
                                     Stereotypy
CNS Stimulation-          Tremors
                                     Convulsions
                                     Straub tail
                                     Analgesia
 Other Parameter-       Mortality
5.2.6 Determination of LD50
The experimental observations of acute toxicity study showed mortality with 
methanol extract of Manilkara hexandra (Roxb.) Dubard leaf (MME). Therefore, 
MME was evaluated for determining LD  value. The doses from 2000 to 9000 mg 50
-1kg  were taken for determining LD . Each group consisted of six mice. Mortality 50
was observed within each group for 10 days after drug administration.
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5.3 RESULTS AND DISCUSSION
The results of acute toxicity studies of crude powder (MCR) and methanol extract 
(MME) of M. hexandra (Roxb.) Dubard leaf is shown in Table 5.1 and Table 5.2 
respectively. The methanol extract exhibited pronounced effect on gross 
behaviour of mice as compared to the crude powder. The crude powder as well as 
methanol extract showed dose dependent effect on gross behaviour with the 
-1increasing dose levels i.e. 390, 780, 1560 and 3120 mg kg  showing strong CNS 
depression and weak CNS stimulation.
Mild to moderate hypoactivity or reduced locomotion was noted at all dose levels 
for crude powder (MCR) of M. hexandra (Roxb.) Dubard leaf. MCR showed no 
effect or mild effect at lower doses while moderate effect at the highest dose level 
-1(3120 mg kg ) for passivity and relaxation. Mild effect for irritability was observed 
-1at 2 h for 3120 mg kg . Mild effect of stereotypy was observed at 1 h, 24 h and 48 h 
-1 -1at 390 mg kg  and 780 mg kg  dose level while analgesic effect was observed at 1 
-1h at 780 and 3120 mg kg  dose level. There was no mortality observed at any 
dose levels for crude powder (MCR).
The methanol extract (MME) of M. hexandra (Roxb.) Dubard leaf showed marked 
-1effect for hypoactivity at the highest dose level  (3120 mg kg ) while moderate 
-1effect at 390 and 780 mg kg  dose levels. The hypoactive effect increased with the 
increasing time period. Moderate effect for passivity and relaxation was observed 
-1at the highest dose level (3120 mg kg ) while there was either no effect or very 
mild effect at other dose levels. MME showed weak CNS stimulation. Irritability 
was not observed. Mild effect for stereotypy was observed at all dose levels 
-1except the highest dose level (3120 mg kg ). Mild effect of analgesia was 
-1 -1observed at 1 h for 390 mg kg  dose level while at 1 h and 2 h for 3120 mg kg  dose 
-1level. Mortality was observed at the highest dose level i.e. 3120 mg kg  with MME. 
Animal death was preceded by symptoms, such as hypoactivity and lethargy. The 
-1further evaluation of LD  at the dose levels 2000-9000 mg Kg  revealed that 50
methanol extract (MME) was devoid of acute toxicity at the studied dose level.
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5.4 CONCLUSIONS
The acute toxicity studies of crude powder (MCR) and methanol extract (MME) of 
M. hexandra (Roxb.) Dubard leaf showed that they did not possess any toxic 
-1effect at the studied dose levels and are safe till the dose level of 9000 mg kg .
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6.1 INTRODUCTION
Diabetes is one of the most common noncommunicable diseases and a serious 
life-long condition appearing worldwide. The etiology of diabetes is a complex 
interaction of genetic and environmental factors. It is a heterogeneous group of 
metabolic disorders characterized physiologically by dysfunction of pancreatic β 
cells and deficiency in insulin secretion or insulin activity and clinically by 
hyperglycemia or impaired glucose tolerance and other manifestable disorders 
(Nyholm et al., 2000). It is an endocrinological syndrome abnormally having high 
levels of sugar in the blood. This may be either due to insulin not being produced 
at all, is not made at sufficient levels, or is not as effective as it should be.
Diabetes is still a serious health problem all over the world since it is associated 
with increased morbidity and mortality rate. When compared with the general 
population, mortality and morbidity increase in diabetes is mainly due to the 
associated chronic complications both specific (microvascular) and nonspecific 
(macrovascular). Since the disease prevails in both genders and in all age 
groups, the general public has a concern about its control and treatment (Safdar 
et al., 2004). 
6.1.1 Classification
Diabetes is classified by underlying cause. The most common forms of diabetes 
are categorized as Type 1, or insulin-dependent diabetes mellitus (IDDM) - an 
autoimmune disease in which the body's own immune system attacks the 
pancreatic β cells, rendering it unable to produce insulin and Type 2, or non-
insulin-dependent diabetes mellitus (NIDDM) - in which there is resistance to the 
effects of insulin or a defect in insulin secretion (DeFronzo, 1997, Xie et al., 2002). 
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Type 2 diabetes commonly occurs in adults associated with obesity. There are 
many underlying factors that contribute to the high blood glucose levels in these 
individuals. An important factor is the resistance to insulin in the body essentially 
ignoring its insulin secretions. A second factor is the decreased production of 
insulin by the β cells of the pancreas. Therefore, an individual with Type 2 diabetes 
may have a combination of deficient secretion and deficient action of insulin. 
In contrast to Type 2 diabetes, Type 1 diabetes most commonly occurs in children 
and is a result of the body's immune system attacking and destroying the β cells. 
The trigger for this autoimmune attack is not clear, but the result is the end of 
insulin production (ECDCD, 2003). 
6.1.2 History
The term “Diabetes” was first used around 250 B.C. It is a Greek word meaning “to 
syphon”, reflecting how diabetes seemed to rapidly drain fluid from the affected 
individual. The Greek physician Aretaeus noted that affected individuals passed 
increasing amounts of urine as if there was “liquefaction of flesh and bones into 
urine”. The complete term “diabetes mellitus” was coined in 1674 by Thomas 
Willis. Mellitus is Latin for honey, which is how Willis described the urine of 
diabetics. 
Historical accounts reveal that as early as 700-200 BC, diabetes mellitus was a 
well recognized disease in India and was even distinguished as two types, a 
genetically based disorder and other one resulting from dietary indiscretion 
(Oubre et al., 1997). Ancient Hindu writings document how black ants and flies 
were attracted to the urine of diabetics. The Indian physician Sushruta in 400 B.C. 
described the sweet taste of urine from affected individuals, and for many 
centuries to come, the sweet taste of urine was a key to the diagnosis. 
Physicians have observed the effects of diabetes for thousands of years. One of 
the effects of diabetes is the presence of glucose in the urine (glucosuria). For 
much of the time, little was known about this fatal disease that caused weight loss 
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of body, extreme thirst, and frequent urination. It was in 1922 that the first patient 
was successfully treated with insulin. Till the mid-1800s, the treatments offered for 
diabetes varied tremendously. A breakthrough in the puzzle of diabetes came in 
1889. German physicians Joseph von Mering and Oskar Minkowski surgically 
removed the pancreas from dogs. The dogs immediately developed diabetes. 
Now that a link was established between the pancreas and diabetes, research 
focused on isolating the pancreatic extract that could treat diabetes. Dr. Frederick 
Banting succeeded in his experiments of isolating a pancreatic extract. The 
diabetic dog was kept alive for eight days by regular injections until supplies of the 
extract, at that time called "isletin", was exhausted. Experiments on dogs showed 
that extracts from the pancreas caused a drop in blood sugar, caused glucose in 
the urine to disappear, and produced a marked improvement in clinical condition. 
A young boy, Leonard Thompson, was the first patient to receive insulin treatment 
in the year 1922 and lived for thirteen years. Over the next 70 years, insulin was 
further refined and purified. A revolution came with the production of recombinant 
human DNA insulin in 1978. Instead of collecting insulin from animals, new 
human insulin could be synthesized. In 1923, Banting and Macloed were awarded 
the Nobel Prize for the discovery of insulin. In his Nobel Lecture, Banting 
concluded the following about their discovery: “Insulin is not a cure for diabetes; it 
is a treatment.”
6.1.3 Epidemiology
Present status projects that incidence of diabetes is on rise. Present number of 
diabetics worldwide is 150 million and according to new estimates from 
researchers at the World Health Organization (WHO), there will be an increase of 
about 300 million or more by the year 2030 (Warner, 2004).  Only in year 2001, 
about 441,004 deaths were registered and 49,855 of them provoked by diabetes, 
representing 11.2% of the total population (INEGI/Health Ministry, 2002). In 
United States, diabetes is the sixth leading cause of death (NIDDK, 1995). The 
prevalence of diabetes mellitus is rapidly increasing worldwide and India is 
estimated to have 31 million diabetics from the total population of the world 
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(Warner, 2004). Diabetes is predicted to become one of the most common 
diseases in the world within a couple of decades, affecting at least half a billion 
people.
The driving force behind the high prevalence of diabetes is the rise of obesity, 
sedentary lifestyle, consumption of energy rich diet, etc. (Yagnik, 2001). The 
diabetes epidemic is accelerating in the developing world, with an increasing 
proportion of affected people in younger age groups. 
The prevalence of Type 2 diabetes is now at epidemic proportions. Type 2 
diabetes has a significant impact on the health, quality of life, and life expectancy 
of patients, as well as on the health care system. Type 2 diabetes accounts for 
about 90-95 % of population while Type 1 diabetes accounts for about 5 -10% of 
the total population. In the past, Type 2 was rarely seen in the young, but recent 
reports describe Type 2 diabetes being diagnosed even in children and 
adolescents (WHO, 2003). 
6.1.4 Sugar Regulation: Carbohydrate, protein and lipid metabolism
Glucose is an essential fuel for the body and is the main source of energy for the 
tissue cell. The amount of glucose in the blood is controlled mainly by the 
hormones insulin and glucagon. The rise in blood glucose following a meal is 
detected by the pancreatic β cells, which respond by releasing insulin. Glucose is 
transported into the β cell by Type 2 glucose transporters (GLUT2). As glucose 
metabolism proceeds, ATP is produced which closes ATP-gated potassium 
+channels in the β cell membrane. Positively charged potassium ions (K ) are now 
prevented from leaving the β cell. The rise in positive charge inside the β cell 
causes depolarization thereby opening the voltage-gated calcium channels and 
2+allowing calcium ions (Ca ) to flood into the cell. The increase in intracellular 
calcium concentration triggers the secretion of insulin via exocytosis. 
Insulin increases the uptake and use of glucose by tissues such as skeletal 
muscle and fat cells. Once inside the cell, some of the glucose is used immediately 
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via glycolysis. Any glucose that is not used immediately is taken up by the liver 
and muscle where it can be converted into glycogen (glycogenesis). When 
glycogen stores are fully replenished, excess glucose is converted into fat in a 
process called lipogenesis by increasing the number of glucose transporters 
(GLUT4) expressed on the surface of the fat cell, causing a rapid uptake of 
glucose. Glucose is converted into fatty acids that are stored as triglycerides for 
storage. 
The rise in glucose also inhibits the release of glucagon, inhibiting the production 
of glucose from other sources, e.g., glycogen break down. Glucose may also 
indirectly contribute to protein synthesis by synthesis of amino acids. Glucagon is 
the main hormone opposing the action of insulin and is released when food is 
scarce. Glucagon also helps the body to switch to using resources other than 
glucose, such as fat and protein during starvation.
6.1.5 Pathophysiology and complications
Diabetes mellitus is characterized by chronic hyperglycemia together with 
biochemical alterations of carbohydrate, lipid and protein metabolism associated 
with absolute or relative deficiencies in insulin secretion and/or insulin action 
(Arky, 1982; Andreoli et al., 1990).
Type 2 diabetes is known to have a strong genetic component along with some 
environmental determinants. Although the disease is genetically heterogeneous, 
there appears to be a fairly consistent phenotype once the disease is fully 
manifested. Whatever the pathogenic causes, the early stage of Type 2 diabetes 
is characterized by insulin resistance in insulin-targeting tissues, mainly liver, 
skeletal muscle and adiposities. Insulin resistance develops from obesity and 
physical inactivity (Gerick, 1998; Chisholm et al., 1997). Insulin resistance in 
these tissues is associated with excessive glucose production by the liver and 
impaired glucose utilization by peripheral tissues, especially muscles. These 
events undermine metabolic homeostasis, but may not directly lead to overt 
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diabetes in early stage. The chronic over-stimulation of insulin secretion gradually 
diminishes and eventually exhausts the islet β cell reserve. A state of absolute 
insulin deficiency renders the fully blown clinical diabetes (DeFronzo, 1988; 
Olefsky, 1999). The transition of impaired glucose tolerance to Type 2 diabetes 
can also be influenced by ethnicity, degree of obesity, distribution of body fat, 
sedentary lifestyle, aging and other concomitant medical conditions (Clark, 
1998).  
In diabetic patients the most common acute complications are metabolic 
problems and infection. The long-term complications are macrovascular 
complications (hypertension, dyslipidemia, myocardial infraction, stroke), 
microvascular complications (retinopathy, nephropathy, diabetic neuropathy, 
diarrhea, neurogenic bladder, impaired cardiovascular reflexes, sexual 
dysfunction), and diabetic foot disorders (Davidson, 1991).  
Hyperglycemia is caused by the increased production of glucose by the liver 
(driven by glucagon) and the decreased use of glucose of insulin by peripheral 
tissues (because of the lack of insulin). If there is too much insulin in the body 
compared to the amount of blood sugar, and the blood sugar falls below normal 
levels, a condition known as hypoglycemia occurs.
Acute metabolic complications like diabetic ketoacidosis (DKA) is a metabolic 
state emerging in some diabetics (Motala et al., 2000). As in starvation, diabetics 
use non-glucose sources of energy, such as fatty acids and ketone bodies, in their 
peripheral tissues. Because the ketones are weak acids, they acidify the blood. 
The result is the metabolic state of diabetic ketoacidosis. Hypertriglyceridemia is 
also seen in DKA. The liver combines triglycerol with protein to form very low 
density lipoprotein (VLDL). It then releases VLDL into the blood. In diabetics, the 
enzyme that normally degrades lipoproteins (lipoprotein lipase) is inhibited by the 
low level of insulin and the high level of glucagon. As a result, the levels of VLDL 
are high in DKA. Hyperlipidaemia is known to accelerate renal injury by activation 
of cytokine dependent pathways and stimulation of macrophage proliferation 
leading to progression of incipient/overt nephropathy (Park et al., 1998). 
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Oxidation of circulating low-density lipoprotein (LDL) has been linked to the 
initiation and progression of atherosclerosis and ultimately to the pathogenesis of 
cardiovascular disease (Steinberg et al., 1989). 
Oxidative stress is also suggested as one of the mechanism underlying diabetes 
mellitus, which affects carbohydrate, lipid and protein metabolism with an 
increased production of damaging free radicals that may be due to auto-oxidation 
of glucose and glycosylated proteins (Jones et al., 1985; Lyons, 1991; Giugliano 
et al., 1995).  Glycation (Vlassara et al., 1994) and hyperglycemic pseudohypoxia 
(Williamson and Lilo, 1993) generates a redox imbalance of reactive oxygen 
species (ROS) inside the cells, especially in the liver (Gallou et al., 1993). 
Reactive oxygen species are thought to be implicated in the pathogenesis of 
various human diseases. They are generated endogenously under physiological 
and pathological conditions (Halliwell, 1984). 
Defence against the reactive oxidants produced during aerobic metabolism is a 
complex process and is provided by a system of antioxidant enzymes (superoxide 
dismutase [SOD], glutathione peroxidase [Gpx], and catalase [CAT]) and low-
molecular-weight antioxidant compounds such as vitamins E and C and 
carotenoids (Halliwell, 1997; Halliwell and Gutteridge, 1989; Sies, 1993). Since 
expression of antioxidant enzymes may be induced at the transcriptional level by 
oxidative stress (Kullik and Storz, 1994), it is possible that the metabolic changes 
accompanying diabetes may induce these enzymes. These enzymes are 
capable of preventing excess radical production, neutralizing free radicals and 
repairing the damage caused by them. Damage caused by free radicals is 
possibly involved in β cell destruction and in the pathogenesis of diabetes mellitus 
(Oberley, 1988). In times of increased free radical production, individuals may 
become deficient in these antioxidants. This may ultimately lead to cell death with 
widespread pathological consequences (Baynes, 1991). Impaired antioxidant 
defense is implicated in the development of cardiovascular complications in non-
insulin-dependent diabetes (NIDDM). There is increasing evidence from 
epidemiological studies, animal experiments, and in vitro investigations that an 
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increased intake of antioxidants is associated with a diminished risk for several 
diseases (Stahl and Sies, 1997).
Aldose reductase inhibitors (ARIs) is a key enzyme in the polyol pathway which 
inhibit glucose flux through the polyol pathway, reduce sorbitol and fructose 
buildup and ameliorate neurovascular abnormalities in experimental diabetes 
(Tomlinson et al., 1982; Greene et al., 1992; Cameron et al., 1996). Sorbitol does 
not readily diffuse across cell membranes, and the intracellular accumulation of 
sorbitol has been implicated in the chronic complications of diabetes such as 
peripheral neuropathy, retinopathy, and cataracts. The polyol pathway becomes 
more active under hyperglycemic conditions and usually results in the 
accumulation of both sorbitol and fructose. Heightened activity of the polyol 
pathway could lead to the depletion of NADPH, which has been reported to be a 
cofactor for fatty acid desaturases (Brenner, 1977). The ability of sorbitol 
dehydrogenase inhibitors to relieve abnormalities in diabetes has also been 
examined, but inconsistent results have been obtained (Tilton et al., 1995; 
Cameron et al., 1997). 
6.1.6 Biochemical changes in diabetes mellitus
Diabetes mellitus is a progressive disorder characterized by hyperglycemia 
associated with malfunctioning of the vital organs of the body due to biochemical 
alterations of glucose, lipid and protein metabolism (Joslin, 1994; Lebovitz, 1994). 
Liver and kidney participates in the uptake, oxidation and metabolic conversion of 
free fatty acids, synthesis of cholesterol, phospholipids and triglycerides. Liver is 
an insulin dependent tissue, which plays a pivotal role in glucose and lipid 
homeostasis and is severely affected during diabetes (Seifter and England, 
1982). Decreased glycolysis, impeded glycogenesis and increased 
gluconeogenesis are some of the changes of glucose metabolism in the diabetic 
liver (Baquer, 1998). Kidney plays an important role in protein and lipid 
metabolism and exhibits a characteristic pattern of changes during diabetes 
(Aragno et al., 1999).  Due to hyperglycemia the delicate filtering system in the 
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kidney becomes destroyed which leads to the leakage of large blood proteins 
such as albumin. 
Estimation of total protein is one way to assess liver function. When disease 
affects the liver cells, the cells lose their ability to make albumin. Therefore, the 
measure of total protein is a rather indirect and inadequate indication of liver 
function. Albumin is the major protein of the blood and increased presence in 
serum indicates malfunctioning of the liver. 
Amino transferases like alanine transferase (ALT) and aspartate transferase 
(AST) measure the concentration of intracellular hepatic enzymes that have 
leaked into the circulation and serve as a marker of liver injury. The enzyme SGPT 
(ALT) speeds up chemical organic reactions that occur within cells. The enzyme 
SGOT (AST) is found in very high concentration in the heart and in the liver and in 
moderately large amounts in the skeletal muscle, kidneys, and pancreas. A 
characteristic rise in transaminases level is found in Type 2 diabetics (Harris, 
2005). The elevation of the enzyme acid phosphatase level in serum is also 
involved with the malfunctioning of liver or kidney during diabetes (Bottini et al., 
2004).
Creatinine is used for skeletal muscle contraction. The serum creatinine level 
provides a more sensitive test of kidney function because kidney impairment is 
the most common cause of elevated creatinine. The elevated levels of the urea 
also indicate the problem of kidney (Almdal and Vilstrup, 1988).
During diabetes a profound alteration in the concentration and composition of lipid 
occurs (Sochor et al., 1985). Triglycerides is a true fat and an important lipid 
component which takes the available cholesterol and makes it "stick" to the artery 
walls causing fat deposit build up. The cholesterol is not a true fat and is carried 
around and attaches to the major fat particles that are called lipoprotein. An 
elevated level of triglyceride and cholesterol level is associated with diabetes and 
increases the risk of coronary diseases (Al-Shamaony, 1994). HDL (Good 
cholesterol) is a lipoprotein that accepts free cholesterol from the tissue for 
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transport to the liver. HDL helps remove lipids (fats) from artery tissues and also 
protects plasma LDL from damaging the artery, thus limiting plaque buildup. LDL 
(Bad cholesterol) typically contain 60-70% of the total serum cholesterol and 
therefore its concentration closely correlates with the concentration of total 
cholesterol. The common alterations in lipid and lipoprotein profile in type 2 
diabetes also involves an elevation in serum VLDL concentrations, a dense LDL 
phenotype, and low levels of HDL cholesterol and are strongly associated with 
heart disease (De Man et al., 1996).
6.1.7 Alloxan induced diabetes mellitus
Much of the evidence for the induction of diabetes mellitus comes from the 
studies of alloxan which produces diabetes in experimental animals (Wolff 1993). 
Alloxan appears to selectively destroy the islets of Langerhans by oxidant 
production. Current evidence suggests that the selective cytotoxicity of alloxan is 
due to the function of 3 factors: efficient uptake, oxidant production by redox 
coupling of the drug with intracellular reductant (ascorbate and thiols) coupled 
with low levels of glutathione peroxidase in islets (Malaisse, 1982). Several 
studies on enzymes involved in hepatic glucose metabolism in rats with alloxan 
induced diabetes have shown well defined changes, which consist primarily of a 
decrease in the activity of glucokinase, hexokinase (Sheela and Augusti, 1992), 
and an increase in the activity of gluconeogenic enzymes including 
aminotransferases (AST and ALT). (Tanaka et al., 1988; Rawi et al., 1998) and 
glucose-6-phosphatase (Sheela and Augusti, 1992; Shibib et al., 1993).
6.1.8 Treatment: An approach to botanicals
Pharmacological treatment of diabetes mellitus is based on oral hypoglycemic 
agents and insulin (Committee Report, 1997). Different types of oral 
hypoglycemic agents such as biguanides, sulphonylurea and thiazolididinones 
are available along with insulin for the treatment of diabetes mellitus (Holman and 
Turner, 1991). These drug therapies (i.e., oral glucose-lowering agents and 
insulin injection) along with having adverse effects (Sameul and Julio, 1997) are 
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not always satisfactory in maintaining glycemia and avoid late stage diabetic 
complications (Kameshwara et al., 1997; Valiathan, 1998). Hence, their use is 
restricted by their limited action, pharmacokinetic properties, secondary failure 
rates and accompanying side effects (Bailey et al., 1989). Moreover, these 
therapies only partially compensate for metabolic derangements seen in 
diabetics and do not necessarily correct the fundamental biochemical lesion 
(Taylor and Agius, 1988). 
The complete cure of the disease has been eluding physicians for centuries and 
the quest for the development of more effective antidiabetic agents is pursued 
relentlessly. Currently available treatment is far from satisfactory and is 
expensive. Treatment and care of diabetes represents a substantial portion of the 
national health care expenditure, over $105 billion annually. This represents a 
substantial portion of health care expenditure  more than one of four Medicare 
dollars (DRWG, 1999).
Inspite of large number of hypoglycemic drugs available in the market, more and 
more people are approaching for an alternative treatment for diabetes mellitus in 
the form of herbal medicine (Bruce and David, 1999; Chang et al., 2006). 
Nowadays there is a growing interest in herbal remedies because of their 
effectiveness, minimal side effects in clinical experience and relatively low costs 
as compared to the synthetic therapeutic agents (Venkatesh et al., 2003). In 
India, indigenous remedies have been used in the treatment of diabetes mellitus 
since the time of Charaka and Sushruta (6th Century BC) (Grover et  al., 2001). 
Plants have been an exemplary source of medicine and many of the currently 
available drugs have been derived directly or indirectly from them. India has 
about 45,000 plant species and the research conducted in last few decades on 
traditional plants reports the ethno-botanical information of about 800 plants that 
may possess anti-diabetic potential (Swanston et al., 1990; Alarcon-Aguilara et 
al., 1998). Very few of the traditional plant treatments for diabetes have received 
scientific scrutiny to assess their efficacy despite the fact that World Health 
Organisation has recommended that pharmacological and a scientific 
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examination of such plants warrants attention (WHO, 1980). Herbal drugs or their 
extracts are prescribed widely, even when their biological active compounds are 
unknown. Therefore studies with plant extracts are useful to know their efficacy 
and mechanism of action and safety. Medicinal plants useful in diabetes were 
reviewed recently (Shukla et al., 2000; Grover et al., 2002). The hypoglycemic 
effect of some herbal extracts has been confirmed in animal and human models of 
Type 2 diabetes (Dey et al., 2002). There are reports of using herbal extracts for 
the treatment of diabetes mellitus in humans (ICMR, 1998). Adverse effects are 
indeed a cause of concern (Gupta and Raina, 1998), however, available evidence 
suggests that herbal medicines are relatively safe (Bailey and Day, 1989).
The potential role of the medicinal plants as hypoglycemic agents has been 
reviewed by several authors (Wang and Ng, 1999; Jouad et al., 2001; Grover et 
al., 2002; Yeh et al., 2003; Biesalski, 2004; Gupta et al., 2005; Antia et al., 2005; 
Djomeni Dzeufiet et al., 2006; Reyes et al., 2006). Many Indian medicinal plants 
are reported to be useful in diabetes (Nandkarni and Nandkarni, 1976; Kirithikar 
and Basu, 1995). Several of the most studied and commonly used medicinal 
herbs for diabetes include Ginseng species, Momordica charantia (BitterMelon), 
Trigonella foenum graecum (Fenugreek), Gymnema sylvestre (Gurmar), Allium 
cepa (Onion) and Allium sativum (Garlic), Petrocarpus marsupium, Vaccinium 
myrtillus (Bilberry), Atriplex halimus (Salt Bush), Aloe vera (Dey et al., 2002). A 
wide array of plant derived active principles representing numerous chemical 
compounds like alkaloids, glycosides, polysaccharides, guanidine, steroids, 
carbohydrates, glycopeptides, terpenoids etc has demonstrated activity 
consistent with their possible use in the treatment of NIDDM (Marles and 
Farnsworth, 1995). 
Medicinal plants have been used for diabetes safely and with reasonable success 
(Marles and Farnsworth, 1994; Duke et al., 1998). Despite the great strides that 
have been made in understanding and management of diabetes mellitus, serious 
complications continue to confront patients and physicians. The graph of 
diabetes related mortality is raising unabated (Olefsky, 2000). Therefore, search 
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for new anti-diabetic drugs continue. 
6.1.9 Diabetes: Hope for the future
Although there are no definitive preventive measures that can be taken against 
diabetes at this time, except for identifying persons at high risk and encouraging 
appropriate management. Research into the causes and control of this disease 
continues to provide the possibility of new cures. The therapy of diabetes will 
surely be altered dramatically over the next few decades (Clinton, 1998).
Research continues on the islet cell transplantation techniques, including 
research that uses stem cells derived from pancreatic ducts. There has been 
laboratory success with transplantation of islet cells derived from stem cells in 
mice, but not yet in humans (ADA, 2003).
Looking further into the future, researchers are studying the use of gene therapies 
to correct the genetic defects that are the original cause of diabetes. As successful 
gene therapy will affect a true cure of the disease, it seems likely that researchers 
will continue to pursue its development, despite many hurdles. At this point, 
however, gene therapy for treatment of diabetes appears far away in the future 
(ADA, 2003).
Considering the aforesaid, the study is aimed to demonstrate the hypoglycaemic 
and antihyperglycemic activity of the crude powder (MCR) and methanol extract 
(MME) of Manikara hexandra (Roxb.) Dubard leaf in diabetic animals with a view 
to explore its use for the treatment of diabetes mellitus in humans. 
Pharmacological action of M. hexandra (Roxb.) Dubard for anti-ulcer activity is 
reported by Shah et al., (2004).
6.2 MATERIALS  AND METHODS
6.2.1 Drug dose and preparation 
The dried leaf powder of Manilkara hexandra (Roxb.) Dubard and its methanol 
extract extracted using Soxhlet extractor were used as the drug. The dose 
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considered for the experiment on rats was obtained on conversion of the human 
-1dose of M. hexandra (Roxb.) Dubard which is 3 g kg .  The conversion factor of 
human dose to rat dose is 0.018 (Paget and Barnes, 1964). Hence the drug dose 
of animal with body weight of 200 g was 60 mg. The required dose of M. hexandra 
(Roxb.) Dubard crude powder (MCR) and methanol extract (MME) was prepared 
-1in distilled water. The standard drug glipizide was given at the dose of 0.5 mg kg  
body weight.
6.2.2 Experimental animals 
Wistar albino rats of either sex (200-300 g) were used for the antidiabetic studies. 
The animals were obtained from Sarabhai Research Center (SRC), Baroda. All 
the rats were housed in standard plastic rat cages with stainless steel coverlids 
and wheat straw as bedding material at the animal house of Department of 
Biosciences, Saurashtra University, Rajkot. The animals were kept in a group of 
6-8 per cage and facilitated with standard environmental condition of photoperiod 
(12:12 h dark: light cycle) and temperature (27 ± 2ºC). They were provided with 
commercial rat and mice feed (Pranav Agro Industries Ltd., Amruth Brand rat & 
mice pellet feed) and water given ad libitum. The use of these animals and the 
study protocols were approved by CPCSEA ethical committee.
6.2.3 Drug administration
The test drugs, cude powder drug (MCR), methanol extract (MME) and glipizide 
(G) was administered orally (p.o.) according to the body weight of all the groups of 
rats with the help of a gastric catheter.
6.2.4 Experimental design
6.2.4.1 Hypoglycemic study of M. hexandra (Roxb.) Dubard leaf on normal 
fasted rats
To investigate hypoglycemic effect of the crude powder and methanol extract of 
Manilkara hexandra (Roxb.) Dubard, the normal rats were fasted overnight. They 
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were divided into 3 groups of 6 each. Fasting blood glucose (FBG) level was 
measured with one touch glucometer (Johnson & Johnson). The animals were 
anesthetized by ether and the blood was collected by puncturing the retro-orbital 
plexuses with the help of sterile glass capillaries. Thereafter, one group received 
distilled water which served as the control group. The other two groups received 
-1suspension of crude powder and methanol extract with dose of 300 mg kg  body 
weight respectively. Blood samples were collected at 1 h, 2 h, 3 h and 4 h after 
drug administration and the blood glucose levels were measured with 
glucometer.
6.2.4.2 Sucrose tolerance test (STT) of M. hexandra (Roxb.) Dubard leaf on 
normal rats
A modified glucose tolerance test (GTT) was carried out on normal rats by 
sucrose loading. To investigate sucrose tolerance test (STT) in crude powder and 
methanol extract of Manilkara hexandra (Roxb.) Dubard, rats were tagged, 
weighed and divided into 3 groups of 6 each. The initial blood glucose level of the 
rats in each group was measured with glucometer. One group received water 
which served as the control group. The other two groups received suspension of 
-1crude and methanol extract with dose of 300 mg kg  respectively. The rats of all 
-1groups were loaded with sucrose at the dose of 40 mg kg  body weight, orally 
(p.o.) 1 h after drug administration. The blood glucose levels were measured at       
2 h, 4 h, 8 h and 24 h after sucrose loading. The animals were anesthetized by 
ether and blood was collected by puncturing the retro-orbital plexuses with the 
help of sterile glass capillaries. 
6.2.4.3 Efficacy of the M. hexandra (Roxb.) Dubard leaf in alloxan induced 
diabetic rats
6.2.4.3.1 Induction of experimental diabetes
The rats selected for the study were weighed and their initial blood glucose level 
was measured with glucometer. A freshly prepared solution of alloxan (Loba 
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-1Chemie) (90 mg kg  body weight) in 0.1 M citrate buffer, pH 4.6 was injected 
intraperitoneally (i.p.) to rats of either sex for two consecutive days at an interval 
-1of 24 h. The total dose of alloxan induced in the rats was 180 mg kg  body weight. 
At the third day of first induction, blood glucose levels were measured to confirm 
the development of diabetes. The diabetic rats exhibiting blood glucose levels in 
-1the range of 200- 590 mg dL  were selected to determine the efficacy of crude 
powder and methanol extract of Manilkara hexandra (Roxb.) Dubard leaf.
6.2.4.3.2 Drug treatment
The alloxan induced diabetic rats of either sex were weighed and divided into 4 
groups of 6 each. Group I was given water, p.o. daily and served as control group. 
Group II and Group III received suspension of the crude powder and methanol 
-1extract of M. hexandra (Roxb.) Dubard leaf p.o., at the dose of 300 mg kg  body 
weight. The standard group received the suspension of glipizide p.o., at a dose of 
0.5 mg kg-1 body weight. All the groups were given the drug treatment for a period 
of 7 days.
6.2.4.3.3 Sacrificing of the animals
The animals were sacrificed by stunning and severing of neck blood vessels on 
the 8th day of treatment. The body weight of animals was noted prior to sacrificing 
them. The blood was collected after sacrificing the animals for evaluating some 
biochemical parameters like total serum protein, serum albumin, total serum 
cholesterol, HDL-cholesterol, serum triglyceride, serum urea, serum creatinine, 
aspartate transaminase (AST), alanine transaminase (ALT), serum acid 
phosphatase and blood glucose. The glycogen content was estimated from the 
liver sample. All the sacrificed animals were dissected and the important organs 
like liver, kidney, heart and pancreas were removed carefully. The absolute 
weight of liver, kidney and heart was noted. All the organs (liver, kidney, heart and 
pancreas) were kept in 4% formalin solution and were subjected to 
histopathological studies.
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6.2.4.3.4 Biochemical parameters
The absorbance of all the biochemical parameters was measured in a UV-VIS 
spectrophotometer (Shimadzu).  
6.2.4.3.4.1 Serum glucose
The estimation of serum glucose was done by GOD/POD method (Trinder, 1969) 
using Glucose Tablet format estimation kit (Bayer Diagnostics).
Principle: Glucose is oxidized by glucose oxidase (GOD) into gluconic acid and 
hydrogen peroxide. Hydrogen peroxide in presence of peroxidase (POD) 
oxidizes the chromogen 4-aminoantipyrene/phenolic compound to a red 
coloured compound. The intensity of the red coloured compound is proportional 
to the glucose concentration and is measured at 505 nm.
Reagents:  Reagent I: Buffer/ Enzymes/ Chromogen
-1
                   Reagent II: Standard (Glucose 100 mg dL )
Assay: 2000 µl of Reagent I was added in clean test tubes. 20 µl of serum was 
added for test, 20 µl of Reagent II was added for standard and 20 µl of distilled 
water was added for blank. It was then mixed well and incubated at 37°C for 15 
min. The absorbance was read at 505 nm  against blank. 
Calculation:
-1Serum Glucose (mg dL ) = Absorbance of test X Calibration factor (64.1)
6.2.4.3.4.2 Serum albumin
The serum albumin was estimated by the method given by Corcoran and Durnan 
(1977) using Albumin test kit (Span Diagnostics Ltd.).
Principle: Determination of albumin in serum or plasma is based on the binding 
behaviour of the protein with the dye bromocresol green. At pH 3.68, albumin acts 
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as a cation and binds to the anionic dye, forming a green complex, the 
absorbance of which is measured at 630 nm.
Reagents: Reagent I- Albumin reagent
-1
                  Reagent II- Albumin standard 4.0 g dL
Assay: 2 ml Reagent I was added to all the test tubes. Thereafter, 20 µl serum 
was added for the test and 20 µl Reagent II was added for the standard. It was 
then mixed well and incubated at room temperature for 1 min. The absorbance 
was read at 630 nm against reagent blank.
Calculation: 
-1Serum albumin (g dL ) =     Absorbance of test         X   4.0
                                        Absorbance of standard 
6.2.4.3.4.3 Serum total protein
The total serum protein was estimated by modified Biuret method (Gornall et al., 
1949) using the Total Protein test kit (Span Diagnostics Ltd.).
Principle: Peptide bonds of proteins react with cupric ions in alkaline solution to 
form a colored chelate, the absorbance of which is measured at 578 nm. The 
biuret reagent contains sodium-potassium tartrate to complex cupric ions and 
maintains their solubility at alkaline pH. Absorbance data are proportional to 
protein concentrations.
Reagents: Reagent I- Biuret reagent
-1
                  Reagent II- Protein standard 6.5 g dL
Assay: 3 ml of Reagent I was added to all the test tubes. Thereafter, 30 µl serum 
was added for the test and 30 µl Reagent II was added for the standard. It was 
then mixed well and incubated at 37ºC for 5 min. The absorbance was read at 578 
nm against reagent blank.
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Calculation: 
-1Serum total protein concentration (g dL ) =         Absorbance of test       X   6.5
                                                                       Absorbance of standard 
6.2.4.3.4.4 Glycogen estimation
Estimation of glycogen is carried out by the method of Caroll et al., (1956).
Reagents: Reagent I- KOH solution (30%)
             Reagent II- Anthrone reagent
-1
             Reagent III- Stock glucose solution, 1gm 100 ml
-1
             Reagent IV- Working glucose solution, 40 µg ml
Assay:  50 mg of liver was digested by boiling it in 2 ml 30% KOH for 20 min. It was 
then left in KOH till the tissue was completely digested. It was cooled and 2-3 ml of 
ethanol was added. Again it was boiled for 1-2 min, cooled and centrifuged. The 
supernatant was discarded and again 2-3 ml of 95% ethanol was added to the 
pellet. It was again boiled a little and cooled. Thereafter it was kept in refrigerator 
for 30 min in order to precipitate the glycogen. Thereafter it was centrifuged and 
the supernatant was discarded. The precipitate was diluted with 10 ml of distilled 
water and from that 1 ml was added for test while 1 ml distilled water was added for 
blank. Then 4 ml of anthrone reagent was added to each tube and kept the tubes 
in ice bath for 5 min. Immediately the tubes were transferred to boiling water bath 
for 4 min. It was again immediately cooled in ice for 5 min. The absorbance was 
read at 620 nm. 
Calculation:
-1Glycogen content (mg dL ) =    O.D. of test X concentration of std.  X dilution  X 100 
                                       O.D. of std. X wt. of tissue (mg) X conversion factor (1.11)
6.2.4.3.4.5 Serum urea
The serum urea was estimated by Enzymatic Urease (Berthelot) method (Fawcett 
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and Scott, 1960) using Urea Berthelot test kit (Span Diagnostics Ltd.).
Principle: Urea in the presence of water and urease produces ammonia and 
carbon dioxide. Under alkaline conditions, ammonia so formed reacts with 
hypochlorite and phenolic chromogen to form a green colored indophenol which is 
measured at 578 nm. The intensity of the colour is proportional to the 
concentration of urea in the sample.
Reagents:  Reagent I- Urea enzyme reagent   
                  Reagent II- Urea chromogen reagent
-1
                  Reagent III- Urea standard 50 mg dL                           
                  Reagent IV- Purified water
Solution I: To Reagent I add 50 ml Reagent IV and mix gently. Enter the date of 
reconstitution and store at 2-8ºC. It is stable for 45 days.
Solution II:  Dilute the contents of Reagent II, with 160 ml reagent 4. Alternatively 
dilute the contents of Regent II as per the requirement. It is stable for 4 months.
Assay:  1500 µl Solution I was added to clean test tubes. 20 µl serum was added 
for the test and 20 µl Reagent II was added for the standard. It was then mixed well 
and incubated at 37ºC for 3 min; then 1500 µl of Solution II was added. It was then 
mixed well and incubated at 37ºC for 5 min. The absorbance was read at 578 nm 
against reagent blank.
Calculation: 
-1Serum urea (mg dL ) =    Absorbance of test          X   50
                                     Absorbance of standard
6.2.4.3.4.6 Serum creatinine
The serum Creatinine was estimated by Alkaline Picrate method (Bonses and 
Taussky, 1945) using Creatinine test kit (Span Diagnostics Ltd.).
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Principle: Creatinine in a protein free solution reacts with alkaline picrate and 
produces a red coloured complex, which is measured colorimetrically.
Reagents: Reagent I- Picric acid
                  Reagent II- Sodium Hydroxide, 0.75N
                  Reagent III- Stock Creatinine standard, 150 mg %
Assay: 
Step A. Deproteinization of test samples
3000 µl Reagent I was added to clean test tubes. Thereafter 500 µl of serum and 
500 µl of purified water were added for the test. It was then mixed well and kept in 
boiling water bath exactly for 1 min. It was then cooled immediately under 
running tap water and centrifuged. 
Step B. Color Development
2000 µl of the supernatant was added to clean test tubes. 500 µl of working 
standard prepared from Reagent III and 500 µl of purified water was added to the 
tubes. Then 1500 µl Reagent I and 500 µl Reagent II was added to the tubes. It 
was then mixed well and allowed to stand at room temperature exactly for 20 
min. The absorbance of blank, standard and test was read at 520 nm.
Calculation: 
-1Serum creatinine (mg dL ) =    Absorbance of test  -  Absorbance of blank   x 3.0
                                              Absorbance of standard - Absorbance of blank
6.2.4.3.4.7 Serum aspartate transaminase (AST) (SGOT) (E.C.2.6.1.1)
The serum aspartate transaminase was estimated by the method of Reitman 
and Frankel (1957) using AST test kit (Span Diagnostics Ltd.).
Principle: β ketoglutarate and L- aspartate react to form L-glutmate and 
oxaloacetate. This reaction is catalysed by aspartate transaminase. 
Materials & Methods
Oxaloacetate so formed is coupled with 2,4-dinitrophenyl hydrazine (2,4-DNPH) 
to give the corresponding hydrazone, which gives brown color  in alkaline 
medium and this can be measured colorimetrically. 
Reagents: Reagent I- Buffered Aspartate á  KG Substrate, pH 7.4
                  Reagent II- DNPH color reagent
                  Reagent III- Sodium hydroxide, 4N
                  Reagent IV- Working Pyruvate standard, 2 mM
Solution 1: Dilute 1 ml of Reagent III to 10 ml with purified water. 
Assay:  250 µl Reagent I was added in clean test tubes and Incubated at 37ºC for 
5 min. 50 µl of serum was added for the test, 50 µl Reagent IV for standard and 50 
µl distilled water was added for the blank. It was mixed well and incubated at 37ºC 
for 60 min. Thereafter, 250 µl Reagent II was added to all the tubes, mixed well 
and allowed to stand at room temperature for 20 min. Now 2500 µl Solution 1 was 
added to all the tubes, mixed well and allowed to stand at room temperature for 10 
min. The absorbance of blank, standard and test was read at 505 nm.
Calculation: Mark the absorbance of test on Y-axis of the standard curve and 
extrapolate it to the corresponding enzyme activity on X-axis.
6.2.4.3.4.8 Serum alanine transaminase (ALT) (SGPT) (E.C.2.6.1.2)
The serum alanine transaminase was estimated by the method of Reitman and 
Frankel (1957) using ALT test kit (Span Diagnostics Ltd.).
Principle: α ketoglutarate and L- alanine react to form L-glutmate and pyruvate. 
This reaction is catalysed by alanine transaminase. Pyruvate so formed is 
coupled with 2,4-dinitrophenyl hydrazine (2,4-DNPH) to give the corresponding 
hydrazone, which gives brown color  in alkaline medium and this can be 
measured colorimetrically. 
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Reagents: Reagent I- Buffered Alanine α  KG Substrate, pH 7.4
                  Reagent II- DNPH color reagent
                  Reagent III- Sodium Hydroxide, 4N
                  Reagent IV- Working Pyruvate standard, 2 mM
Solution 1: Dilute 1 ml of Reagent III to 10 ml with purified water. 
Assay:  250 µl Reagent I was added to clean tubes and was incubated at 37ºC for 
5 min. 50 µl of serum was added for the test, 50 µl of Reagent IV was added for the 
standard and 50 µl distilled water was added for the blank. It was then mixed well 
and incubated at 37ºC for 30 min. 250 µl of Reagent II was added to the tubes; 
mixed well and allowed to stand at room temperature for 20 min. Then 2500 µl 
Solution 1 was added, mixed well and allowed to stand at room temperature for 10 
min. The absorbance of blank, standard and test was read at 505 nm.
Calculation: Mark the absorbance of test on Y-axis of the standard curve and 
extrapolate it to the corresponding enzyme activity on X-axis.
6.2.4.3.4.9 Serum acid phosphatase
The serum acid phosphatase was determined by King's method (King and 
Jagatheesan, 1959) using Acid Phosphatase test kit (Span Diagnostics Ltd.).
Principle: Acid phosphatase from serum converts phenyl phosphate to inorganic 
phosphate and phenol at pH 4.9. Phenol so formed reacts in alkaline medium with 
aminoantipyrine in presence of oxidizing agent potassium ferricyanide and forms 
an orange red coloured complex, which is measured colorimetrically. The color 
intensity is proportional to the enzyme activity. Since tartrate inhibits the prostratic 
fraction of the enzyme, the difference in acid phosphatase activity without and 
with tartrate represents the activity of the prostratic fraction.
Reagents: Reagent I- Buffered substrate, pH 4.9
                  Reagent II- Sodium hydroxide, 0.5 N
                  Reagent III- Sodium bicarbonate, 0.5 N
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                  Reagent IV- 4-aminoantipyrine, 0.6%
                  Reagent V- Potassium ferricyanide, 2.4%
                  Reagent VI- Stock phenol standard, 10 mg %
Preparation of working solutions:
Solution 1: Reconstitute each vial of Reagent I with 2.0 ml of purified water and 
mix well.
Solution 2: Dissolve Reagent IV in 25 ml of purified water
Solution 3: Dissolve Reagent V in 25 ml of purified water
Working standard: Dilute stock phenol standard 0.5à5 with purified water
Assay: The clean test tubes were marked as blank, standard, control and test. 
500 µl Solution 1 was added in control and test. Then 500 µl of purified water was 
added in control and test and in blank and standard 1100 µl and 600 µl of purified 
water was added respectively. It was mixed well and incubated at 37ºC for 3 min. 
Thereafter, 500 µl of working standard solution was added in standard and 100 µl 
of serum was added in test. It was mixed well and incubated at 37ºC for 60 min. 
Now 500 µl Reagent II was added in all blank, standard, control and test; 100 µl of 
serum was added in control; 500 µl Reagent III , Solution 2 and Solution 3 were 
added in all blank, standard, control and test. The tubes were mixed well and the 
absorbance was read at 510 nm.
Calculation: 
Serum acid phosphatase (KA units) :
             Total =     Absorbance of test  -  Absorbance of control     X   5.0
                         Absorbance of standard - Absorbance of blank
6.2.4.3.4.10 Serum triglyceride
The serum triglyceride was estimated by Enzymatic GPO method (Cole et al., 
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1997; Rifai et al., 1999) using Triglyceride EP* LS test kit (Euro Diagnostic 
Systems Pvt. Ltd.). 
Principle: 
Triglycerides  à   Glycerol + Fatty acid
Glycerol + ATP à Glycerol- 3-Phosphate + ADP
Glycerol- 3-Phosphate + O  à Dihydroxyacetone phosphate + H O2 2 2
2H O    + Aminoantipyrine + 4-Chlorophenol  à  Quinoneimine + HCl + 4 H O2 2 2
Reagents: Reagent I- Monoreagent 
-1
                  Reagent II- Triglyceride standard 200 mg dL
Assay: 2000 µl Reagent I was added to clean test tubes. 20 µl of serum was 
added for the test and 20 µl Reagent II was added for the standard. It was then 
mixed well and incubated at 37ºC for 10 min. The absorbance was read at 500 nm 
against reagent blank.
Calculation: 
-1Serum triglyceride (mg dL ) =    Absorbance of test    X   Conc. of  standard (40)
                                               Absorbance of standard
6.2.4.3.4.11 Serum cholesterol
The serum cholesterol was estimated by CHOD-PAP method (Trinder, 1969) 
using Cholesterol EP LS test kit (Euro Diagnostic Systems Pvt. Ltd.).
Principle: Cholesterol esters are hydrolysed by Cholesterol Esterase (CE) to 
give free cholesterol and fatty acids. In subsequent reaction, cholesterol oxidase 
(CHOD) oxidises the 3-OH group of free cholesterol to liberate Cholest-4-en-3-
one and hydrogen peroxide. In the presence of the peroxidase (POD), hydrogen 
oxide couples with 4-aminoantipyrene (4-AAP) and phenol to produce red 
quinoneimine dye. Absorbance of colored dye is measured at 505 nm and 
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proportional to the amount of total cholesterol concentration in the sample.
Reagents: Reagent I- Monoreagent
-1
                  Reagent II- Cholesterol standard 200 mg dL
Assay: 2000 µl Reagent I was added to all the test tubes. Thereafter, 20 µl serum 
was added for the test, 20 µl Reagent II for standard and 20 µl distilled water in 
blank. It was then mixed well and incubated at 37ºC for 10 min. The absorbance 
was read at 505 nm against reagent blank.
Calculation: 
-1Serum cholesterol (mg dL ) =     Absorbance of test      X   Conc. of standard (40)
                                                Absorbance of standard 
6.2.4.3.4.12 HDL-cholesterol
The HDL-cholesterol was estimated by PTA method (Friedwaid et al., 1972) 
using HDL-cholesterol test kit (Euro Diagnostic Systems Pvt. Ltd.).
Principle: The chylomicrons, VLDL and LDL are precipitated from serum by the 
addition of phosphotungstic acid and magnesium chloride. After centrifugation, 
high density lipoprotein fractions recovered as clear supernatant and the 
cholesterol content is estimated by enzymatic method.
Reagents: Reagent I- Precipitating reagent
                  Reagent II- Cholesterol reagent
-1
                  Reagent III- Standard 50 mg dL
Assay: 200 µl of serum sample and 200 µl of Reagent I was added to all the test 
tubes. It was mixed well and allowed to stand for 10 min at room temperature. The 
test tubes were centrifuged for 10 min at 3000 rpm. The clear supernatant was 
separated and used for HDL-cholesterol estimation. 1000 µl Reagent II was 
added in clean test tubes. 50 µl separated supernatant for the test and 50 µl 
Reagent 3 for standard was added. It was then mixed well and incubated at 37ºC 
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for 10 min. The absorbance was read at 505 nm against reagent blank.
Calculation: 
-1HDL-cholesterol (mg dL ) =    Absorbance of test   X  Conc. of standard (25) X   2  
                                          Absorbance of standard
6.2.4.3.4.13  LDL-cholesterol
The LDL-cholesterol value was calculated from the values of serum cholesterol, 
serum triglyceride and HDL-cholesterol estimated (Friedewald et al., 1972). The 
Frieldewald's formula for the calculation of LDL-cholesterol is expressed as 
follows:
LDL-cholesterol = Cholesterol  -  [ Triglyceride + HDL-cholesterol ]
                           5
6.2.4.3.4.14 VLDL-cholesterol
The VLDL-cholesterol value was calculated from the values of serum cholesterol 
and serum triglyceride estimated (Friedewald et al., 1972). The Frieldewald's 
formula for the calculation of VLDL- cholesterol is expressed as follows:
VLDL-cholesterol = [ Triglyceride]
                                        5
6.2.4.3.5 Changes in the body weight and their organs
The changes in the body weight during 7 days treatment was determined. The 
changes in absolute and relative weight of organs like liver, kidney and heart of all 
the experimental groups was evaluated after seven days treatment.
6.2.4.3.6 Histopathological study
Histopathological study of liver, kidney, heart and pancreas was performed.
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6.2.4.3.6.1 Histology of studied organs
6.2.4.3.6.1.1 Heart
The heart is centrally located in the thoracic cavity. It contains four chambers. The 
two dark colored chambers at the top are the atria, and the bottom chambers are 
the ventricles. The heart is covered by a thin membrane called the pericardium. 
Valves guard the exits of the chambers, preventing backflow of blood. The wall of 
heart includes the cardiac muscle, a fibrous skeleton for attachment of the valves, 
and a specialized internal conducting system involved in the regulation of heart 
rate. The fibrous skeleton, comprised of dense connective tissue, is situated 
around the openings of the two arteries leaving the heart and around the 
openings between the atria and the ventricles. The wall of the heart contains three 
layers: the epicardium, myocardium and the endocardium. The layers are 
essentially the same in the atria and the ventricles. The epicardium consists of a 
lining of mesothelial cells and an underlying layer of connective tissue. Blood 
vessels and nerves supplying the heart lie within the epicardium, often 
surrounded by adipose tissue. The myocardium consists of cardiac muscle. The 
myocardium can be divided into three layers: an inner layer of endothelium and 
subendothelial connective tissue, a middle layer comprised of connective tissue 
and smooth muscle cells, and an outer layer, also called the subendocardial layer, 
which is continuous with the connective tissue of the myocardium. The 
interventricular septum serves as the wall between the right and left ventricles. 
The interatrial septum is much thinner than the interventricular septum. Fibrous 
thread like cords, called the chordae tendinae, extend from the free edge of the 
atrioventricular valves to muscular projections from the wall of the ventricles 
called papillary muscles.
6.2.4.3.6.1.2 Liver
Liver is an organ suspended just under the diaphragm. There are four parts of the 
liver- median or cystic lobe which is located at top, there is a central cleft left lateral 
lobe - large and is covered by the stomach, right lateral lobe- partially divided into 
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an anterior and posterior lobule, hidden from view by the median lobe caudate 
lobe- small and folds around the esophagus and the stomach, seen most easily 
when liver is raised.
The rat liver stained with hematoxylin and eosin shows a classic lobule and a 
liver acinus located. The arrangement of the portal triad, hepatocytes, sinusoids, 
and central veins within the lobule and acinus can be seen. At higher power the 
portal triad with hepatic artery, portal vein, bile duct and connective tissue can be 
located. The portal vein is the largest vessel to have a thin wall. The hepatic 
artery is small, with 1-3 muscle layers in the tunica media. The bile duct is lined 
with simple cuboidal epithelium. The hepatic sinusoids are seen and the wall of 
the sinusoid is lined with endothelial cells and Kupffer cells. Kupffer cells have 
nuclei, which tend to be larger and more ovoid than the flattened endothelial 
cells. The space of Disse is visible between the sinusoidal endothelial cell and 
the hepatocyte. The hepatocytes are mono- and binucleate cells, and the 
presence of small and large nuclei. The ergastoplasm of the hepatocytes 
appears as darkly stained, irregularly shaped areas in the. The central vein is 
lined by endothelial cells with minimal underlying connective tissue. There is a 
continuation of a sinusoid with the central vein and the serosa of this organ can 
be seen. 
6.2.4.3.6.1.3 Kidney
The two bean-shaped kidneys lie up against the dorsal body wall. The kidney is 
divided into two regions, an outer cortex and an inner medulla. The nephron (the 
functional unit of the kidney) is organized so that Bowman's Capsule and the 
proximal and distal tubules are located in the cortex and the loop of Henle and 
the collecting tubules are located primarily in the medulla. In the cortical region 
Bowman's capsules are relatively abundant and appear as spherical structures 
with a coiled mass of capillaries, the glomerulus in the center. Surrounding the 
Bowman's capsule are the elements of proximal and distal convoluted tubules 
cut in various plains of section. The cells making up the walls of the tubules are 
cuboid in shape and contain a prominent nucleus. In the medulla there are 
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elements from the loop of Henle and the collecting tubules which cut mostly in 
longitudinal section.
6.2.4.3.6.1.4 Pancreas
The rat pancreas is a filamentous organ divided into 3 anatomic regions- 
gastroplenic, duodenal and biliary. There are exocrine and endocrine glands in 
the pancreas. 
The exocrine pancreas consists of several thousand loosely connected lobes or 
tubuloacinar glands. The lobes are separated by their connective tissue septa 
and each lobe contains a group of branched ducts with their acini. Acini may have 
a multitude of shapes and sizes. They are long, club-shaped acini with humped 
surfaces as well as single round acini. 3-5 acini assemble to a cluster. Their 
individual ducts combine to a common duct. A single layer of pyramidal shaped 
cells forms the secretory acini. The supranuclear and cytoplasmic spaces are 
densely packed with secretory granules.  is filled with secretory vesicles 
containing the precursors of digestive enzymes. The first portion of the duct 
system extends into the centre of the acini, which is lined by small centroacinar 
cells. These are numerous capillaries in the interstitial connective tissue. They 
form the first part of intercalated ducts. Intercalated ducts are lined by low 
columnar or cuboidal epithelium. The columnar cells of the secretory cells of the 
acini conain basal nuclei. They empty into interlobular ducts, which are lined by a  
columnar epithelium. Interlobular ducts in turn empty into the main pancreatic 
duct, which is lined by a tall columnar epithelium. 
The endocrine glands are the islets of Langerhans. Islets are comprised of a 
heterogenous population of the endrocrine cells, including insulin-producing β-
cells, glucagon-secreting β-cells, somatostatin-secreting β-cells and polypeptide 
(PP) secreting cells.
6.2.4.3.6.2 Methods for histopathological studies
The organs were transferred to 10% formalin (37-40%) solution for fixation and 
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thereafter processed for histopathological studies following the procedure of 
Raghuramulu et al., (1983). The microtome sections were cut, processed and 
stained with haematoxylin and eosin. The section thus obtained was scanned in 
Trinocular Carl-Zeiss microscope (Germany) under different magnifications. 
Any changes in the cytoarchitechture of the tissue were determeined.
6.2.4.3.6.2.1 Fixation
Fixation is the process of preserving, hardening and preventing postmortem 
changes of the tissues. The tissues were excised out immediately after 
sacrificing, cleaned off extraneous tissues, cut in to pieces of appropriate 
thickness so that the fixative readily penetrated throughout the tissue to be fixed. 
Tissue was then transferred to 10% formaldehyde solution (37-40% 
formaldehyde) and allowed to remain until they were processed.
6.2.4.3.6.2.2 Tissue processing
The processing of tissue involves dehydration, clearing and infiltration of the 
tissue with paraffin. The usual dehydrating agent is ethyl alcohol; acetone and 
isopropyl alcohol can also be used. Following dehydration, the tissue was 
transferred to a paraffin solvent, which is miscible with the dehydrating agent as 
well. These are known as clearing agents such as chloroform and xylene. 
Tissues were thoroughly washed by placing them under running tap water and 
then passed through a series of following solvents as per schedule for 
dehydration, clearing and paraffin infiltration.
Alcohol 70% -   20 minutes
Alcohol 80% -   20 minutes
Alcohol 90% -   20 minutes
Alcohol 95% (2 changes) -   20 minutes each
Isopropyl alcohol -   20 minutes
Acetone (2 changes) -   20 minutes each
Chloroform (3 changes) -   20 minutes each
Melted paraffin wax (60°C) (3 changes) - 30 minutes each
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Thereafter, the tissues were embedded in paraffin wax to prepare tissue blocks, 
which are oriented so that sections are cut in desired plane of the tissue. After 
trimming them to suitable size the tissues were fixed to metal object holder.
6.2.4.3.6.2.3 Section Cutting
A smear of 5% Mayer's egg albumin was prepared and smeared on to the slide 
and dried. The tissue sections of 6 µm thickness were cut with the help of Spencer 
type rotating microtome. The tissue sections were put on slide and the section 
floated in water on slide between 55-60°C, water was drained off and slide was 
dried on hot plate at about 50°C for 30 minutes. 
6.2.4.3.6.2.4 Staining Procedure
Reagent: 1). Mayer's heamotoxyline stain
                 2). Eosin stain, 2% w/v in alcohol
After fixing the section on slide, the sections were stained by serially placing them 
in the following reagents:
Xylol (2 changes) -   3 minutes
Acetone -   3 minutes
Alcohol 95% -   3 minutes
Haematoxyline stain -   20 minutes
Running water -   20 minutes
Eosin stain -    5 minutes
Alcohol 95% (3 changes) -    3 minutes each
Acetone (2 changes) -    3 minutes each
Xylol (2 changes) -    3 minutes each
When the slides were passed through all the above reagents, the slides were 
mounted with D.P.X. (Diphenyl Phthalate Xylene) and cover slip was placed. 
During mounting the slide care should be taken for avoiding the air bubbles. The 
slides were viewed under Trinocular research Carl Zeiss microscope (Germany) 
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at various magnifications to note down the changes in the microscopic features of 
the tissues studied.
6.2.5 Statistical analysis
Data is expressed as mean ± S.E.M. for all the experiments. The biochemical 
parameters were analyzed statistically using analysis of variance (ANOVA) 
(significance level was fixed at F<0.05) followed by Dunnett's multiple 
dcomparison test (significance level was fixed at P<0.05). Statistical difference 
amongst the data was analyzed by Students “t” test. The minimum level of 
significance was fixed at P<0.05.
6.3 RESULTS AND DISCUSSION 
Diabetes is possibly the world's fastest growing metabolic disease, so there 
arises need for more appropriate therapies. Management of diabetes without any 
side effects is still a challenge to the medical community. Despite insufficient 
evidences to support its therapeutic efficacy, the use of herbal medicine has 
increased considerably. 
6.3.1 Hypoglycemic study of Manilkara hexandra (Roxb.) Dubard leaf on 
normal fasted rats
The hypoglycemic effect of M. hexandra (Roxb.) Dubard leaf is shown in Table 
st6.1. The blood glucose level of the control group at 1  h was 69.6 ± 5.74 mg/dL, 
that of crude drug (MCR) treated group was 56.6 ± 2.32 which was 18.67 % less 
that the control group and the blood glucose level of the methanol extract (MME) 
sttreated group at 1  h was 63.8 ± 3.19 mg/dL which was 8.33 % less than the 
ndcontrol group. The blood glucose levels at the 2  h for control group was 60.2 ± 
2.07, that of crude drug administered group was 60.8 ± 1.40 mg/dL which was 
0.99 % higher than the control group and that of the methanol treated group was 
69.8 ± 3.45 mg/dL which was 15.94 % higher as compared to the control group.  
rdThe blood glucose level at the 3  h for the control group was 70.0 ± 3.52 mg/dL, 
that of crude drug treated group was 61.2 ± 2.51 mg/dL which was 12.57 % less 
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than the control group and that of the methanol treated group was 64.8 ± 5.56 
mg/dL which was 7.42 % less than the control group. The blood glucose level at 
ththe 4  h of the control group was 70.8 ± 1.20 mg/dL, of the crude drug treated 
group was 63.8 ± 3.24 mg/dL which was 9.88 % less than the control group and 
that of the methanol group was 72.2 ± 3.63 mg/dL which was 2.82 % higher than 
the control group.
6.3.2 Sucrose tolerance test (STT) of Manilkara hexandra (Roxb.) Dubard 
leaf on normal rats
The data related to the evaluation of antihyperglycemic activity of M. hexandra 
(Roxb.) Dubard leaf on the sucrose fed normal rats is shown in the Table 6.2.
 The percent elevation of the blood glucose level of the control group as compared 
-1 nd -1 thto the initial level was 21.61 ± 5.39 mg dL  at 2  h, 20.29 ± 6.91 mg dL  at 4  h, 
-1 th -1 th27.76 ± 10.64 mg dL  at 8  h and 15.98 ± 10.77 mg dL  at 24  h.
The percent change as compared to the initial blood glucose level for the crude 
-1 nd ddrug group was 38.34 ± 5.33 mg dL  at 2  h which was 77.41 % (P< 0.05, P< 
th0.05) higher than the control group; at 4  h the percent rise of the blood glucose 
-1level as compared to the initial level was 47.10 ± 4.67 mg dL  which was 132.13 % 
th(P< 0.05) more than the control group; at 8  h the percent change in blood glucose 
-1level was 31.26 ± 6.97 mg dL  which was 12.60 % higher than the control group 
th -1and at 24  h the glucose level was 20.13 ± 4.10 mg dL  which was 25.96 % more 
than the control group.
The percent change in the blood glucose level of the methanol drug treated group 
-1 stas compared to the initial level was 36.56 ± 3.77 mg dL  at 1  h which was 69.18 % 
th -1higher than the control group; at 4  h  the glucose level was 36.05 ± 2.38 mg dL  
which was 77.67 % higher as compared to the control group; the elevation of 
th -1blood glucose at 8  h was 62.03 ± 9.90 mg dL  which was 123.45 % more than 
th -1control group and at 24  h the rise in glucose level was 32.59 ± 5.67 mg dL  which 
was 103.94 % more than the control group.
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6.3.3 Effect of Manilkara hexandra (Roxb.) Dubard leaf on blood glucose 
level in alloxan induced diabetic rats 
Alloxan is widely used as an agent for the development of experimental diabetes 
to induce selective dysfunctioning of pancreatic β-cells (Rerup, 1970; Lenzen and 
Panten, 1988) and the destruction is almost complete (Khan and Shechter, 
1991). Alloxan causes massive reduction in insulin release, through the 
destruction of β-cells of the islets of Langerhans (Oberley, 1988). In vitro studies 
have shown that alloxan is selectively toxic to pancreatic β cells, leading to the 
induction of cell necrosis (Jorns et al., 1997).  The cytotoxic action of alloxan is 
mediated by reactive oxygen species, with a simultaneous massive increase in 
cytosolic calcium concentration, leading to a rapid destruction of β cells 
(Szkudelski, 2001).
Diabetes mellitus is characterised by hyperglycaemia together with biochemical 
alterations of glucose and lipid metabolism (Arky, 1982). Experimental diabetes 
in animals has provided considerable insight into physiologic and biochemical 
derangement of the diabetic state. Insulin deficiency leads to various metabolic 
aberrations in the animals, viz. increased blood glucose, decreased protein and 
albumin content, increased cholesterol and triglycerides levels, increase in 
alkaline phosphatase, acid phosphatase and transaminases (alanine 
transaminase and aspartate transaminase) activities (Shanmugasundaram et 
al., 1983). Fat tissue acts as an endocrine organ, promoting lipolysis via release 
of mediator substances. This leads to a rise in the concentration of free fatty acids 
in the blood. This, in turn, not only exacerbates hyperinsulinemia and insulin 
resistance, but has other undesirable effects such as stimulation of the synthesis 
of triglyceride-rich very-low-density lipoproteins (VLDL). Cholesterol is likewise 
esterified by these free fatty acids and bound to high-density lipoprotein (HDL) to 
form HDL-cholesterol or to low-density lipoprotein (LDL) to form LDL-cholesterol. 
Reduced levels of HDL-cholesterol and increased levels of LDL-cholesterol 
particles have been found in Type 2 diabetes. Taking these factors into 
consideration the effect of Manilkara hexandra (Roxb.) Dubard leaf powder and 
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its extract on a number of biochemical parameters in alloxan induced diabetic rats 
was studied.
6.3.3.1 Biochemical parameters
6.3.3.1.1 Serum glucose level
Glucose measurement is useful in the diagnosis and treatment of pancreatic islet 
cell carcinoma and of carbohydrate metabolism disorders, including diabetes 
mellitus, neonatal hypoglycemia, and idiopathic hypoglycemia. The results of the 
effect of crude powder and methanol extract of M. hexandra (Roxb.) Dubard leaf 
on the serum glucose level in alloxan diabetic rats is shown in Table 6.3.
Table 6.3 Effect of Manilkara hexandra (Roxb.) Dubard leaf powder and its 
methanol extract on alloxan induced hyperglycemia in rats
Values are Mean ± SEM, n = 5, Decrease â, MCR: Crude powder, MME: Methanol 
extract, G: Glipizide
The crude drug (MCR) and methanol drug (MME) showed decrease in serum 
glucose level as compared to the control group. The serum glucose of the control 
-1group was 298.19 ± 70.71 mg dL . The serum glucose of the crude drug at the 
-1 -1dose of 300 mg kg  was 261.39 ± 33.47 mg dL  which was 12.34 % less than the 
control group while the serum glucose level of the methanol drug at the same 
-1dose level was 271.46 ± 25.58 mg dL  which was 8.96 % less than the control 
group. The serum glucose level of the standard drug glipizide (G) at the dose of 
-1 -10.5 mg kg  was 245.43 ± 38.80 mg dL  which was 17.69 % less as compared to 
the control group. However, the observed decrease in blood glucose level in test 
drug administered groups was found to be statistically non-significant in 
comparison to control diabetic rats.
Treated Group Glucose Level
-1(mg kg ) -1(mg dL )
Control 298.19 ± 70.71 -
MCR-300 261.39 ± 33.47 12.34 
MME-300 271.46 ± 25.58   8.96 
G-0.5 245.43 ± 38.80 17.69 
% Decrease
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6.3.3.1.2 Serum albumin level 
Albumin measurement is used in the diagnosis and treatment of numerous 
diseases primarily involving the liver or kidneys. The results of the effect of crude 
powder and methanol extract of M. hexandra (Roxb.) Dubard leaf on the serum 
albumin level is shown in Table 6.4.
Table 6.4 Effect of Manilkara hexandra (Roxb.) Dubard leaf powder and its 
methanol extract on serum albumin level in alloxan induced hyperglycemic 
rats
Values are Mean ± SEM, n = 5, Decrease â, MCR: Crude powder, MME: Methanol extract, 
G: Glipizide
-1The serum albumin level of the diabetic control group was 3.80 ± 0.11 g dL . The 
-1serum albumin levels of the crude drug (MCR) was 3.62 ± 0.14 g dL  which was 
4.73 % less than the control group while that of methanol group (MME) was 3.45 ± 
-10.11 g dL  which was 9.21 less than the control group. The standard drug glipizide 
-1(G) showed 3.66 ± 0.12 g dL  of serum albumin level with the percent decrease of 
3.68 as compared to the control group. The changes were not statistically 
significant in comparison to diabetic control group.
The decrease in albumin level has been attributed to several causes like massive 
necrosis of liver, deterioration of liver function, hepatic resistance to insulin and 
glycogen impairment of oxidative phosphorylation (Ezzat et al., 1989; Guler et al., 
1994; Rao, 1995). Nevertheless, hypoalbuminemia is a common problem in 
diabetic animals and is generally attributed to the presence of diabetic 
nephropathy (Porte and Halter, 1981).  In the present study the test drugs did not 
modulate albumin level to significant extent indicating lack of effect on albumin 
Treated Group Serum Albumin Level
-1(mg kg ) -1(g dL )
Control 3.80 ± 0.11 -
MCR-300 3.62 ± 0.14 4.73 
MME-300 3.45 ± 0.11 9.21 
G-0.5 3.66 ± 0.12 3.68 
% Decrease
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turnover.
6.3.3.1.3 Serum total protein level
Total protein measurement is used in the diagnosis and treatment of a variety of 
diseases involving the liver or kidney as well as other metabolic disorders. The 
data related to the effect of crude powder and methanol extract of M. hexandra 
(Roxb.) Dubard leaf on the serum total protein level is shown in Table 6.5.
Table 6.5 Effect of Manilkara hexandra (Roxb.) Dubard leaf powder and its 
methanol extract on serum protein level in alloxan induced hyperglycemic 
rats
Values are Mean ± SEM, n = 5, Decrease â, Increase á, MCR: Crude powder, MME: 
Methanol extract, G: Glipizide
-1The serum protein level of the control group was 7.08 ± 0.18 g dL . The serum 
-1protein level of the crude drug (MCR) administered group was 6.84 ± 0.06 g dL  
with the percent decrease of 3.38 as compared to control group while that of 
-1methanol extract (MME) group was 7.18 ± 0.14 g dL  with slight increase of        
1.41 % than the control group. The serum protein level of the standard drug 
-1glipizide (G) administered group was 6.99 ± 0.15 g dL  which was 1.27 % less 
than the control group. However, none of the observed changes in the test drug 
treated group were found to be statistically significant.
Treated Group Serum  Protein Level
-1(mg kg ) -1(g dL )
Control 7.08 ± 0.18 -
MCR-300 6.84 ± 0.06 3.38 
MME-300 7.18 ± 0.14 1.41 
G-0.5 6.99 ± 0.15 1.27 
% Change
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6.3.3.1.4 Glycogen level
The data on the effect of crude powder and methanol extract of M. hexandra 
(Roxb.) Dubard leaf on the glycogen level in the liver is shown in Table 6.6.
Table 6.6 Effect of Manilkara hexandra (Roxb.) Dubard leaf powder and its 
methanol extract on glycogen level in alloxan induced hyperglycemic rats
d #@Values are Mean ± SEM, n = 5, Increase á, *: P< (0.05), : P< (0.05), : F< (0.05), MCR: 
Crude powder, MME: Methanol extract, G: Glipizide
The glycogen content in the control group was 0.41 ± 0.09 mg/100 mg tissue. The 
glycogen level of the crude drug (MCR) treated group increased to 0.71 ± 0.04 
dmg/100 mg tissue which was 73.17 % (P< 0.05, P< 0.05, F< 0.05) higher than the 
control group and also for the methanol extract (MME) administered group the 
glycogen levels increased to 0.47 ± 0.06 mg/100 mg tissue which was 14.63 % 
(F< 0.05) higher as compared to the control group. The glycogen content of the 
standard drug glipizide (G) treated group was 0.48 ± 0.03 mg/100 mg tissue 
which was 17.07 % (F< 0.05), higher than the control group.
The hyperglycemia and decrease in liver glycogen content observed in diabetic 
group are due to lack of insulin, increased gluconeogenesis and/or 
glycogenolysis (Kobayashi and Olefsky, 1979; Defronzo and Simonson, 1992). 
Impairment of liver glycogen synthesis in diabetic rats has been reported by 
Whitton and Hems, (1975) and by Huang et al., (2000). Anti-diabetic drugs are 
expected to reverse this decrease. In the present study the crude drug (MCR) 
showed marked and significant elevation of glycogen as compared to the 
methanol extract (MME) and the standard drug glipizide treated groups. This 
indicated that at the dose level studied MCR possessed weak anti-diabetic 
activity.
Treated Group Glycogen Level
-1(mg kg ) (mg/100mg tissue)
Control 0.41 ± 0.09 -
MCR-300 0.71 ± 0.04 *73.17 @#
MME-300 0.47 ± 0.06
   14.63#
G-0.5 0.48 ± 0.03
   17.07#
% Increase
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6.3.3.1.5 Serum urea level 
In diabetes there is a relationship between glucose homeostasis and renal 
damage (Rasch, 1979a, b). The diabetic hyperglycemia induces elevation of the 
plasma levels of urea which is considered as significant marker of renal 
dysfunction (Almdal and Vilstrup, 1988). The data on the effect of crude powder 
and methanol extract of M. hexandra (Roxb.) Dubard leaf on the serum urea level 
is shown in Table 6.7.
Table 6.7  Effect of Manilkara hexandra (Roxb.) Dubard leaf powder and its 
methanol extract on serum urea level in alloxan induced hyperglycemic 
rats
Values are Mean ± SEM, n = 5, Decrease-â, Increase-á, MCR: Crude powder, MME: 
Methanol extract, G: Glipizide
-1The serum urea level in the control group was 31.13 ± 6.51 mg dL . The serum 
-1urea level in the crude drug (MCR) administered group was 24.80 ± 5.52 mg dL  
which was 20.33 % less than the control group while that of the methanol extract 
-1(MME) administered group was 32.77 ± 5.10 mg dL  which was 5.26 % higher 
than the control group. The serum urea level of the glipizide (G) administered 
-1group was 25.62 ± 3.62 mg dL  which was 17.69 % less than the control group.
The highly significant increase in serum urea concentration of diabetic rats 
reported earlier (Ganong, 1995) is attributed to depletion of serum protein, 
increase in the rate of circulating amino acids and deamination that consequently 
leads to the formation of large amount of ammonia which is eventually converted 
to urea. The breakdown of amino acids during gluconeogenesis in the liver results 
in increased production of urea, fostering negative nitrogen balance (Ganong, 
1995). However, in the present study the serum urea level in diabetic control rats 
Treated Group Serum Urea Level 
-1(mg kg ) -1(mg dL )
Control 31.13 ± 6.51 -
MCR-300 24.80 ± 5.52 20.33 
MME-300 32.77 ± 5.10  5.26  
G-0.5 25.62 ± 3.62 17.69 
% Change
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was within the normal range. The decrease observed in crude drug and glipizide 
may be indicator of their effect on gluconeogenesis.
6.3.3.1.6 Serum creatinine level 
Creatinine measurement serves as a test for normal glomerular filtration. 
Elevated levels are associated with acute and chronic renal insufficiency and are 
indicated as significant marker of renal dysfunction (Almdal and Vilstrup, 1988).  
The data on the effect of crude powder and methanol extract of M. hexandra 
(Roxb.) Dubard leaf on the serum creatinine level is shown in Table 6.8.
Table 6.8 Effect of Manilkara hexandra (Roxb.) Dubard leaf powder and its 
methanol extract on serum creatinine level in alloxan induced 
hyperglycemic rats
Values are Mean ± SEM, n = 5, Decrease-â, MCR: Crude powder, MME: Methanol extract, 
G: Glipizide
-1The serum creatinine level of the control group was 2.94 ± 0.50 mg dL . The 
serum creatinine levels of crude drug (MCR) administered group was 2.73 ± 0.51 
mg/dL which was 7.14 % less as compared to the control group while that of the 
-1methanol extract (MME) administered group was 2.48 ± 0.26 mg dL  which was 
15.64 % less than the control group. The serum creatinine level of the standard 
-1drug glipizide (G) administered group was 2.51 ± 0.15 mg dL  which was 14.62 % 
less than the control group.
The creatinine level observed in diabetic control rats is comparatively higher. This 
indicates possible renal dysfunction. The moderate decrease observed in test 
drug administered groups is indicative of reversal of this dysfunction.
Treated Group Serum Creatinine Level
-1(mg kg ) -1(mg dL )
Control 2.94 ± 0.50 -
MCR-300 2.73 ± 0.51   7.14 
MME-300 2.48 ± 0.26 15.64 
G-0.5 2.51 ± 0.15 14.62 
% Decrease
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6.3.3.1.7 Serum aspartate transaminase level (AST)
Aspartate transaminase (AST) measurements are used in the diagnosis and 
treatment of certain types of liver and heart disease. Elevated levels of the 
transaminases can signal myocardial infarction, hepatic disease, muscular 
dystrophy, or organ damage. The data on the effect of crude powder and 
methanol extract of M. hexandra (Roxb.) Dubard leaf on the serum aspartate 
transaminase level is shown in Table 6.9. 
Table 6.9 Effect of Manilkara hexandra (Roxb.) Dubard leaf powder and its 
methanol extract on serum aspartate transaminase level in alloxan induced 
hyperglycemic rats
Values are Mean ± SEM, n = 5, Increase-á, MCR: Crude powder, MME: Methanol extract, G: 
Glipizide
The control group showed 221.09 ± 22.26 IU/L of the serum aspartate 
transaminases (AST) level. The serum AST level increased in both the test drugs 
(MCR and MME) and standard drug glipizide (G). For the crude drug treated 
group the serum AST level was 236.03 ± 22.07 IU/L which was 6.75 % more than 
the control group while that of the methanol extract group was 240.98 ± 26.42 IU/L 
which was 8.99 % more than the control group. The AST level of the glipizide 
administered group was 237.11 ± 23.76 IU/L which was 7.24 % more than the 
control group.
6.3.3.1.8 Serum alanine transaminase level (ALT)
Alanine aminotransferase (ALT) measurements are used in the diagnosis and 
treatment of certain liver diseases and heart diseases. Elevated levels of the 
transaminases can indicate myocardial infarction, hepatic disease, muscular 
Treated Group
-1(mg kg )
Control 221.09 ± 22.26 -
MCR-300 236.03 ± 22.07 6.75 
MME-300 240.98 ± 26.42 8.99 
G-0.5 237.11 ± 23.76 7.24 
Serum Aspartate 
Transaminase Level  (IU/L) % Increase
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dystrophy, or organ damage. Alanine transaminase is a more liver-specific 
enzyme than asparate aminotransferase. The data on the effect of crude powder 
and methanol extract of M. hexandra (Roxb.) Dubard leaf on the serum alanine 
transaminase level is shown in Table 6.10. 
Table 6.10 Effect of Manilkara hexandra (Roxb.) Dubard leaf powder and its 
methanol extract on serum alanine transaminase level in alloxan induced 
hyperglycemic rats
Values are Mean ± SEM, n = 5, Increase-á, MCR: Crude powder, MME: Methanol extract,           
G: Glipizide
The control group showed 99.79 ± 10.81 IU/L of serum alanine transaminases 
(ALT) level. The serum ALT level for the crude drug (MCR) treated group was 
107.71 ± 12.63 IU/L which was 7.93 % more than the control group while that of 
the methanol extract (MME) treated group was 126.75 ± 20.18 IU/L which was 
27.01 more than the control group. The serum ALT level of the standard drug 
glipizide (G) administered group was 27.35 % more than the control group.
The activities of serum AST, ALT which are known as the marker enzymes for liver 
damage, showed weak to moderate elevation in all the experimental groups 
investigated here. Several studies on rats with alloxan diabetes have shown an 
increase in the activity of gluconeogenic enzymes including aminotransferases 
(AST and ALT).  (Tanaka et al., 1988; Rawi et al., 1998). Although the activities of 
aspartate and alanine transaminase  in the serum have been found to be a useful 
indicator of liver damage in the diagnosis and study of acute hepatic disease, 
these enzymes are located not only in the liver, but also in the extrahepatic tissues 
(He and Aoyama, 2003). The rise in the activity of alanine transaminase is due to 
hepatocellular damage and is usually accompanied by a rise in aspartate 
Treated Group
-1(mg kg )
Control 099.79 ± 10.81 -
MCR-300 107.71 ± 12.63  7.93 
MME-300 126.75 ± 20.18 27.01
G-0.5 127.09 ± 23.87 27.35 
Serum Alanine Transaminase 
Level (IU/L) % Increase
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transaminase (Mohan Rao et al., 1989). Since only moderate and statistically 
non-significant elevation was observed in transaminase activities, it can be 
suggested that the test drug has no modulatory effect on diabetes induced 
increase in the ALT and AST levels. 
6.3.3.1.9 Serum acid phosphatase level (ACP)
The data on the effect of crude powder and methanol extract of M. hexandra 
(Roxb.) Dubard leaf on the serum acid phosphatase level is shown in Table 6.11.
Table 6.11 Effect of Manilkara hexandra (Roxb.) Dubard leaf powder and its 
methanol extract on serum acid phosphatase level in alloxan induced 
hyperglycemic rats
Values are Mean ± SEM, n = 5, Decrease-â, Increase-á, MCR: Crude powder, MME: 
Methanol extract, G: Glipizide
The serum acid phosphatase (ACP) level of the control group was 2.08 ± 0.40 KA 
units. The serum ACP level of the crude drug (MCR) treated group was 2.25 ± 
0.11 KA units which was 3.36 % more than the control group; for the methanol 
extract (MME) administered group, the ACP level was 2.52 ± 0.36 KA units which 
was 21.15 % more than the control group and for the standard drug glipizide (G) 
treated group, it was 5.76 % less than the control group.
The elevation of the ACP level in serum is involved with the malfunctioning of liver 
or kidney during diabetes (Bottini et al., 2004). It has been shown that the alloxan 
injection causes a significant increase in the activity of acid phosphatase (Witek 
et al., 2001).  The observed effect indicates lessening of the diabetic induced 
changes; however, there was no exact correlation.
Treated Group Serum Acid Phosphatase Level 
-1(mg kg ) (KA units)
Control 2.08 ± 0.40 -
MCR-300 2.15 ± 0.11 03.36 
MME-300 2.52 ± 0.36 21.15 
G-0.5 1.96 ± 0.20 05.76 
% Change
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 Lipid profile
Apart from the regulation of carbohydrate metabolism, insulin also plays an 
important role in the metabolism of lipids. Insulin is potent inhibitor of lipolysis. 
The abnormal high concentration of serum lipids in diabetic subject is mainly due 
to increased mobilization of free fatty acids from the peripheral fat depots, insulin 
inhibits the hormone sensitive lipase (Al-Shamaony et al., 1994). The marked 
hyperlipidemia that characterizes the diabetic state may therefore be regarded as 
a consequence of the uninhibited actions of lipolytic hormones on the fat depots 
(Garber, 1998).  The increase in concentration of free fatty acids in liver and 
kidney may be due to lipid breakdown. 
In the alloxan-induced diabetes increased levels of total cholesterol, LDL-
cholesterol, VLDL-cholesterol and triglyceride and decreased level of HDL 
cholesterol were found, all of which contribute to the coronary artery disease 
(Palumbo, 1998; Arvind et al., 2002). Lowering of serum lipid levels through 
dietary or drug therapy is associated with a decrease in the risk of vascular 
disease (Rhoads et al., 1976). 
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6.3.3.1.10 Serum triglyceride level
Triglyceride measurement is used in the diagnosis of diabetes mellitus, 
nephrosis, liver obstruction, and other diseases involving lipid metabolism and 
various endocrine disorders and in the treatment of patients with these diseases. 
Accumulation of triglycerides is one of the risk factors in coronary heart disease. 
The data on the effect of crude powder and methanol extract of M. hexandra 
(Roxb.) Dubard leaf on the serum triglyceride level is shown in Table 6.12.
Table 6.12 Effect of Manilkara hexandra (Roxb.) Dubard leaf powder and its 
methanol extract on serum triglyceride level in alloxan induced 
hyperglycemic rats
Values are Mean ± SEM, n = 5, Decrease-â, Increase-á, MCR: Crude powder, MME: 
Methanol extract, G: Glipizide
-1The serum triglyceride level of the control group was 135.98 ± 2.40 mg dL . The 
serum triglyceride level of the crude drug (MCR) treated group was 130.56 ± 5.78 
-1mg dL  which was 3.98 % less than the control group while that of methanol 
-1extract (MME) administered group was 154.13 ± 23.68 mg dL  which was 13.34 
% more than the control group and that of the glipizide (G) treated group was 
-1136.43 ± 4.87 mg dL  which was 0.33 % more than the control group. There was 
negligible decrease in crude drug treated group however this change was not 
statistically significant. 
Treated Group Serum Triglyceride Level
-1(mg kg ) -1(mg dL )
Control 135.98 ± 02.40 -
MCR-300 130.56 ± 05.78   3.98 
MME-300 154.13 ± 23.68 13.34 
G-0.5 136.43 ± 04.87   0.33 
% Change
Results & Discussion
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6.3.3.1.11 Serum cholesterol level
An elevated cholesterol level is associated with diabetes, nephrosis, 
hypothyroidism, biliary obstruction, and those rare cases of idiopathic 
hypercholesterolemia and hyperlipidemia; low levels are associated with 
hyperthyroidism, hepatitis, and sometimes severe anemia or infection. The 
results of the effect of crude powder and methanol extract of M. hexandra (Roxb.) 
Dubard leaf on the serum cholesterol level is shown in Table 6.13.
Table 6.13 Effect of Manilkara hexandra (Roxb.) Dubard leaf powder and its 
methanol extract on serum cholesterol level in alloxan induced 
hyperglycemic rats
Values are Mean ± SEM, n = 5, Decrease-â, Increase-á, MCR: Crude powder, MME: 
Methanol extract, G: Glipizide
-1The serum cholesterol level of the control group was 78.34 ± 5.42 mg dL . The 
serum cholesterol level of the crude drug (MCR) treated group was 67.72 ± 4.41 
-1mg dL  which was 13.55 % less than the control group while that of the methanol 
-1extract (MME) group was 83.65 ± 13.98 mg dL  which was 6.77 % more than the 
control group and that of the standard drug glipizide (G) treated group was 79.52 
-1± 8.39 mg dL  which was 1.50 % more than the control group. The crude drug 
showed little decrease in the cholesterol level which indicated that the drug might 
possess components aiding in reduction of cholesterol levels in diabetic 
conditions. 
Treated Group Serum Cholesterol Level 
-1(mg kg ) -1(mg dL )
Control 78.34 ± 05.42 -
MCR-300 67.72 ± 04.41 13.55 
MME-300 83.65 ± 13.98   6.77 
G-0.5 79.52 ± 08.29   1.50 
% Change
Results & Discussion
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6.3.3.1.12 Serum HDL-cholesterol level
The main anti-atherogenic lipoprotein (HDL) is involved in the transport of 
cholesterol from peripheral tissues into liver (Segal et al., 1984) and thereby it 
acts as a protective factor against coronary heart disease (Gordon et al., 1977). 
The results of the effect of crude powder and methanol extract of M. hexandra 
(Roxb.) Dubard leaf on the serum HDL-cholesterol level is shown in Table 6.14.
Table 6.14  Effect of Manilkara hexandra (Roxb.) Dubard leaf powder and its 
methanol extract on serum HDL-cholesterol level in alloxan induced 
hyperglycemic rats
Values are Mean ± SEM, n = 5, Decrease-â, MCR: Crude powder, MME: Methanol extract, 
G: Glipizide
-1The serum HDL-cholesterol level of the control group was 27.65 ± 2.54 mg dL . 
The serum HDL-cholesterol level showed moderate decrease in both the test 
drugs (MCR and MME) and the standard drug glipizide (G) administered groups. 
The level of HDL-cholesterol of the crude drug treated group was 22.58 ± 1.58 
mg/dL which was 18.33 % less than the control drug while that of the methanol 
-1extract group was 23.13 ± 3.06 mg dL  which was 16.34 % less than the control 
-1group and that of the standard drug was 25.44 ± 4.26 mg dL  which was 7.99 % 
less than the control group. 
Treated Group Serum HDL-Cholesterol Level
-1(mg kg ) -1(mg dL )
Control 27.65 ± 2.54 -
MCR-300 22.58 ± 1.58 18.33 
MME-300 23.13 ± 3.06 16.34 
G-0.5 25.44± 4.26   7.99 
% Decrease
Results & Discussion
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6.3.3.1.13 Serum LDL-cholesterol level
LDL is known as bad cholesterol as it transfers cholesterol from the liver to 
circulation. LDL-cholesterol particles play an important role in the formation of 
atherosclerotic plaques on the internal lining of blood vessels. If these plaques 
become dislodged and carried away in the blood, they can obstruct small blood 
vessels and thus cause myocardial infarction and strokes. The data on the effect 
of crude powder and methanol extract of M. hexandra (Roxb.) Dubard leaf on the 
serum LDL-cholesterol level is shown in Table 6.15.
Table 6.15 Effect of Manilkara hexandra (Roxb.) Dubard leaf powder and its 
methanol extract on serum LDL-cholesterol level in alloxan induced 
hyperglycemic rats
Values are Mean ± SEM, n = 5, Decrease-â, Increase-á, MCR: Crude powder, MME: 
Methanol extract, G: Glipizide
-1The serum LDL-cholesterol level of the control group was 23.50 ± 4.53. mg dL . 
The serum LDL-cholesterol level of the crude drug (MCR) treated group was 
-119.03 ± 3.73 mg dL  which was 19.02 % less than the control group while that of 
-1the methanol extract (MME) group group was 29.69 ± 7.75 mg dL  which was 
26.34 % more than the control group and that of the standard drug glipizide (G) 
-1administered group was 26.79 ± 6.50 mg dL  which was 14 % more than the 
control group. There was little decrease in LDL-cholesterol level in crude drug 
treated group while standard drug glipizide could not reduce the LDL-cholesterol 
level which indicated that crude drug has better potential in lowering LDL-
cholesterol levels in diabetes. However, none of the changes were statistically 
significant.
Treated Group Serum LDL-Cholesterol Level
-1(mg kg ) -1(mg dL )
Control 23.50 ± 4.53 -
MCR-300 19.03 ± 3.73 19.02 
MME-300 29.69 ± 7.75 26.34 
G-0.5 26.79 ± 6.50 14.0 
% Change
Results & Discussion
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6.3.3.1.14 Serum VLDL-cholesterol level
The level of glycemic control is the major determinant of total and very low density 
lipoprotein (VLDL) concentrations (Laakso, 1995). The data on the effect of crude 
powder and methanol extract of M. hexandra (Roxb.) Dubard leaf on the serum 
VLDL-cholesterol level is shown in Table 6.16.
Table 6.16 Effect of Manilkara hexandra (Roxb.) Dubard leaf powder and its 
methanol extract on serum VLDL-cholesterol level in alloxan induced 
hyperglycemic rats
Values are Mean ± SEM, n = 5, Decrease-â, Increase-á, MCR: Crude powder, MME: 
Methanol extract, G: Glipizide
-1The serum VLDL-cholesterol level of the control group was 27.19 ± 0.48 mg dL . 
The serum VLDL-cholesterol level of the crude drug (MCR) group was 26.11 ± 
-11.15 mg dL  which was 3.97 % less than the control group while that of the 
-1methanol extract (MME) group was 30.82 ± 4.73 mg dL  which was 13.35 % more 
than the control group and that of the standard drug glipizide (G) administered 
-1group was 27.28 ± 0.97 mg dL  which was 0.33 % more than the control group. 
The crude drug showed negligible decrease in VLDL-choloesterol level while 
standard did not show any reduction in the increased VLDL-choloesterol level 
induced by diabetes. 
Treated Group Serum VLDL-Cholesterol Level
-1(mg kg )
Control 27.19 ± 0.48 -
MCR-300 26.11 ± 1.15 3.97 
MME-300 30.82 ± 4.73      13.35 
G-0.5 27.28 ± 0.97 0.33 
% Change
-1(mg dL )
Results & Discussion
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6.3.3.2 Change in the weight of the organs and body weight of the 
experimental animals
6.3.3.2.1 Weight of liver
The absolute and relative weights of the rat liver of all the experimental groups are 
shown in the Table 6.17.
Table 6.17 Effect of Manilkara hexandra (Roxb.) Dubard leaf powder and its 
extracts on absolute and relative weight of liver in alloxan induced 
hyperglycemic rats
Values are Mean ± SEM, n = 5, Increase-á, MCR: Crude powder, MME: Methanol extract, G: 
Glipizide
The absolute weight of the liver for the control group was 7.14 ± 0.63 g while the 
relative weight was 3.06 ± 0.13 g. The absolute weight of the liver for crude drug 
(MCR) group was 7.49 ± 0.50 g which was 4.90 % more than the control group 
whereas the relative weight was 3.10 ± 0.11 g which was 1.30 % more than the 
control group. The absolute weight of the liver for the methanol extract (MME) 
treated group was 7.64 ± 0.58 g which was 7 % more than the control group while 
the relative weight was 3.37 ± 0.11 g which was 10.13 % more than the control 
group. The absolute weight of the liver for the glipizide (G) administered group 
was 7.21 ± 0.55 g which was 0.98 % more than the control group while the relative 
weight was 3.28 ± 0.15 g which was 7.18 % more than the control group. The 
observed changes in the test drug administered were found to be statistically non-
significant in comparison to diabetic control group
Treated Group
-1(mg kg )
Weight  (g) % Increase Weight  (g) % Increase
Control 7.14 ± 0.63 - 3.06 ± 0.13 -
MCR-300 7.49 ± 0.50 4.90 3.10 ± 0.11   1.30 
MME-300 7.64 ± 0.58 7.00 3.37 ± 0.11 10.13 
G-0.5 7.21 ± 0.55 0.98 3.28 ± 0.15   7.18 
Absolute Weight of Liver Relative Weight of Liver(g/100 g body weight)
Results & Discussion
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6.3.3.2.2 Weight of kidney
The absolute and relative weights of the rat kidney of all the experimental groups 
are shown in the Table 6.18.
Table 6.18 Effect of Manilkara hexandra (Roxb.) Dubard leaf powder and its 
extracts on absolute and relative weight of kidney in alloxan induced 
hyperglycemic rats
Values are Mean ± SEM, n = 5, Decrease-â, MCR: Crude powder, MME: Methanol extract, G: 
@ dGlipizide, *: P< (0.05), : P< (0.05)
The absolute weight of the kidney for the control group was 1.28 ± 0.06 g whereas 
the relative weight was 0.56 ± 0.06 g. The absolute weight of the kidney for crude 
drug (MCR) group was 1.17 ± 0.07 g which was 8.59 % less than the control group 
while the relative weight was 0.48 ± 0.01 g which was 14.28 % less than the 
control group. The absolute weight of the kidney for methanol extract (MME) 
dtreated group was 1.04 ± 0.05 g which was 18.75 % (P< 0.05, P< 0.05) less than 
the control group while the relative weight was 0.46 ± 0.02 g which was 17.85 % 
less than the control group. The absolute weight of the kidney for the glipizide (G) 
administered group was 1.06 ± 0.08 g which was 17.18 % less than the control 
group while the relative weight was 0.48 ± 0.02 g which was 14.28 % less than the 
control group. However, none of the observed changes in the test drug treated 
group were found to be statistically significant.
Treated Group
-1(mg kg )
Weight  (g) % Decrease % DecreaseWeight  (g)
Absolute Weight of Kidney Relative Weight of Kidney
(g/100 g body weight)
1.28 ± 0.06
1.17 ± 0.07
1.04 ± 0.05
Control
MCR-300
MME-300
G-0.5 1.06 ± 0.08
-
  08.59 
 18.75*@  
 17.18 
0.56 ± 0.06 -
0.48 ± 0.01 14.28 
0.46 ± 0.02 17.85 
0.48 ± 0.02 14.28 
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6.3.3.2.3 Weight of heart
The absolute and relative weights of the rat liver heart of all the experimental 
groups are shown in the Table 6.19.
Table 6.19 Effect of Manilkara hexandra (Roxb.) Dubard leaf powder and its 
extracts on absolute and relative weight of heart in alloxan induced 
hyperglycemic rats
Values are Mean ± SEM, n = 5, Increase-á, MCR: Crude powder, MME: Methanol extract, G: 
Glipizide
The absolute weight of the heart for the control group was 0.75 ± 0.03 g while the 
relative weight was 0.32 ± 0.01 g. The absolute weight of the heart for the crude 
drug (MCR) treated group was 0.80 ± 0.04 g which was 6.66 % higher than the 
control group while the relative weight was 0.33 ± 0.01 g which was 3.12 % higher 
than the control group. The absolute weight of the heart for the methanol extract 
(MME) treated group was 0.81 ± 0.04 g which was 8 % higher than the control 
group while the relative weight was 0.36 ± 0.02 g which was 12.5 % higher than 
the control group. The absolute weight of heart for the glipizide (G) administered 
group was 0.79 ± 0.07 g which was 5.33 % higher than the control group whereas 
the relative weight was 0.36 ± 0.03 g which was 12.5 % higher than the control 
group. The observed changes in the test drug administered were found to be 
statistically non-significant in comparison to diabetic control group
Treated Group
-1(mg kg )
Control
MCR-300
MME-300
G-0.5
Weight  (g)
0.75 ± 0.03
0.80 ± 0.04
0.81 ± 0.04
0.79 ± 0.07
% Increase
-
6.66 
8.00 
5.33 
Absolute Weight of Heart
Weight  (g) % Increase
0.32 ± 0.01 -
0.33 ± 0.01 3.12 
0.36 ± 0.02 12.5 
0.36 ± 0.03 12.5 
Relative Weight of Heart
(g/100 g body weight)
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6.3.3.2.4 Change in the body weight
The change in the body weight during the treatment of 7 seven days is shown in 
Table 6.20.
Table 6.20 Effect of Manilkara hexandra (Roxb.) Dubard leaf powder and its 
extracts on body weight of albino rats
Values are Mean ± SEM, n = 5, Decrease-â, MCR: Crude powder, MME: Methanol extract, G: 
Glipizide
The body weight of the control group as compared to the initial body weight on the 
th thon the 4  day was 8.58 ± 2.43 g and on the 7  day it increased more to 11.86 ± 4.61 
thg. The body weight for the crude drug treated group on the on 4  day was found to 
thbe 1.39 ± 2.33 g which was 83.79 % less than the control group and on the 7  day 
it was 5.18 ± 3.30 g which was 56.32 % less than the control group. The body 
thweight for the methanol extract treated drug on the 4  day was 0.61 ± 1.90 g which 
thwas 92.89 % less than the control group while on the 7  day it was 1.82 ± 3.28 g 
which was 87.65 % less than the control group. The body weight for the standard 
thdrug on the 4  day was 3.70 ± 3.68 g which was 56.87 % less than the control 
thgroup while on the 7  day it was 3.94 ± 3.16 g which was 66.77 % less than the 
control group.
Body wt. % Body wt. % 
(g)  Decrease (g) Decrease
Control 8.58 ± 2.43 - 11.86 ± 4.61 -
MCR-300 1.39 ± 2.33 83.79  5.18 ± 3.30 56.32 
MME-300 0.61 ± 1.90 92.89 1.82 ± 3.28 87.65 
G-0.5 3.70 ± 3.68 56.87 3.94 ± 3.16 66.77 
Change in Body weight (g)
4th Day 7th DayTreated Group
-1(mg kg )
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6.3.3.3 Histopathological study
The histopathological study of four tissues was performed. Heart, liver, kidney 
and pancreas were selected to observe effect of drug treatment on 
cytoarctitecture of tissue in alloxan induced diabetic animals (Figures 6.3-6.6).
The crude extract (MCR), methanol extract (MME) and glipizide (G) treatment did 
not produce any gross changes in cell density and pattern in heart (Figure 6.3) 
and liver (Figure 6.4)  section with control group. In heart no significant 
pathological changes were observed as a result of diabetes. 
Mild fatty degenerative changes were observed in the kidney section of all the 
treated groups (MCR, MME and G) including control group. This indicated that the 
drug treatment had no significant effect on cytoarchitecture of kidney (Figure 6.5).
During histological examination of pancreas moderate degenerative changes 
were observed in the β cells of islets of Langerhans as a result of injection of 
alloxan toxicant. Crude drug (MCR) and methanol extract (MME) were not able to 
prevent the observed degenerative changes but in comparision to control group 
less degeneration was observed in glipizide (G) treated group ((Figure 6.6). This 
indicated moderate protection of β cell. 
6.4 CONCLUSIONS
The crude powder (MCR) and methanol extract (MME) of Manilkara hexandra 
st(Roxb.) Dubard leaf produced lowering of blood glucose level at 1  h. The 
treatment of MCR on normal fasted rats produced significant hypoglycemic effect 
-1as compared to MME at the dose level 300 mg kg .  Both the drugs MCR and 
MME showed increase in blood glucose level after sucrose loading on normal rats 
thtill 24  h. Hence, crude powder and methanol extract of M. hexandra leaf does not 
show sucrose tolerance at the studied dose level.
The present study showed that the crude powder (MCR) and methanol extract 
(MME) of M. hexandra leaf showed decreased level of glucose in alloxan diabetic 
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rats. However, there was a significant elevation in the glycogen level in the crude 
drug treated group as compared to methanol extract and and glipizide (G) treated 
groups. The crude drug of M. hexandra (Roxb.) Dubard leaf showed reduction in 
the triglyceride level, total cholesterol level, LDL level and VLDL level as 
compared to the diabetic control group. Similarly the effect of aqueous extract of 
Scoparia dulcis on lipid profile was reported by Latha and Pari (2005) and extract 
of Azadirachta indica leaf extract on lipid profile was reported by Chattopadhyay 
and Bandyopadhyay (2005). Hence, the results of the present study indicated 
that crude drug of M. hexandra (Roxb.) Dubard leaf may possess 
antihyperlipidemic activity if studied at higher dose levels. The methanol extract 
and glipizide treated group did not show any significant changes in biochemical 
parameters studied.
The histopatholgical studies showed that the tissues possessed almost normal 
cytoarchitecture. Therefore, the results show that the crude drug (MCR) of 
Manilkara hexandra (Roxb.) Dubard leaf possesses weak antidiabetic activity at 
-1the dose level of 300 mg kg . Further studies of Manilkara hexandra (Roxb.) 
Dubard leaf at the higher dose level may show better antidiabetic activity.  
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Medicinal plants, since time immemorial, have been used in virtually all cultures 
as a source of medicine. Encompassing concepts and methods for protection and 
restoration of health, traditional medicine has served as a fount of alternative 
medicine, new pharmaceuticals and health care-products. Recently, public, 
scientific and medical interest in this key topic has soared as the importance of the 
indigenous collective wisdom in the use of herbal preparations, has been 
recognized. 
Worldwide, at least 122 chemical substances of known structure are extracted 
and purified for medicinal purposes. There are hundreds of species recognized to 
possess therapeutic value. Although these are not purified into separate 
compounds, many are believed to exert therapeutic effects good enough to be 
proven effective by modern analysis.
Recently the search for components with novel biological properties has gained 
increasing importance due to growing world wide concern about the alarming 
increase in the rate of deadly diseases like infections by antibiotic resistant 
microorganisms, AIDS, cancer, diabetes, tuberculosis etc. This situation has 
forced scientists for searching newer drugs from various sources like medicinal 
plants which are the good source of novel chemotherapeutic agents. Considering 
the bioprospectus of medicinal flora, the present study was conducted to 
investigate antimicrobial properties of some plants of Saurashtra region against a 
wide array of microorganisms. Amongst these, the most promising plant was 
selected for further evaluation of pharmacognostical studies, phytochemical 
studies, toxicological studies and pharmacological activity.
In the present work, 108 different plant species belonging to 54 different families 
were screened for their potential antimicrobial property against 5 Gram-positive 
bacteria, 9 Gram-negative bacteria and 1 yeast by agar well and agar disc 
diffusion method. Out of 216 extracts, 143 plant extracts (35 aqueous and 108 
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methanol/ethanol) showed activity against at least one of the tested 
microorganism. Although plants differed significantly in their activities against 
microorganisms tested, more of the extracts showed antibacterial activity against 
Gram-positive bacteria than Gram-negative bacteria. Amongst the 15 microbial 
strains tested, the most susceptible bacteria was B. cereus which is a Gram-
positive bacteria and the most resistant bacteria was E. coli which is a Gram-
negative bacteria. 
Amongst aqueous and methanol/ethanol extracts of the studied plant species, 
methanol/ethanol extracts were found to be more active against the test microbial 
strains than the aqueous extracts. Amongst 54 families, 8 families viz. 
Anacardiaceae, Casuarinaceae, Combretaceae, Lythraceae, Myrtaceae, 
Sapotaceae, Trapaceae, and Vitaceae inhibited more than 50 % bacterial strains. 
Amongst 108 plant species, the most active plant was Terminalia chebula Retz. 
while the most inactive plant was Solanum surattense Burm.f.  
The methanol extracts of 20 selected medicinal plants were screened for 
antifungal activity against 11 fungal strains.  The antifungal activity was evaluated 
by agar disc diffusion method at three different concentrations (500 g/disc, 250 
µg/disc and 125 g/disc). The moulds were more susceptible than yeast.  All the 
concentrations of the extracts investigated, inhibited the fungal species with 
varying degree of sensitivity. Aspergillus flavus was the most susceptible and 
Candida glabrata was the most resistant fungal strain. The antifungal activity of 
the screened plants did not show any concentration effect.  
On the basis of the results evaluated for in vitro antibacterial and antifungal 
potencies of the plants, Woodfordia fruticosa kurz., Trapa natans L., Terminalia 
chebula Retz., Mesua ferra L., Manilkara hexandra (Roxb.) Dubard, Mangifera 
indica L., Eucalyptus citriodora Hook., Bauhinia variegata L., Caesalpinia 
pulcherrima (L.) Swartz., Vitis vinifera L. and  Euphorbia hirta L. showed the best 
antimicrobial activity. Manilkara hexandra (Roxb.) Dubard (Sapotaceae) leaf was 
selected for further pharmacognostic, phytochemical, toxicological and 
pharmacological evaluations on the basis of availability and literature search.
µ
µ
196
Summary
Manilkara hexandra (Roxb.) Dubard is an evergreen tree with 3-12 m tallness. 
The leaves of M. hexandra (Roxb.) Dubard are dark green in color and bitter in 
taste. The crude powder was successively extracted with petroleum ether, 
acetone and methanol. The methanol extract (MME) had the maximum yield of 23 
% while acetone extract (MAC) had minimum extractive yield of 4.8 %. 
The microscopic study of Manilkara hexandra (Roxb.) Dubard leaf was done by 
evaluating different characteristics from the T.S. and crude powder of leaf. T.S of 
leaf showed upper epidermis with epidermal cells which were single layered, 
straight walled, rectangular in shape and covered with thin cuticle. The simple, 
unicellular, conical and thick trichomes with single covering were present. The 
lower epidermis had more number of trichomes than the upper epidermis. The 
anomocytic stomata were present in lower epidermis. Prisms of calcium oxalate 
were present in the lower epidermal cells. The vascular bundle was collateral. 
Leaf was dorsiventral. The specific characteristics observed in powder studies 
were anomocytic stomata, simple covering unicellular trichome, group of 
pericyclic fibers, prisms of calcium oxalate crystals and xylem vessels in 
longitudinal sectional view showed spiral thickening.
The result of proximate analysis of crude powder (MCR) of M. hexandra (Roxb.) 
Dubard leaf showed 4 % of loss on drying, It contained 6 % of total ash and 1 % of 
acid insoluble ash. The percent extractive yield of crude powder extracted in 
petroleum ether was 3.74 %; that extracted in alcohol was 10.60 % and extracted 
in water was 12.30 %. MME and MAC were soluble in almost all the solvents while 
MPE showed comparatively less solubility due to its hydrophobic nature. All the 
samples were acidic in nature. All the sample drugs (MCR, MPE, MAC and MME) 
showed minor presence of some heavy metals but the extracts did not exceed the 
limit reported by WHO guidelines. The sample drugs investigated were free from 
heavy metal and microbial contamination.
The results of preliminary phytochemical analysis of crude powder and different 
extracts of M. hexandra (Roxb.) (MCR, MPE, MAC and MME)  Dubard showed 
maximum presence of cardiac glycosides and steroids in all the four sample 
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drugs. Tannins and saponins were present in all the extracts except MPE. 
Alkaloids were present in MCR, MPE, MAC and MME with Wagner's test. The 
alkaloids were present only in MCR and MPE with Dragendroff's test and in MCR 
and MME with Mayer's test. Flavonoids were absent in all the four drug samples. 
The HPTLC fingerprinting showed maximum 14 peaks for MAC, followed by 13 
peaks for MME and 7 peaks for MPE. There were four constituents common in 
MAC and MME with Rf values of 0.06, 0.21, 0.50 and 0.55 and there were two 
constituents common in MPE and MAC with Rf values of 0.23 and 0.67. None of 
the constituents were common in MPE and MME. The constituents can be further 
isolated and purified to find its potency for biological activities.
Bacteria and fungi cause some important human diseases. Despite the existence 
of potent antibacterial and antifungal agents, the past three decades have seen a 
dramatic increase in microbial resistance to antimicrobial agents, imposing the 
need for a permanent search and development of new drugs. Plant based 
antimicrobials represent a vast untapped source of medicines and there is a need 
for further exploration of plant antimicrobials. In the present study, the 
antimicrobial potential of the petroleum ether, acetone and methanol extracts of 
M. hexandra (Roxb.) Dubard leaf were evaluated at two different concentrations 
against 9 Gram-positive, 14 Gram-negative, 7 yeast and 4 moulds by agar disc 
diffusion method. The results showed that methanol extract (MME) was better 
than the other two extracts (MPE and MAC) which implied that antimicrobial 
activity is better with the polar solvents. Also, the antimicrobial activity observed 
was concentration dependent for each extract. 
Amongst all the microbial strains investigated, a Gram-negative bacteria- 
Citrobacter freundii, yeasts- Candida albicans (2), Candida glabrata, 
Cryptococcus luteolus, Cryptococcus neoformans and mould- Aspergillus 
candidus, were most resistant strains whereas a Gram-positive bacteria - Bacillus 
cereus and Gram-negative bacteria Enterobacter aerogenes and Pseudomonas 
putida, yeast - Trichosporon begelli and mould- Aspergillus flavus were most 
susceptible strains.
198
Summary
The results showed that methanol extract (MME) of M. hexandra (Roxb.) Dubard 
leaf possessed measurable in vitro antimicrobial activity against many of the 
microorganisms implicated in the pathogenesis of the human infections. The 
broad range of inhibition implied that the extract had a comparable antimicrobial 
activity. The MIC of M. hexandra was evaluated within a range of concentration 
from 250-32,000 µg/ml. 
Toxicology is a relatively young biological science that involves a complex 
interrelationship among dose, absorption, distribution, metabolism and 
elimination. A toxic substance is a material which has toxic properties. 
Knowledge of how toxic agents damage the body has progressed along with 
medical knowledge.  Toxicity depends not only on the dose of the substance but 
also on the toxic properties of the substance. The relationship between these two 
factors is important in the assessment of therapeutic dosage in pharmacology 
and herbalism. Considering the aforesaid, crude powder (MCR) and methanol 
extract (MME) of Manilkara hexandra (Roxb.) Dubard leaf was evaluated for the 
acute toxicity studies.
The results of acute toxicity studies showed that the crude powder as well as 
methanol extract showed dose dependent effect on gross behaviour. The 
methanol extract exhibited pronounced effect on gross behaviour of mice as 
compared to the crude powder. Mild to moderate hypoactivity or reduced 
locomotion was noted at all dose levels for crude powder (MCR) of M. hexandra 
(Roxb.) Dubard leaf. Mortality was not observed at any dose levels for crude 
powder (MCR). The methanol extract (MME) of M. hexandra (Roxb.) Dubard leaf 
showed marked effect for hypoactivity at the highest dose level. Mortality for 
-1
methanol extract (MME) was observed at the highest dose level i.e. 3120 mg kg . 
Animal death was preceded by symptoms, such as hypoactivity and lethargy. The 
-1further evaluation of LD  at the dose levels 2000-9000 mg Kg  revealed that 50
methanol extract (MME) was devoid of acute toxicity at the studied dose level 
therefore, crude drug (MCR) and methanol (MME) extract are safe till the dose 
-1level of 9000 mg  kg .
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Diabetes is a growing public health concern worldwide causing severe and costly 
complications including blindness, cardiac and kidney diseases. The diabetic 
epidemic is accelerating in the developing world, with an increasing proportion of 
affected people in younger age groups. Worldwide, approximately 120 million 
people have diabetes and that could double in 10 years. In addition to different 
synthetic drugs, plant remedies play an effective role in diminishing the suffering. 
In the present work, M. hexandra (Roxb.) Dubard leaf was evaluated for 
antidiabetic activity. 
The hypoglycemic study of the crude powder (MCR) and methanol extract (MME) 
of Manilkara hexandra (Roxb.) Dubard leaf produced lowering of blood glucose 
stlevel at 1  h. The treatment of MCR on normal fasted rats produced significant 
-1hypoglycemic effect as compared to MME at the dose level 300 mg kg .  In the 
sucrose tolerance test, both the drugs MCR and MME showed increase in blood 
thglucose level after sucrose loading on normal rats till 24  h. Hence, crude powder 
and methanol extract of M. hexandra leaf does not show sucrose tolerance at the 
studied dose level.
The present study showed that the crude powder (MCR) and methanol extract 
(MME) of M. hexandra leaf showed decreased level of glucose in alloxan induced 
diabetic rats. However, there was a significant elevation in the glycogen level in 
the crude drug treated group as compared to methanol extract and glipizide (G) 
treated groups. The crude drug of M. hexandra (Roxb.) Dubard leaf showed 
reduction in the triglyceride level, total cholesterol level, LDL level and VLDL level 
as compared to the diabetic control group. Hence, the results of the present study 
indicated that crude drug of M. hexandra (Roxb.) Dubard leaf may possess good 
antihyperlipidemic activity if studied at higher dose levels. The methanol extract 
and glipizide treated group did not show any significant changes in biochemical 
parameters studied.
The histopatholgical studies showed that the tissues (heart, liver, kidney and 
pancreas) possessed almost normal cytoarchitecture. Therefore, the results 
show that the crude drug (MCR) of Manilkara hexandra (Roxb.) Dubard leaf 
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-1possesses weak antidiabetic activity at the dose level of 300 mg kg . Further 
studies of Manilkara hexandra (Roxb.) Dubard leaf at the higher dose level may 
show better antidiabetic activity.  
Overall, it can be concluded that M. hexandra (Roxb.) Dubard leaf possessed 
moderate antimicrobial property. Also, it possesses weak antidiabetic activity 
however, the results were not significant. It showed lipid lowering property. This 
study therefore warrants investigation to isolate and identify the antidiabetic and 
antihyperlipidemic principles to elucidate their exact mechanism of action.
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